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CHAPTER I 
 
DISCOVERIES AND CHALLENGES ENCOUNTERED TOWARDS THE DEVELOPMENT 
OF A METABOTROPIC GLUTAMATE RECEPTOR 3 POSITIVE ALLOSTERIC 
MODULATOR 
 
Background and Introduction  
Metabotropic Glutamate Receptors 
 Metabotropic glutamate receptors (mGluRs) belong to the G-protein-coupled receptor 
(GPCR) superfamily of proteins. [1] GCPRs are membrane bound and are activated by a variety 
of extracellular ligands (i.e. peptides, neurotransmitters, hormones) or physical stimuli (i.e. light) 
and are responsible for inducing intracellular signaling cascades via activation of G proteins.  
These receptors are ubiquitous in numerous cellular processes and disease states; roughly one 
third of known medicinal agents target GPCRs. [2] By way of brief mechanistic overview, a 
ligand activated GPCR acts as a guanine nucleotide exchange factor. [1] The receptor will 
exchange a guanosine 5’-diphosphate (GDP) residue located within the α subunit of a particular 
G protein for a guanosine 5’-triphosphate (GTP) residue. Once activated, a G protein can 
modulate the function of numerous other cellular molecules such as enzymes or transcription 
factors until becoming inactive again.  GPCRs are grouped into 6 classes (A-F or 1-6) based on 
sequence homology and functional similarity.  The mGluRs belong to class C (metabotropic 
glutamate/pheromone) GPCRs and earn this distinction by the presence of a large venus flytrap 
extracellular N-terminal domain which contains the endogenous ligand binding site (Figure 1.1). 
This domain is connected via a cysteine-rich domain to a characteristic 7-member 
transmembrane domain.  The cysteine-rich domain contains nine cysteine residues, eight of  
2 
 
 
 
 
 
 
 
  
Figure 1.1. Generic representation of a mGluR dimer with major structural features highlighted. 
 
which are linked by disulfide bridges.  The ninth cysteine residue is believed to play a critical 
role in receptor signaling as this cysteine forms a disulfide bridge with another cysteine on the 
venus flytrap domain after ligand binding.  Support for this mechanism was provided by 
mutating the ninth cysteine residue resulting in a fully formed receptor devoid of signaling 
ability in presence of orthosteric agonist. [3] More recent investigations supported by X-ray 
crystallography and cryo-electron microscopy indicate that this additional cysteine disulfide 
bridge is formed between two receptor monomers which have dimerized in the lipid bilayer. [4] 
The transmembrane domain, sometimes referred to as the hepatahelical domain, is where the 
majority of known mGluR allosteric modulators (see below) bind. [5] The intracellular C-termini 
of mGluRs is the site at which G-proteins interact with the receptor. [1] These receptors function 
as constitutive dimers in all pharmacological contexts studied to date, although, it is unclear if 
one or both VFD need be bound to glutamate to induce signal transduction. Keeping to their 
namesake, mGluRs’ endogenous ligand is the major neurotransmitter L-glutamate and as such 
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these receptors play a critical role in the central nervous system (CNS). [2]  Upon binding to 
glutamate, the VFD will close and induce a conformational change of the receptor resulting in 
formal activation. To date genes for eight mGluR subtypes have been identified and each appears 
to be uniquely expressed in distinct cell types throughout the CNS. The mGluRs are divided into 
three different groups based on sequence homology, G-protein coupling, and ligand selectivity.  
Group I includes mGluRs 1 and 5, Group II includes mGluRs 2 and 3, and Group III includes 
mGluRs 4,6,7, and 8.  The work presented in this chapter will focus on Group II mGluRs and as 
such background on the other two groups is intentionally omitted, but readily obtainable in 
references provided. [1,5]  Both mGluR2 and mGluR3 are widespread within the CNS pre and 
post-synaptically however mGluR2 is most prominently localized in the Golgi cells of the 
cerebellum while mGluR3 is most prominent in the neuronal cells of the cerebral cortex.
[6] There 
are currently no known splice variants for mGluR2 while three have been found for mGluR3 and 
these have the functional consequence of either generating different C-terminal tails or in one 
case a complete lack of a transmembrane domain.[1] The most commonly encountered mGluR3 
variant is GRM3Δ4 which lacks the transmembrane domain yet is still translatable in vivo 
suggesting it may serve as a special kind of glutamate receptor. [7] However, the physiological 
relevance of the splice variants is still poorly understood. The downstream signaling pathway of 
this group inhibits adenylyl cyclase and Ca2+ channels while activating K+ channels and is 
mediated by coupling to the G protein Gi/o.  This has the downstream effect of decreasing 
NMDA receptor activity and lowering risk of neuronal excitotoxicity. [8] The general signaling 
profile of group II mGluRs is quite similar to that of the group III mGluRs including coupling to 
other pathways such as activation of the MAPK or phosphatidyl inositol 3-kinase pathway. [9] By 
comparison, the group I mGluRs have a significantly different signaling pathway which is 
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mediated by coupling to the G protein Gq. 
[1] This pathway acts to activate phospholipase C, 
PKC, and increase Ca2+ channel activity.  While a fair generalization is that group I mGluRs 
have the opposing signaling effects as the group II and III receptors it has been noted that some 
group I mGluRs can modulate pathways stemming from Gi/o activation as well. 
[10] It is through 
these basic mechanisms that the mGluRs regulate a whole suite of critical neurological functions, 
which are covered in a later subheading with emphasis placed on mGluR3. 
Allosteric Modulators 
 All receptors and proteins possess an orthosteric binding site for their respective 
endogenous ligand(s).[11] Additionally, some may possess an allosteric binding site which can 
play an orthogonal role if bound by a small molecule.  This observation has enjoyed increasing 
awareness since the inception of the concept of allosterism in 1965. [12] Allosteric binding sites 
are spatially non-overlapping and functionally distinct from their corresponding orthosteric sites.  
Small molecules which bind to the allosteric site of a protein or receptor have been shown to 
modulate both endogenous ligand binding affinity and biomolecule efficacy. [13] To date 
allosteric sites have been identified in GPCRs, ion channels, kinases, and other highly studied 
and therapeutically relevant proteins.  Some (potentially most) cellular receptors have multiple 
confirmed allosteric binding sites. Historically, drug discovery programs have targeted 
orthosteric sites and nearly all small molecules approved by the U.S. Food and Drug 
Administration (FDA) bind accordingly.  While a powerful approach, orthosteric ligands may 
suffer from poor receptor selectivity (i.e. more off-target effects), development of resistance, and 
decreased efficacy upon chronic administration. [14] It was not until fairly recently that the 
advantages of targeting the allosteric site of a receptor became clear.  Benzodiazepines showed 
great clinical success as allosteric modulators of the ionotropic γ-aminobutyric acid receptor A 
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(GABAA) for the treatment of CNS disorders. 
[15] These molecules were able to avoid high 
toxicity associated with traditional GABAA orthosteric binding ligands while retaining 
aggregable efficacy.  Benzodiazepines are considered a prime example of the therapeutic 
promise held by allosteric modulators and are currently one of the most widely prescribed 
pharmacologic agents in the United States.  On a peculiar note, it took researchers nearly two 
decades after the first benzodiazepine entered the US market to understand these molecules 
mechanism of action. [16] 
 Molecules which bind to the allosteric site are traditionally referred to as modulators.  For 
GPCRs allosteric modulators function primarily in a positive, negative, or neutral manner. 
Positive allosteric modulators (PAMs) potentiate receptor response to agonist while negative 
allosteric modulators (NAMs) decrease receptor activity noncompetitively. [11] Neutral allosteric 
modulators (also referred to as silent allosteric modulators, SAMs) bind to allosteric sites thus 
blocking activity of PAMs or NAMs but do not modulate the receptor in any manner.  More 
complex mechanisms of action have been observed by allosteric modulators such as partial 
NAMs (incapable of producing a response equivalent to a pure NAM) and Ago-PAMs (PAMs 
which also act as agonists of the receptor). [17] Not all modes of action for allosteric modulators 
can hold therapeutic potential for a given GPCR in a disease state. For example, Ago-PAMs and 
PAMs of the muscarinic acetylcholine receptor 1 (M1) are both known to enhance cognitive 
function.  However, Ago-PAMs possess seizure liabilities on basis of their partial agonist 
activity, while pure acting M1 PAMs do not.[18]  More complexity is introduced when 
considering that many GCPRs have the potential to activate numerous signaling pathways upon 
activation. Allosteric ligands have the ability to equally modulate all potential downstream 
signalling pathways of a receptor or stabilize a receptor conformation such that some, or one, 
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pathway is preferred above the others. This concept is known as signal bias. It is possible to 
generate ligands (allosteric or orthosteric) capable of biasing a particular GCPR to one pathway 
and this concept has become a major paradigm in GPCR drug discovery. [19] Recent evidence 
from research on the precise physical nature of allosteric interactions across a diverse set of 
cellular membrane receptors supports a hypothesis that such receptors are continually sampling 
numerous conformations and that allosteric modulators bind only to particular transient 
conformation(s) of the receptor.  Upon binding that conformation is stabilized resulting in the 
changes associated with allosteric modulators. [13] This has been postulated in direct 
disagreement with the initial induced-fit model of allosteric modulators which suggests the 
opposite; that an allosteric ligand binds first followed by a resulting receptor conformation 
becoming stabilized. [20] Awareness of these characteristics of allosteric modulation is critical to 
success of a program aimed at development of novel modulators. 
 Allosteric modulators offer a number of advantages over their orthosteric counterparts in 
regards to becoming potential therapeutics. [21] Due to the less conserved nature of allosteric sites 
across a receptor family, it is often easier to generate family or subtype selective allosteric 
ligands as opposed to orthosteric ligands. [11] Pure acting PAMs or NAMs will display no effect 
in a given system unless endogenous ligand is also present thus potentially avoiding toxicity 
issues. Furthermore, allosteric modulators may have limits on their pharmacological effect 
meaning that these compounds can be dosed at higher concentrations without causing additional 
effect at a receptor, again unlike orthosteric ligands.  In many instances the chemical tractability 
or physicochemical properties of an allosteric modulator chemical scaffold are far more 
appealing than orthosteric ligands. [22] A fitting example of this are orthosteric ligands of 
mGluRs.  As a result of the need for these compounds to have structural analogy to glutamate, 
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they often require amino acid like functionality which challenges these molecules ability to 
penetrate the blood-brain barrier. [23] Allosteric modulators need not abide by this constraint. [11] 
Despite these advantages allosteric modulators are not without drawbacks.  The most commonly 
encountered issue associated with the development of these molecules is “steep SAR”. [24] Many 
allosteric ligand programs have noted that a molecular scaffold may lose all activity following a 
modest structural modification. [25] This phenomenon is most often explained by recognizing the 
flaws inherent in relying on EC50 values for driving allosteric modulator programs.  As 
mentioned above allosteric modulators may have several effects on a receptor which are defined 
mathematically as intrinsic efficacy (τβ), cooperativity (α and β), and affinity (pKB) modulation. 
[11] These highly contextual relationships may be lost when activity is portrayed as a single EC50 
value and simple scaffold modification may only be affecting one parameter. Studies have shown 
SAR studies around allosteric modulators are more enlightened if one dissects a molecule’s 
contribution to each allosteric parameter. [24] The nuanced activation (both spatial and temporal) 
an allosteric modulator may have on a receptor is often modeled in detail using the allosteric 
ternary complex model. [26] Another potential pitfall in the development of allosteric ligands is 
the significant structural difference of the allosteric pocket between species. [11] This mandates 
that programs must, at a minimum, test compounds routinely against both human and rodent 
versions of the receptor.  Despite these challenges and the myriad of pharmacological outcomes 
possible from the activity of an allosteric modulator, as of 2014 two allosteric modulators of 
GPCRs entered the market: cinacalcet (calcium-sensing receptor PAM) [27] and maraviroc (CCR5 
NAM) [28].  
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Physiological Role of Metabotropic Glutamate Receptor 3 
Most of what is known about the pharmacology of the mGluRs has been learned from 
mouse genomic knockout studies or from the use of subtype or group selective ligands. [1] The 
structural similarity between mGluR2 and mGluR3 has made it difficult to develop selective 
orthosteric ligands for between the Group II mGluRs and as such only a few discrete receptor 
functions have been made clear. Some general observations are that the activation of mGluR3 
results in inhibition of glutamate release, inhibition of voltage-gated calcium channels, positive 
modulation of potassium channels, and stimulation of neurotrophic factor production in 
astrocytes.  Aside from these canonical signaling roles mGluR3 is also capable of protein-protein 
interactions at the C-terminus with either calmodulin or protein phosphatase 2C (PP2C). [29] The 
consequences of this observation are still being studied but it appears that there is a regulation of 
mGluR3 phosphorylation / dephosphorylation via a PP2C & PKA system. 
 More specific roles 
that have otherwise been identified follow. The main receptor localization disparity is that 
mGluR3, and not mGluR2, is found in glial cells and appears to have an important role in glial 
function and glial-neuronal interactions. [30] Neuroprotection against NMDA toxicity by dual 
mGluR2/3 receptor agonists requires activation of astrocytic mGluR3 and not mGluR2. 
[31] 
Hippocampal long-term depression (LTD) is strongly influenced by mGluR3 as this was blocked 
in rats after administration of a known mGluR3 antagonist. 
[32] In the same study it was noted 
mGluR3 was not required for long-term potentiation (LTP).  Recent studies by collaborators in 
the VCNDD have clarified the consequences of the mGluR3-LTD connection. 
[33] That is, 
activation of mGluR3 induces LTD of excitatory transmission in the prefrontal cortex which has 
the effect of inducing anhedonia. Blocking mGluR3 activation in this context prevent these 
stress-induced maladaptive changes to CNS physiology and motivational behavior.  Of the eight 
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known mGluRs, only mGluR3 and mGluR5 experience age related decline in expression in the 
prefrontal cortex which may contribute to an impairment in working memory. [34] mGluR3 
knockout mice show hyperactivity and impaired working memory across a number of tests (i.e. 
open field and T-maze tests). [35] This is of importance as both behaviors are endophenotypes of 
schizophrenia. Support for the apparent non-essential nature of mGluR3 in hippocampal long-
term potentiation was also provided from these knockout studies. Polymorphisms of mGluR3 
have been associated with psychosis and impaired cognition. [36] Reductions of dimeric mGluR3 
in the brains of schizophrenic individuals has been recorded as well as a strong correlation 
between SNPs in the mGluR3 gene and schizophrenia diagnosis. 
[37] Substantial evidence 
suggests activation of group II mGluRs, therefore reduction of excess glutamatergic tone, could 
be an efficacious manner by which to treat schizophrenia; however, a promising Group II agonist 
(LY2140023) failed to show efficacy greater than placebo and current standard of care in phase 
II clinical trials. [38] 
Other small molecule group II selective mGluR agonists and antagonists have been 
developed and used to further establish a wide range of potential therapeutic applications for the 
dual receptor system. [39] Group II mGluR activation shows relevancy in anxiety, addiction, and 
certain types of neuroprotection.  This is exemplified with dual mGluR2/3 agonist LY379268 
which showed promise as a neuroprotective agent via its ability to increase glial cell line-derived 
neurotrophic factor production in mouse striatum. [40] LY379268 also performed well in rodent 
models of cocaine dependence. [41] Another dual mGluR2/3 agonist (2R,4R-APDC) showed 
efficacy in a rodent model of Parkinson’s disease via a decrease in microglial markers in the 
substanti migra pars compacta which perhaps resulted in lower neuroinflammation. [42] Finally, 
another group II mGluR agonist improved both positive and negative symptom clusters in 
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patients suffering from schizophrenia. [43] Inhibition of these receptors may hold promise in 
treating obsessive-compulsive disorder, cognition, and Alzheimer’s disease. [39] However, one 
example, LY395756 a mGluR2 agonist and mGluR3 antagonist, failed to reverse chemical 
induced working memory impairment. [44] Unfortunately, due to the unselective nature of the 
chemical tools used in these studies it is unclear what the specific role, if any, of mGluR3 may 
be.  This is a frustrating fact to face as among all mGluR receptor subtypes, the activation of 
group II is perhaps the best studied due to extensive work published by Eli Lilly. [45] Some 
success has been had in probing the individual function of mGluR3 via preferential activation 
with the neuropeptide N-acetylaspartylglutmatae (NAAG). [46] Local peripheral application of 
NAAG highlighted that activation of mGluR3 may be beneficial in pain reduction as evidenced 
by positive results in a hindpaw inflammatory pain model. [47] Direct treatment of mGluR3 
receptors with NAAG or increasing NAAG levels with a NAAG peptidase inhibitor has revealed 
many more activities which may be specific to mGluR3. 
[48] However, these discoveries will not 
be discussed further due to the controversy surrounding NAAG. [49] This includes suspicion that 
commercially available NAAG has trace amounts of glutamate present which is the true 
chemical species activating the receptor.  Furthermore, NAAG agonism fails to activate K+ 
channels in cells transfected with both mGluR3 and a G-protein coupled potassium channel even 
when the commercial NAAG was purified to remove trace glutamate. [50] It should be noted 
though that NAAG peptidase inhibitors still appear to be viable compounds to selectively 
activate mGluR3 over mGluR2 although some wish to explore this pathway further being drawing 
a definite conclusion. [51]  
The same high conservation between mGluR2 and mGluR3 which challenges the 
development of selective orthosteric ligands also hinders the development of selective allosteric 
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modulators.  To date selective mGluR3 PAMs remain highly elusive despite the discovery of 
selective mGluR3 NAMs, mGluR2 PAMs, and mGluR2 NAMs. 
[39] Studies with a selective 
negative allosteric modulator showed that mGluR3 activation is required for long-term 
depression and fear extinction. [52] Another study implicated reduction in mGluR3 activity (out of 
a dual mGluR2/3 system) as having a significant effect in a reducing obsessive-compulsive 
disorder like activity in mice and in reducing depression like activity in rats. [53] Having a pure 
acting mGluR3 PAM may be able to produce effects similar to those seen with group II mGluR 
agonists but with increased efficacy or diminished side effects due to the intentional avoidance of 
mGluR2 activation. Indeed, it has been observed that activation of mGluR2 receptors amplifies β-
amyloid toxicity in neurons while activation of a mGluR2/3 dual system has neuroprotective 
properties associated with the treatment of Alzheimer’s disease. [54] 
Recently, it has been discovered that group II mGluRs are capable of interacting with 
non-group cellular receptors.  For example, mGluR3 activation has been reported to positively 
modulate mGluR5 signaling. 
[55] It has also been shown that mGluR2 can heterodimerize with 
serotonin 5-HT2A receptors [56] and activation of mGluR2 can greatly reduce serotonin-
stimulated increases in spontaneous excitatory postsynaptic potentials [57].  Knowing this, one 
might expect that mGluR3 can form heterodimers with other GPCRs and that these receptor 
species may play a critical role in mGluR3 chemical biology.
  
Current mGluR3 Positive Allosteric Modulators 
As previously mentioned, pure mGluR3 PAMs have remained elusive despite numerous reports 
of selective mGluR2 PAMS 
[39,45,58,59,60] and selective Group II mGluR PAMs [39,45,58].  Examples 
of compounds which display reasonable mGluR3 PAM character in the literature are rare (Figure 
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1.2).  Compound 1.1 was identified after a slight structural modification of a mGluR2 SAM 
yielded a compound which displayed NAM activity against mGluR2 but PAM activity at 
mGluR3. 
[61] This discovery highlights one challenge of drug discovery at is concerns allosteric 
modulators of mGluRs; seemingly slight structural modifications can completely oblate or 
change activity of a compound.  This phenomenon is commonly prescribed the phrase 
“molecular switch” and accompanies the traditionally steep SAR around molecules of interest. 
[62] Dual PAM 1.2a was identified from structure-activity-relationship studies around a group of 
known group II mGluR PAMs. [63] This chemical series has no activity at non-group II mGluRs, 
is systemically active, and efficacious in rat models of cocaine self-administration.  In 2018 
Mavalon Therapeutics patented a novel series of compounds which they disclosed as mGluR3 
PAMs despite a lack of group II selectivity (of type 1.2b). 
[64] The difficulty in developing a 
mGluR3 PAM is somewhat surprising, however, given that the group II mGluRs share only ~ 
75% sequence homology between their transmembrane regions. [63] 
 
Figure 1.2. Structures of allosteric modulators with known mGluR3 PAM activity. 
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Conclusion 
 Extensive pharmacological profiling has identified mGluR3 as an attractive target for a 
variety of CNS diseases. These diseases include such burdensome ones as schizophrenia, 
Alzheimer’s disease, Parkinson’s disease, anxiety, and drug dependence (see above). Against the 
backdrop of many large pharmaceutical companies leaving the area of CNS drug discovery the 
unmet need to not only identify new therapeutics but first new tool compounds to probe receptor 
function in the CNS is magnified. [65] In spite of great success in identifying the roles of group II 
mGluRs via probing with selective agonists, there has been historical difficulty in identifying 
mGluR3 specific processes.  Given that all therapeutics based on an approach of dual group II 
mGluR involvement have failed it is reasonable to believe that activation of each receptor 
individually may result in superior outcomes.  While orthosteric ligands have not yielded 
selectivity, targeting the less conserved allosteric site may provide selective small molecules.    
Indeed, allosteric ligands have already been developed with intra- mGluR group II selectivity 
(i.e. mGluR2 over mGluR3 selective NAMs). However no purely functioning or selective 
mGluR3 PAMs have been reported to date despite the large impact such a compound could have 
on advancing understanding of this receptor.  Given the anecdotal evidence that agonists of 
group II mGluRs hold more therapeutic potential than antagonists (see above) the benefit of a 
selective PAM becomes more striking.   The following sections of this chapter detail progress, 
discoveries, and lessons learned in the pursuit of a selective mGluR3 PAM with chemical matter 
originating from a high-throughput-screen. 
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Materials and Methods 
General Synthetic Methods and Instrumentation. 
 All chemical reactions were carried out employing standard laboratory techniques under 
air, unless otherwise noted. Solvents used for extraction, washing, and chromatography were 
HPLC grade. All commercially available reactants and reaction solvents were used as received 
without further purification.  Analytical thin layer chromatography was performed on 250 μm 
silica gel plates from Sorbent Technologies.  Analytical LC/MS analysis was performed on an 
Agilent 1200 LCMS with electrospray ionization in positive ion mode and UV detection at 215 
and 254 nM. Compounds submitted for assays were determined to be >95% purity by UV 
absorbance.  All NMR spectra were recorded on a 400 MHz Bruker AV-400 instrument unless 
otherwise noted. 1H chemical shifts were reported as δ values in ppm relative to the residual 
solvent peak (CDCl3 = 7.28, (CD3)2SO = 2.50, CD3OD = 3.31).  Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = 
quartet, m = multiplet, br = broad), coupling constant (Hz), and integration.  13C chemical shifts 
are reported as δ values in ppm relative to the residual solvent peak (CDCl3 = 77.16, (CD3)2SO = 
39.52, CD3OD = 49.00).  Low resolution mass spectra were obtained on an Agilent 1200 LCMS 
with electrospray ionization.  High resolution mass spectra were recorded on a Waters QToF-
API-US plus Acquity system with electrospray ionization.  Automated flash column 
chromatography was performed on a Teledyne ISCO Combiflash Rf system.  Preparative 
purification of library compounds was performed on a Gilson chromatography system using a 
GX-271 liquid handler and either a Luna 30 x 50 mm 5u C18 100A column using an acetonitrile 
/ 0.1% TFA (aq) gradient or a Gemini 30 x 50 mm 5u C18 110A column using an acetonitrile / 
0.05% NH4OH (aq) gradient. 
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 Following purification, final compounds were diluted to a concentration of 10 μM in 
dimethylsulfoxide (DMSO) in barcoded vials and registered with a 7-digit VU number. While all 
analogs presented in this chapter have a VUID this erroneous information is omitted for brevity 
and included only for featured compounds. Upon registration each compound is simultaneously 
uploaded into the DotmaticsTM database.  This database stores molecular pharmacology 
information gathered on each compound after assay and is maintained by the Vanderbilt Center 
for Neuroscience Drug Discovery (VCNDD). 
mGluR2/3 Calcium Mobilization Assay  
 All compounds which were subjected to a primary screen against mGluR2/3 utilizing this 
protocol were done so under a triple add procedure (Figure 1.3). In brief, compounds are added 
to cells followed by an EC20 then an EC80 concentration of glutamate.  Under this paradigm an 
analog can be tested for agonist, PAM, or NAM activity from a single experiment. 
 Gα15/TREx cells stably expressing rat mGlu3 were plated in black-walled, clear-
bottomed, poly-D-lysine coated 384-well plates in 20 μL of assay medium (DMEM containing 
10% dialyzed FBS, 20 mM HEPES, 25 ng/mL tetracycline, and 1 mM sodium pyruvate) at a 
density of 15K cells/well. The cells were grown overnight at 37 ºC in the presence of 5% CO2. 
The next day, medium was removed and the cells incubated with 20 μL of 2.3 μM Fluo-4, AM 
prepared as a 2.3 mM stock in DMSO and mixed in a 1:1 ratio with 10% (w/v) pluronic acid F-
127 and diluted in assay buffer (Hank’s balanced salt solution, 20 mM HEPES, and 2.5 mM 
probenecid) for 60 minutes at room temperature. Dye was removed, 20 μL of assay buffer was 
added, and the plate was incubated for 10 minutes at room temperature.  Ca2+ flux was 
measured using the Functional Drug Screening System (FDSS7000, Hamamatsu, Japan). After 
16 
 
establishment of a fluorescence baseline for about 3 seconds, the compounds of interest were 
added to the cells, and the response in cells was measured.  2.3 minutes later an EC20 
concentration of the mGlu3 receptor agonist glutamate was added to the cells, and the response 
of the cells was measured for 1.9 minutes; an EC80 concentration of agonist was added and 
readings taken for an additional 1.7 minutes.  All test compounds were dissolved and diluted to a 
concentration of 10 mM in 100% DMSO.  Compounds were then serially diluted 1:3 in DMSO 
into 10 point concentration response curves, transferred to daughter plates, and further diluted 
into assay buffer to a 2x stock.  Calcium fluorescence measures were recorded as fold over basal 
fluorescence; raw data was then normalized to the maximal response to glutamate. 
mGluR3 Thallium Flux Assay 
 In some instances, compounds were also screened against mGluR3 utilizing an 
endogenous signaling pathway which results in assay readout via thallium flux.  This assay was 
run in a similar fashion as outline above, with the following modifications.  Polyclonal rat 
mGlu3/HEK/GIRK cells were used for these studies. For dye loading, media was exchanged 
with Assay Buﬀer (HBSS containing 20 mM HEPES, pH 7.4) using an ELX405 microplate 
washer (BioTek), leaving 20 μL/well, followed by addition of 20 μL/ well 2× FluoZin-2 AM 
(164 nM ﬁnal) indicator dye (Life Technologies, prepared as a DMSO stock and mixed in a 1:1 
ratio with pluronic acid F-127) in Assay Buﬀer. After a 1 h incubation at room temperature, dye 
was exchanged with Assay Buﬀer, leaving 20 μL/well. Thallium ﬂux was measured at room 
temperature using a Functional Drug Screening System 7000 (FDSS 7000, Hamamatsu). 
Baseline readings were taken (2 images at 1 Hz; excitation, 470 ± 20 nm; emission, 540 ± 30 
nm), and test compounds (2×) were added in a 20μL volume and incubated for 140 s before the 
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addition of 10 μL of Thallium Buﬀer with or without agonist (5×). Data were collected for an 
additional 2.5 min then analyzed. 
Plasma Protein and Brain Homogenate Binding 
 Protein binding of select compounds was determined in plasma via equilibrium dialysis 
experiments utilizing RED plates (ThermoFisher Scientific, Rochester, NY).  Plasma was added 
to a 96 well plate containing test compound for a final compound concentration of 5 μM.  An 
 
Figure 1.3. Graphical representation of the triple add protocol used in primary screens at mGluR3 
utilizing a calcium mobilization assay. The solid black line represents signal in the absence of compound 
while the dashed blue lines represent signal in the presence of a PAM or NAM.  Potencies can be 
obtained after dosing at multiple concentrations from serial dilutions of compound stock  
 
aliquot of the plasma-compound mixture is then transferred to the cis chamber (red) of the RED 
plate and phosphate buffer (25 mM, pH 7.4) was added to the trans chamber.  The RED plate 
was sealed and incubated for 4 hours at 37 oC with shaking.  Aliquots from each chamber were 
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then diluted 1:1 with either plasma (cis chamber) or buffer (trans chamber) and transferred to a 
new 96 well plate.  Ice-cold acetonitrile containing an internal standard (50 ng/mL 
carbamazepine) is added to extract the matrices.  The plate was centrifuged (3000 RFC, 10 min) 
and supernatants transferred to another 96 well plate and diluted 1:1 with water in preparation for 
LC/MS/MS analysis Thermo Electron TSQ Quantum Ultra triple quad mass spectrometer, San 
Jose, CA).  Each compound was assayed in triplicate within the same 96-well plate and the 
fraction unbound was calculated using the following equation: 
𝐹𝑢 =
𝐶𝑜𝑛𝑐𝑏𝑢𝑓𝑓𝑒𝑟
𝐶𝑜𝑛𝑐𝑝𝑙𝑎𝑠𝑚𝑎
 
 Protein binding in brain homogenate can be calculated similarly with some modifications 
to the above procedure.  First, final compound concentration is adjusted to 1 μM from 5 μM. 
Second, naïve rat brains were homogenized in DPBS (1:3 w/w ratio of brain:DPBS buffer) using 
a Mini-Bead Beater machine in order to obtain brain homogenate, which was then used similarly 
to the plasma as previously described.  Fraction unbound was then calculated using the above 
equation, replacing Conc(plasma) with Conc(brain homogenate). 
 
Hepatic Microsomal Intrinsic Clearance 
 Human or rat hepatic microsomes (0.5 mg/mL) and 1 μM test compound were incubated 
in 100 mM potassium phosphate pH 7.4 buffer with 3 mM MgCl2 at 37 
oC while shaken.  After 5 
minutes NADPH (1 mM) was added to initiate microsomal reactions.  At time intervals of 0, 3, 
7, 15, 25, and 45 minutes  aliquots were removed and placed into a 96-well plate containing cold 
acetonitrile and an internal standard (50 ng/mL carbamazepine).  The plates where then 
centrifuged at 3000 rcf for 10 minutes at 4 oC and the resulting supernatant transferred to a new 
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96-well plate and diluted 1:1 with water for LC/MS/MS analysis (Thermo Electron TSQ 
Quantum Ultra triple quad mass spectrometer, San Jose, CA).  In vitro parameters of half-life 
(T1/2), intrinsic clearance (CLint), and predicted hepatic clearance (CLhep) are then calculated 
using the following equations after the slope from linear regression analysis of the natural log 
percent of remaining test compound as a function of time (k) has been calculated. 
𝑇1
2
=
ln(2)
𝑘
 
𝐶𝐿𝑖𝑛𝑡 =
ln(2)
𝑇1/2
×
𝑚𝐿 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛
𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
×
45 𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
𝑔𝑟𝑎𝑚 𝑙𝑖𝑣𝑒𝑟
×
20𝑎
𝑘𝑔 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
 
𝐶𝐿ℎ𝑒𝑝 =
𝑄ℎ × 𝐶𝐿𝑖𝑛𝑡
𝑄ℎ + 𝐶𝐿𝑖𝑛𝑡
 
Where a is a scale up factor (20 for human microsomes, 45 for rat), and Qh is species hepatic 
blood flow (21 mL/min/kg for humans, 70 mL/min/kg for rats). 
In vivo DMPK Experimental 
 IV pharmacokinetic experiments were conducted at the Vanderbilt Center for 
Neuroscience Drug Discovery in male rats (n = 2) at a dose of 1.0 mg/kg in a solution of 10% 
EtOH, 50% PEG 400, and 40% saline.  Each compound formulation was administered via IV to 
the jugular vein to dual-cannulated (carotid artery and jugular vein) adult male Sprague-Dawley 
rats, each weighing between 250 and 350 grams (Harlan, Indianapolis, IN.).  Whole blood 
collections from the carotid artery were performed at 0.033, 0.117, 0.25, 0.5, 1, 2, 4, 7, and 24 
hours post dose and plasma samples were prepared for bioanalysis.  Discrete oral PK 
experiments in rats were carried out analogously using a 3 mg/kg dose in a Tween 80 and 0.5% 
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methyl cellulose (MC) vehicle administered by oral gavage.  Whole blood collections from the 
carotid artery were performed at0.5, 1, 2, 4, 7, and 24 hours post dose.  Single time point samples 
of plasma and brain were collected after 1 hour from oral dosing of each compound to assess 
brain distribution (brain:plasma partition coefficient, Kp).  In vivo samples were analyzed via 
LC/MS/MS utilizing electrospray ionization (ESI). 
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Early Stage Structure-Activity Relationship Studies 
Discovery of VU0547533 Through High-Throughput Screening. 
 
 
Figure 1.4. Structures of promising chemical hits from the HTS screen performed at Vanderbilt 
University. Each compound is listed with corresponding potency and Glumax values.  
 Upon completion of the in-house HTS, a set of compounds emerged as the most 
promising leads (Figure 1.4).  Common structural features were identified among some (1.3-1.5) 
such as a central pyridazine core and a 3,4-dimethoxy aryl substituent.  Despite being the most 
promising compounds identified all suffered from modest potentiation. All also had potencies in 
the low to mid micromolar range with the exception of 1.3. This compound registered as a very 
weak potentiator but did so at sub-micromolar potency. Featuring a unique 4H-pyrido[1,2-
a]pyrimidin-4-one heterocyclic motif, 1.3 was also an attractive lead on the basis it reached into 
novel chemical space.  At the onset of the project it was envisaged that a SAR campaign 
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beginning at 1.3 could be the most promising path forward. It is a known phenomenon within 
GPCR allosteric modulator drug discovery that seemingly minor substituent changes on a 
scaffold can have profound consequences on that scaffold’s modulating ability. With this in mind 
the questionable efficacy of 1.3 was cast aside in favor of the compound’s apparent strong 
potency and unique fused heterocyclic motif.  Another attractive quality of this lead is the 
presumed facile analog synthesis which was eventually realized by a novel one-pot procedure 
developed concurrently with early medicinal chemistry efforts. [66] 4H-pyrido[1,2-a]pyrimidin-4-
one derivative 1.10 (or analogs thereof) can be readily prepared by the condensation reaction of a 
commercially available 2-aminopyridine with 4-chloro ethylacetoacetate mediated by 
polyphosphoric acid under solvent free conditions (Scheme 1.1).  Crude heterocycles can be 
purified via recrystallization to afford analogs with suitable purity for the proceeding one-pot 
transformation. First treating generic 1.10 with 2-thio-4-chloropyridazine and cesium carbonate 
in warm 1,4-dioxanes yields the substitution product which is not isolated.  Rather, the necessary 
components of the proceeding Suzuki-Miyaura cross coupling are added to the reaction vial 
followed by a brief purge with argon.  Continued heating then affords target analogs of nature 
1.11. Most analogs generated in this chapter were synthesized using this methodology or an 
obvious extension of it. Specialized synthetic schemes are provided when required. 
 
Scheme 1.1. Synthesis of 1.3 and analogs thereof (i.e. 1.11) by a one-pot methodology. Reagents and 
conditions: (a) PPA, 60-83%; (b) 2-thio 4-chloro pyridazine, Cs2CO3, 1,4-dioxane then aryl boronic acid, 
Pd(dppf)Cl2, H2O, 10-42% 
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Structure-Activity Relationships of Substitution Patterns on the VU0547533 (1.3) core 
 Initial SAR studies aimed to elucidate the impact that the simplest substituent changes on 
the western and eastern aromatic nucleuses of 1.3 could have on activity.  Screening of some 
functional groups in different positions of the 4H-pyrido[1,2-a]pyrimidin-4-one core (Figure 
1.5) implied that fluorinated analogs may be equivalent in activity compared to their chlorinated 
counterparts.  The small data set also showed an apparent preference for substitutions in the “2” 
or “3” positions of the scaffold as even a 3-methyl analog had modest activity. This was  
 
Figure 1.5. Graphical summary of analogs prepared surveying substituent changes on 1.3’s western 
aromatic core.  The left-hand chart shows %Glumax values with the cut-off for active PAMs marked in red.  
The right-hand chart shows EC20 values for the cut off for active modulators shown in red. An ideal 
PAM would have a high %Glumax value and a low EC20 value. 
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contradicted by the inactivity of a 3-trifluoromethyl group which may have been due to steric 
bulk or electronic factors.  When examining substituent tolerance on the eastern aromatic ring we 
were shocked to find all analogs tested were inactive, including replacing the phenyl system with 
some common heterocyclic motifs (Figure 1.6).  This finding highlighted the critical nature of 
the 3,4-dimethoxy substitution pattern found in both hit compound 1.3 and other hits 
from the HTS. Learning from both data sets we embarked on a library analog generation effort to  
 
Figure 1.6. Graphical summary of analogs prepared surveying substituent changes on 1.3's eastern 
aromatic core.  The left-hand chart shows %Glumax values with the cut-off for active PAMs marked in red.  
The right-hand chart shows EC20 values for the cut off for active modulators shown in red. An ideal 
PAM would have a high %Glumax value and a low EC20 value. 
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create analogs of differing substitutions on the western aromatic ring paired with novel eastern 
phenyl substitutions (Table 1.1). Analogs featuring an internal alkyne (1.15-1.17) were 
synthesized according to the procedure mentioned previously utilizing Sonogashira cross 
coupling conditions in place of Suzuki-Miyaura conditions. Generally, all analogs prepared 
under this ideology failed to be remarkable. If potentiators at all, analogs struggled to reach 
the40% Glumax cut-off required for consideration as PAMs. A few general observations could be 
made from this data set.  Shifting the presumed key 3,4 di-methoxy eastern aryl substitution 
pattern to a 2,3 di-methoxy pattern within the context of a fluorinated western ring (1.13) or a 2,5 
di-methoxy pattern (1.14) indicated such a change is frivolous. Fusing the methoxy groups 
together into a benzodioxolane motif (1.18 and 1.20) was also fruitless.  It appeared that eastern 
3-pyridine aryl analogs (1.23-1.26) were not tolerated but 2,6-dimethylpyridine analogs could be 
weak potentiators depending on the nature of the R group on the western ring (i.e. 1.21 vs 1.33).  
 The final aspect of 1.3 to be subjected to peripheral interrogation was the internal 
thiopyridazine motif. As summarized in Table 1.2, multiple scaffolds were examined but none 
were particularly promising. Exchange for a thiopyridine or thioaryl ether linker (1.34 and 1.35, 
respectively) generated compounds with aggregable potencies but which barely classified as 
potentiators. The 1,4 arrangement of substituents around the central ring is apparently of 
importance as the angular analogs 1.36 and 1.37 were inactive. Surprisingly, phenolic reagents 
failed to react successfully in the one-pot methodology used to fuel analog generation and 1.42 
was the only phenol analog synthesized, and subsequently found to be inactive. A pyrimidine 
ether linker (1.41) and amino pyridazine linker (1.43) also were found inactive.  The observation  
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Table 1.1. Structures of paired eastern/western ring substituent modifications 1.12 – 1.33 and associated 
PAM activity from duplicate or triplicate runs at rat mGluR3. Calcium mobilization responses for each 
compound are reported as a percentage of the maximum glutamate release.  
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that aryl thioether 1.35 had some trace activity was of great interest to us given that it lacked the 
pyridazine heterocycle common to some of the initial HTS hits. When compared to 1.38 
(synthesized as shown in Scheme 1.2 via a key Blaise reaction [67]) primary assay results 
indicated that the sulfur atom is critical for activity. Believing this may be a fruitful change to 
pursue further, analogs were generated in a library fashion holding the thioaryl moiety constant.  
The results were mixed (Table 1.3). First, it was intriguing to see some analogs possessed weak 
NAM activity in the context of fluorinated eastern aryl systems (1.47,1.53) and pyridyl eastern 
systems (1.64-1.66) seemingly regardless of the substituent on the western fused heterocycle. 
Analog 1.52, with a 3-Me substituent found to be active earlier, had modest potency with low 
potentiation as did 1.57 with a novel 2,6-dimethylpyridine moiety. Otherwise all analogs failed 
to be spectacular. The weak NAM activity of these analogs prompted the more thorough 
inspection of fluorinated eastern aryl system in the context of 1.3.  
 
Scheme 1.2. Synthesis of 1.38. Reagents and conditions: (a) Zno, THF, 41%; (b) 2-amino-5-
chloropyridine, PPA, 23% 
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Table 1.2. Structures of modifications 1.34 – 1.43 aimed at examining different linker systems between 
eastern and western aryl motifs. Associated PAM activity is from duplicate or triplicate runs at rat 
mGluR3. Calcium mobilization responses for each compound are reported as a percentage of the 
maximum glutamate release. 
 
 
 
 
 
 
30 
 
Table 1.3. Structures of analogs 1.47 – 1.69 aimed at examining different eastern aryl systems in 
conjunction with thioaryl ether analogs of 1.3. Associated PAM activity is from duplicate or triplicate 
runs at rat mGluR3. Calcium mobilization responses for each compound are reported as a percentage of 
the maximum glutamate release. 
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Discovery of Structurally Novel mGluR3 Negative Allosteric Modulators. 
 Inspired by observations of NAM activity in our initial SAR survey we sought to 
investigate the impact of fluorinated eastern aryl system with more vigor. Delightfully, we 
discovered a suite of compounds with legitimate NAM activity (Table 1.4).  A number of 
differentially fluorinated analogs were synthesized which displayed a rather clear structure-
activity-relationship correlation.  That is, fluorine in the para position of the eastern aryl ring is 
seemingly highly detrimental to compound activity as all analogs with this structural feature 
were found inactive.  In the case of trifluorinated analogs 1.82-1.84 some weak NAM activity 
was retained despite the unfavorable para fluorine but these analogs also became weakly active 
modulators of mGluR2.  Fluorine in the meta position of the eastern aryl system was favorable 
for activity, as is a 2-chloro substituted western fused aryl system (see 1.76-1.78 and 1.79-1.81).  
Along routine extensions of SAR unrelated to this hypothesis we also discovered three 
substituted pyridyl analogs with NAM activity as well.  A pair of thiomethyl substituted pyridyl 
analogs (1.85 and 1.86) showed NAM activity but with less impressive potencies as the active 
fluorine derivatives, albeit in the case of 1.85 with strong efficacy.  This pair also reinforced the 
finding that the 2-chloro substituted 4H-pyrido[1,2-a]pyrimidin-4-one core engenders more 
active compounds. Methoxy substituted pyridyl analog 1.87 is highly active and shows that 
sulfur substituted pyridine analogs may be inferior.  Perhaps the most impressive aspect of these 
compounds is their inactivity at the other group II mGluR receptor, mGluR2.  This novel class of 
selective mGluR3 NAMs is hindered, however, but very poor solubility in DMSO limiting 
potential applications as tool compounds. Also, the selectivity profile of these compounds 
against other mGluRs is unknown.  In addition to these drawbacks the two most activate analogs 
1.70 and 1.87 exhibited high plasma protein binding in rats (Rat Fu = 0.001  
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Table 1.4. Structures of fluorinated eastern aryl system analogs and others displaying NAM character 
1.70 – 1.87. Associated NAM activity is from duplicate or triplicate runs at rat mGluR3 or rat mGluR2. 
Calcium mobilization responses for each compound are reported as a percentage of the minimum 
glutamate release. * denotes average from a total of nine runs 
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and 0.007, respectively). In the same species both compounds also exhibited moderate to high 
predicted hepatic clearance; 1.70 = 64.2 mL/min/Kg and 1.87 = 51.9 mL/min/kg. Given these 
drawbacks, along with the knowledge that mGluR3 NAMs with better DMPK properties were 
already known [68,69] we continued to advance our efforts to discover a PAM without further 
consideration of these scaffolds. 
Middle Stage Structure-Activity Relationship Studies 
Exploration of Replacements for Western 4H-pyrido[1,2-a]pyrimidin-4-one core 
 At this juncture it appeared that novel western aryl systems may be required to generate 
analogs of 1.3 which could carry with them an agreeable level of PAM activity.  Thus far the 
fused [6.6] ring system found in 1.3 has been held constant and we now looked to incorporate 
other fused heterocyclic systems as well as monocyclic or aliphatic systems.  Additionally, we 
desired to probe the effect of methyl substituents on the methylene carbon of the aryl thioether 
linker when synthetically feasible (Table 1.5).  The three alkyl analogs tested (1.88, 1.95, and 
1.97) hinted that aromatic systems are key for activity.  Substituted benzyl analogs (1.92-1.94) 
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Table 1.5. Structures of analogs 1.88 – 1.109 aimed at examining different western aryl or alkyl systems 
of 1.3. Associated PAM activity is from duplicate or triplicate runs at rat mGluR3. Calcium mobilization 
responses for each compound are reported as a percentage of the maximum glutamate release. 
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were either inactive or weak potentiators.  A set of three pyrimidine analogs 1.89 – 1.91 served 
to show that the oxidation state of the sulfur atom in the linker region was of no concern for 
activity, at least in that particular chemical context.  Curiously, 1.89 displayed different behavior 
over two discrete assays on two different days moving from a highly potent, weakly efficacious 
compound to a low potency weak potentiator.  This was an early warning sign of reproducibility 
issues which would later be encountered (and more recognized) when assaying against our in 
house mGluR3 cell line utilizing calcium mobilization. Benzimidazole, quinoline, and 4-methyl 
quinazoline groups produced weak potentiators. The latter, 1.101, was able to produce a 
reasonable %Glumax value when compared to almost all other compounds screened thus far.  This 
prompted further exploration of substitutions at the 4 position as well as on 6 position of the 
quinazoline core to match substitution patterns seen in 1.3.  These analogs where synthesized 
according to Scheme 1.3.  A tandem amide formation / cyclization between commercially 
available 2-aminobenzamides and chloroacetic acids provides intermediates of nature 1.110. [70]   
These intermediates can be converted to quinazolines first by treating with phosphorus 
oxychloride followed by a desired nucleophile to arrive at generic compounds such as 1.112. 
From there target analogs were acquired following the method presented in Scheme 1.1.  This 
brief survey indicated that methoxy (1.106), dimethylamine (1.107), and piperidine (1.109) 
groups at the four position of the quinazoline core were unable to improve %Glumax values.  
Additionally, a 6-chloro analog (1.108) and two 6-fluoro analogs with either a R or S methyl 
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group on the methylene carbon of the linker (1.103 and 1.104) failed to improve efficacy as well. 
However, both 1.103 and 1.104 achieved sub-micromolar potencies.  This survey of chemical 
space failed to produce an analog with desirable potency and efficacy but did however serve to 
stimulate ideas for future directions.  We were intrigued about the possible SAR around 4 and 6 
– substituted quinazolines as well as encouraged to see that these systems in the western region 
were apparently a welcome change for efficacy over the endogenous 4H-pyrido[1,2-a]pyrimidin-
4-one core of 1.3.  Therefore, we sought to generate further analogs to incorporate this chemical 
motif and expand our SAR.   
 
Scheme 1.3. Synthesis of generic substituted quinazolines akin to 1.112. Reagents and conditions (a) 
N,N-diisopropylamine, HATU, DCE, 46-70%; (b) POCl3, N,N-diisopropylamine, benzene, 65-77%; (c) 
NuH, triethylamine, THF, quant. Nu = nucleophile 
 
Confirmation of Pyridazinone Analog Connectivity and Pursuit of N-alkylated analogs 
During our investigation into alternative linkers for the thioheteroaryl ether of 1.3 (See 
Table 1.2) it did not escape our attention that linkers derived from a pyridazinone core could be 
suitable replacements. However, it was at first unclear what the outcome of the substitution 
reaction between a pyridazinone and a generic primary chloride such as 1.10 would be in terms 
of N vs. O alkylation (Figure 1.7). [71] To address this issue two compounds were prepared 
(1.117 and 1.120) using known chemistry such that the heteroaryl ether linker of 1.120 would be 
guaranteed. The 13CNMR spectra of 1.120 indicated the methylene carbon of the linker region  
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Figure 1.7.  (A) The two possible products arising from a substitution reaction of 1.10 and a generic 
pyridazinone.(B) Synthesis of 1.117 and 1.120 for comparative 13CNMR measurements to confirm 
structure of 1.117.  Reagents and conditions: (a) Cs2CO3, 1-4-dioxanes; (b) NaH, DMF. 
 
has a chemical shift of 78 ppm.  The product obtained from reacting 1.115 with pyridazinone 
1.116 utilizing conditions outline in Scheme 1.1 had a methylene carbon linker 13CNMR 
chemical shift of 54 ppm.  This led us to the conclusion that compound 1.117 must not have the 
same linker atom connectivity as 1.120 thus having the N-alkylated structure as depicted in 
Figure 1.7.  This issue was not encountered with thiopyridazines previously employed in analog 
generation, as a crystal structure of an intermediate obtained using the protocol in Scheme 1.1 
showed the desired regioselectivity was exclusively obtained (Figure 1.8).  We were pleased 
with the unusually high regioselectivity of this reaction [72] and thus engaged in an effort to  
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Figure 1.8. Crystal structure of 1.121 
 
develop analogs around this new chemical infrastructure (Table 1.6).  During this analog 
generation effort, we sought to incorporate 4-substituted quinazoline cores for the western aryl 
segment in light of improved promise this motif showed over the 4H-pyrido[1,2-a]pyrimidin-4-
one core of 1.3.  To our delight, this hypothesis was supported when 1.122 was found to be 
essentially inactive while a number of quinazoline N-alkylated pyridazinone analogs produced 
%Glumax values far above earlier analogs.  The SAR survey was divided into two categories: 4-
aminoquinazolines (1.123 – 1.149) and 4-oxyquinazolines (1.150 – 1.169).  A variety of 
compounds in each group were also prepared as fluorinated quinazoline analogs for assessment 
of that atom’s impact on activity.  Several cyclized secondary amine analogs (i.e. 1.124, 1.126, 
1.129, 1.134) were capable of modest potentiation but were burdened with less than ideal 
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potencies.  These compounds retained promise however after it was found that they were all 
inactive at mGluR2.  Fluorinated quinazoline homologues of these compounds (1.125, 1.127, and 
1.130) showed either no significant improvement in activity or complete loss thereof. This 
indicates in the context of cyclic secondary amines at the 4-position of the quinazoline core 
fluorine substitutions are a hindrance.  Uncyclized secondary amine analogs (1.123, 1.132, and 
1.135) all were shown to be low potency potentiators.  Other analogs in this group featured 
substituted morpholine / thiomorpholines, substituted piperidines and pyrrolidines, and a 
piperazine.   These all were unfortunately found to be either weakly active or low potency 
potentiators at best.  In the context of primary amine substituents, it appears steric bulk is 
preferred and two analogs (1.146, 1.147) produced impressive %Glumax values compared to less 
sterically demanded counterparts.  However, initial assessment shows that this structural feature 
allows these compounds to activate mGluR2 more strongly.   
The data set derived from screening of 4-oxyquinazolines shows more robust activity.  
Here we see an opposite trend as before where sterically demanding analogs (1.159-1.161) suffer 
from greatly reduced activity while less hindered analogs display activity superior to the 
collection of 4-aminoquinazoline analogs.  Of particular note are compounds 1.150, 1.151, and 
1.168 which show potencies approaching the desired sub-micromolar range while 
simultaneously potentiating the receptor with agreeable efficacy.  Two of these compounds 
(1.150, 1.151) were shown to be inactive at mGluR2.  Therefore these analogs could well be 
early precursors to a selective mGluR3 PAM.  Some relevant DMPK parameters were assessed 
on these compounds and the profiles obtained were typical of allosteric modulators of GPCRs.  
That is, all compounds displayed high clearance and low free fractions in plasma (Table 1.7).  A 
full DMPK profile was obtained on 1.150 and we 
42 
 
Table 1.6. Structures of analogs 1.122 – 1.169 aimed at examining different analogs of N-alkylated 
pyridazinone derivatives of 1.3. Unless otherwise stated, R2 = H. Associated PAM activity is from 
duplicate or triplicate runs at rat mGluR3 or rat mGluR2. Calcium mobilization responses for each 
compound are reported as a percentage of the maximum glutamate release. * denotes average from a total 
of nine runs 
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were disheartened to find this attractive molecule had low brain penetrance and relatively low 
total concentration in the brain, although free fraction in brain homogenate was quite high.  We 
concluded that the low concentration of the compound in both plasma and brain homogenate was 
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Table 1.7. In vitro and in vivo DMPK profiles of select active compounds in Sprague-Dawley rat and 
human.  Liver microsomal clearance was predicted using the well-stirred model with 20 and 45 g liver per 
kg body weight and 21 and 70 ml/kg hepatic blood flow for human and rat, respectively.  PPB = plasma 
protein binding, BHB = brain homogenate binding. 
Parameter 
1.148 
(VU6010539) 
1.150 
(VU6009817) 
1.151 
(VU6010541) 
1.168 
(VU6010463) 
In Vitro PK 
Rat CLHEP 66.1 69.2 68.8 66.5 
Human CLHEP  18 
  
Rat PPB (Fu) 0.016 0.005 0.002 0.005 
Human PPB (Fu)  0.19     
In Vivo Rat PK 
Plasma (ng/mL)  10.9     
Brain (ng/mL)  30.2     
Brain:Plasma 
(Kp) 
 
0.39 
    
BHB Fu 
 0.22     
 
likely a direct consequence of the molecule’s rapid predicted hepatic clearance.  The fluorinated 
analog of this compound with similar mGluR3 activity (1.151) showed no improvement on 
predicted clearance or free fraction in rat. 
 Overall we were encouraged by the data obtained on 4-oxyquinazoline analogs.  These 
analogs represented a chemotype capable of low potency, selective potentiation of mGluR3 over 
mGluR2.  Moving forward we sought to lower the potency of these analogs into the sub-
micromolar range while also improving the DMPK properties without losing selectivity.  Our 
first approach to meet this goal focused on finding replacements for the 3,4di-methoxy aryl 
system – one that is known to be a metabolic liability (Table 1.8).  This SAR survey focused 
primarily on non-fluorinated 4-OMe quinazoline cores and we were disappointed to find that 
nearly all compounds synthesized were found to be inactive.  This inactivity was common to 
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Table 1.8. Structures of analogs 1.170 – 1.201 aimed at examining replacements for the 3,4 di-methoxy 
aryl system of promising 4-oxyquinazoline analogs. Associated PAM activity is from duplicate or 
triplicate runs at rat mGluR3. Calcium mobilization responses for each compound are reported as a 
percentage of the maximum glutamate release. 
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both substituted phenyl systems as well as a variety of heterocyclic systems.  The only 
noteworthy analog (1.170) showed no drastic improvement in activity as compared to the active 
di-methoxy analogs previously identified.  However, 1.170 showed distinct improvement in 
predicted hepatic clearance as compared to 1.150 in both humans (9.75 vs 18) and rats (58.6 vs 
69.2) reconfirming that the 3,4-dimethoxy aryl group which is apparently critical for activity is 
also a metabolic liability.  A small sample of O-allyl analogs (1.186-1.188) were tested and 
found to be inactive.  In accordance with earlier observations, fluorination of the quinazoline 
core in the context of various substitution patterns did not provide drastic improvements in 
activity; fluorinated analogs (1.197-1.201) were all found to be low potency potentiators.  When 
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reflecting back on previous SAR studies we were not necessarily surprised at the results obtained 
here.  In fact, these results again support the necessary nature of the 3,4di-methoxy aryl system 
for activity which is echoed when examining replacements for this motif in other chemical 
contexts (Figure 1.6, Table 1.1, Table 1.3). 
Examination of Different N and O-alkylated Heterocyclic Central Aromatic Systems 
At this stage we believed in the critical nature of the eastern 4-oxyquinazoline aryl 
system.  We also believed strongly in the necessity of the eastern 3,4-di-methoxy aryl system for 
activity but still believed some modifications may be required to reduce metabolic liabilities and 
improve analog activity.  Therefore, moving forward, we considered it important to embark on 
an exhaustive screen of different “linker” systems.  Namely, we sought to synthesize different N-
alkylated heterocycles as well as other O-alkylated systems as replacements in the central 
aromatic linker region.  While an approach similar to this has already been undertaken (Table 
1.2), we believed the new quinazoline core combined with a more exhaustive survey of “linker” 
motifs could still be fruitful (Table 1.9).  Synthesis of these analogs follows the general reaction 
schemes previously presented with a diverse set of commercially available building blocks.  A 
select number of O-alkylated heterocyclic systems were derived from primary alcohols of type 
1.118 which can be readily prepared (Scheme 1.4). [73]  In brief, the large library of analogs 
prepared under this ideology failed to improve on the activity of 1.150 (or related compounds).  
 
Scheme 1.4. Synthesis of primary alcohol 1.118. Reagents and conditions (a) KOAc, DMF; (b) LiOH, 
THF, H2O, 57% for two steps. 
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Table 1.9. Structures of analogs 1.203 – 1.282 which incorporate a variety of N and O-alkylated aromatic 
systems in the “linker” region. Associated PAM activity is from duplicate or triplicate runs at rat mGluR3. 
Calcium mobilization responses for each compound are reported as a percentage of the maximum 
glutamate release. 
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as one reviews the data presented herein it is obvious that many linker systems were interrogated. 
It took us by surprise to see that the only active compound from this data set (1.212) was of a 4-
aminoquinazoline series in spite of experimental data from previous rounds of SAR which 
suggested sterically unencumbered 4-oxyaminoquinolines were superior for activity.  Otherwise 
the only other intriguing detail worth noting is three structurally distinct analogs (1.214, 1.221, 
and 1.249) displayed weak NAM activity. 
 The discovery that N-alkylated pyridazinone analogs were capable of potentiation, albiet 
with poor potencies, remained a major discovery for this project.  This had hinted to the 
possibility that “bent” analogs were more efficacious than linear counterparts.  The term bent 
refers to how simple molecular modeling software (Chem 3D Version 15.0) shows that analogs 
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of type 1.150 have a V-shape such that the 3,4-di-methoxy aryl motif resides perpendicular to 
and above the 4-methoxyquinazoline ring.  This is, of course, a striking structural difference 
between linear analogs of type 1.3 and runs against observations that allosteric modulators of 
mGluRs are often fairly linear and uncyclized compounds. [74] It was for this reason we 
considered the structural change of these analogs to be the major basis for their activity.  We then 
designed a number of analogs with different heterocyclic linkers to mimic this shape as part of 
the analog generation effort already mentioned.  These analogs (1.257-1.281) unfortunately were 
found to be inactive in our cellular assays despite having similar predicted shapes.  Therefore, we 
put to rest our putative “bent” hypothesis and in a larger context put to rest our pursuit of analogs 
which derive their chemotype from 1.3.  This decision was made for two primary reasons: 
reproducibility issues were being encountered in our primary assay against mGluR3 (utilizing 
calcium mobilization for read out) and it appeared the potential for structural modifications to 
improve the activity of 1.150 and related compounds was meager at best. 
Late Stage Structure-Activity Relationship Studies 
Return to High-Throughput Screen Data for New Chemotypes to Pursue; Elimination of 
VU0493906 (1.6) From Consideration. 
 
Although much time had been spent and a lot had been learned about the SAR around 
1.3, it was decided to move on from that particular scaffold and apply some of our knowledge to 
other chemotypes which the HTS had identified as potential hits (Figure 1.4) Both 1.4 and 1.5 
seemed like logical new starting points given the common conserved N-alkylated pyridazinone / 
3,4-dimethoxy aryl motif. Keeping in mind that most success of the project thus far had been 
driven by investigation into alternative western (now to be referred to as northern) aryl systems it 
was encouraging to see how 1.4 and 1.5 were readily suited for SAR at this position.  We were 
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also intrigued by 1.6 which arguably could have been considered the strongest lead from the 
beginning. Compound 1.7 was barred from further consideration at this juncture given its low 
activity and failure of freshly obtained material to reconfirm activity in our assay. In the SAR 
which follows 1.4 and 1.5 will be considered a single hit given their structural similarity and that 
analogs thereof can be readily obtained using previously described chemistry.  Analogs of 1.6 
will be approached discreetly and can also be readily accessed in just two synthetic operations 
(Scheme 1.5). [75] Given the structural novelty of this hit SAR studies were conducted here first 
and focused on coupling diverse carboxylic acids onto the 2-thiazolamine core 1.284. Akin to 
results from previous SAR studies undertaken, we discovered that a diverse range of chemical 
matter rendered analogs of 1.6 inactive (Table 1.10).  Most of the diversity incorporated was of 
small, aliphatic type but inactivity was also discovered in aromatic analogs (1.286,1.287,1.295, 
1.296, 1.300-1.302) as well as bulkier analogs (1.289,1.303).  Not shown here and still inactive 
were several analogs with fluorine and methoxy incorporated onto the chromane skeleton.  
Attempts to remove the cyclic constraints of 1.6 also failed to produce viable compounds 
(1.310,1.311).  
 
Scheme 1.5. Synthesis of analogs of 1.6.  Reagents and conditions (a) I2, thiourea, EtOH, 35%; (b) 
DMAP, EDC-HCl, DMF, variable yields. 
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Table 1.10 Structures of analogs 1.286 – 1.311 which investigate diversity around the amide portion of 
1.6.  Other analogs which modify the chromane core are included Associated PAM activity is from 
duplicate or triplicate runs at rat mGluR3. Calcium mobilization responses for each compound are 
reported as a percentage of the maximum glutamate release. * Denotes data obtained from thallium flux 
assay on compounds not tested in calcium mobilization 
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During the course of this SAR study a decision was made to transfer primary screening of 
analogs from the historically used calcium mobilization assay to a thallium flux assay.  This 
change was prompted after concerns over the reproducibility of the calcium mobilization assay 
had reached a critical level.  The cell lines which the thallium flux assay is performed on are not 
only more stable but the signaling pathway used for thallium mobilization is endogenous to the 
cells, as opposed to a foreign pathway that cells utilizing the calcium mobilization pathway had 
to adopt.  Despite these strong arguments to favor thallium flux assay some analogs synthesized 
around 1.6 were also found to inactive in their respective primary screens.  This, of course, did 
nothing to discredit the merit of the new assay and moving forward thallium flux was used to 
screen new analogs.  Rather, the overwhelming inactivity served to discredit 1.6 as a potential 
new lead molecule for efforts to identify a mGluR3 PAM. 
Structure-Activity-Relationship studies around VU0497808 (1.4) and VU0497814 (1.5) and 
abandonment of efforts towards identifying a mGluR3 PAM 
 After multiple rounds of failed hypothesis and several hundred inactive molecules 
synthesized, we arrived at the conclusion to pursue the last remaining hits from the HTS, 1.4 and  
66 
 
Table 1.11. Structures of analogs 1.312 – 1.356 which investigate diversity around the “northern” linker 
and head groups.  Associated PAM activity is from duplicate or triplicate runs at rat mGluR3. Calcium 
mobilization responses for each compound are reported as a percentage of the maximum glutamate 
release. * Denotes analogs which where inactive in thallium flux assay despite activity in calcium 
mobilization. ** Denotes data obtained from thallium flux assay on compounds not tested in calcium 
mobilization 
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1.5. As mentioned previously due to the structural similarity of these two compounds SAR 
around the pair was conducted in unison (Table 1.11).  We began by synthesizing a library of 
compounds to investigate different “northern” linker and head groups.  While a number of 
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analogs prepared in this series displayed weak potentiating ability in calcium mobilization 
assays, select analogs failed to recapitulate that activity when tested in thallium flux assay 
(1.313, 1.315, 1.317,1.322, 1.325, 1.329).  Otherwise, we were again witness to how a decent set 
of chemical diversity failed to improve activity of the parent hit molecule.   This raised alarm and 
brought back concerns encountered with previous analogs (i.e. 1.89) in which data was not 
consistent over a series of runs on discrete days with the calcium mobilization assay.  With 
official hesitation on the quality of the chemical matter that the HTS provided us (as well as the 
quality of data we had been basing SAR around on) we continued to pursue analog generation 
efforts.  Next, we reflected upon the northern aryl amide substituted compounds 1.317 and 1.325 
and inspired by their potential activity and ease of rapid diversification decided to synthesize a 
library aimed at expanding the diversity of amide substituents (Table 1.12).  In stride with earlier 
results all analogs tested where inactive in the thallium flux assay.  Secondary cyclic and acyclic 
amines were tested, but not primary amines.  Perhaps primary amines then could hold activity 
although almost certainly not.  Lastly, several analogs were synthesized which varied the alkyl 
group attached to the oxygen at the para position of the ring (not shown).  Some alkyl 
replacements for the methoxy group at this position were ethyl, D5-ethyl, propyl, allyl, butyl, 
cyclopropyl methylene, cyclobuytl methylene, and neopentyl methylene.  The rationale behind 
this library was that activity of the 3-4-dimethoxy group could be retained while mitigating 
clearance labilities.  However, these analogs were also found to be inactive. 
 Having now confirmed inactivity of our analogs against an assay featuring a more stable 
cell line which utilizes an endogenous signaling pathway (thallium flux) and also observing how 
analogs which are active against a calcium mobilization assay are inactive against the thallium  
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Table 1.12. Structures of analogs 1.357 – 1.373 which incorporate diversity around the amide portion of 
the molecule as indicated.  Associated PAM activity is from duplicate or triplicate runs at rat mGluR3. 
Calcium mobilization responses for each compound are reported as a percentage of the maximum 
glutamate release. * Denotes analogs which where inactive in thallium flux assay despite activity in 
calcium mobilization. ** Denotes data obtained from thallium flux assay on compounds not tested in 
calcium mobilization 
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flux assay we reexamined some of our previous promising compounds.  Perhaps to no surprise, 
although to our great dismay, it was found that our first HTS hit 1.3 as well as our most 
promising compounds 1.148, 1.150, 1.151, and 1.168 were all inactive in the thallium flux assay.  
This fact combined with poor DMPK profiles of lead molecules, irreproducibility of data in 
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calcium flux assay, and intractable SAR around every chemical context studied forced our hand 
to abandoned this project.   
Summary and Future Directions 
 Several hundred analogs (many were intentionally omitted from this thesis chapter due to 
redundant inactivity) of chemotypes provided by an HTS screen were synthesized and tested 
against one or two primary assays run within the VCNDD to asses activity against mGluR3.  
While some of these analogs displayed weak activity in the calcium mobilization assay, all 
analogs were found to be inactive in the thallium flux assay.  The latter uses a signaling pathway 
endogenous to mGluR3 while the calcium mobilization assay does not.  Both assays were 
performed on rat mGluR3.  Furthermore, analogs which displayed activity in the calcium 
mobilization assay did so with a great deal of variability between assay runs on discrete days.  A 
select few analogs had either partial or full DMPK profiles assessed which indicated that our best 
analogs were predicted to be highly cleared in both humans and rats.  The course of our SAR 
campaign lead us to discover a series of structurally novel, selective mGluR3 NAMs with good, 
reproducible activity in the calcium mobilization assay.  However, these analogs remain untested 
in the thallium flux assay and have worse DMPK profiles as compared to other known mGluR3 
NAMs.  As this thesis chapter is concerned work halted after exploration of the SAR around 1.4-
1.6.  The closest this study came to a selective mGluR3 PAM was the discovery of compounds 
like 1.150, however this data is in question given the variability of the assay which provided it. 
The effort within the VCNDD to discover a mGluR3 PAM did continue though and analogs 
designed around the control compound for our assays (same chemical family as 1.2) were shown 
to have reproducible activity.  To date, these findings have not been published.  It appears clear 
that the chemical matter identified by the HTS was a sub-optimal starting point for our medicinal 
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chemistry campaign as 1.3 failed to show reproducible activity in our calcium mobilization assay 
and was found to be inactive in the thallium flux assay.  It is the goal of this thesis chapter to 
have shown that another HTS (or other source of novel chemical matter) is required to discover 
new molecules from which to begin the pursuit of a selective mGluR3 PAM again.  It should also 
be noted that reexamining of the primary assay should be conducted to ensure assay results are 
reliable for future endeavors. 
Experimental Methods 
General Synthetic Methods and Instrumentation 
 All reagents and solvents were commercial grade and used as received.  All reactions 
were carried out employing standard chemical technique under air, unless otherwise noted.  Thin 
layer chromatography (TLC) was performed on glass-backed silica gel of 250 μm thickness.  
Visualization was accomplished with UV light and/or the use of KMnO4 stain.  Analytical HPLC 
was performed on an Agilent 1200 LCMS with UV detection at 215 and 254 nm and 
electrospray ionization.  MS parameters were as follows: capillary voltage: 3000V, nebulizer 
pressure: 40 psi, drying gas flow: 11 L/min, drying gas temperature: 350 oC.  Samples were 
separated on an internal column (Thermo Accucore C18 2.1 x 30 mm, 2.6 μm) before ionization 
with the following solvent gradient: 7% to 95% MeCN in H2O (0.1% TFA) over 1.6 min, hold at 
95% MeCN for 0.35 min, 1.5 mL/min flow, 45 oC. Chromatography on silica gel was performed 
using Teledyne ISCO pre-packed silica gel columns using gradients of EtOAc/Hexanes or 
DCM/MeOH.  1H and 13C NMR spectra were recorded on Bruker DRX-400 (400 MHz) 
instrument and chemical shifts are reported in ppm relative to residual solvent as outlined 
previously in this chapter 
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General synthesis of substituted 2-(chloromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one 
derivatives (i.e. of type 1.10) 
 To a round bottom equipped with a heavy stir bar was added substituted 2-aminopyridine 
(1 eq, 1 mmol) followed by polyphosphoric acd (PPA, 5x mass of 2-aminopyridine).  The 
mixture was sealed then warmed to 120 oC.  Once freely stirring, ethyl 4-chloroacetoacetate (1 
eq, 1 mmol) via syringe in a single portion.  Stirring was continued at 120 oC for two hours at 
which time the reaction mixture was immediately poured into 15 mL ice water and stirred for 15 
minutes.  The solution was then diluted with DCM (40 mL) and washed twice each with 
saturated aqueous sodium bicarbonate (10 mL portions) and brine (10 mL portions).  The 
resulting organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo.  
Crude product is purified either by recrystallization from a 1:1 mixture of MeOH:EtOAc or via 
normal phase chromatography. 
 
2-(chloromethyl)-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one (1.376). Purified using Teledyne 
ISCO Combi-Flash system (liquid loading, 4 G column, 30-70% EtOAc/Hex, 25 min run) with 
desired material eluting around 35% EtOAc.  White powder, 37% yield.  1HNMR (400.1 MHz, 
CDCl3) δ (ppm): 8.94 (1H, m), 7.70 (2H, m), 6.65 (1H, s), 4.52 (2H, s).  13CNMR (100.6 MHz, 
CDCl3) δ (ppm), including split signals: 162.01, 157.51, 155.33, 152.88, 148.93, 129.31, 129.06, 
128.11, 128.04, 113.64, 113.23, 102.50, 45.49. 
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2-(chloromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one (1.377). Purified via recyclization.  White 
powder, 42% yield.  1HNMR (400.1 MHz, CDCl3) δ (ppm): 9.08 (1H, d, J = 7.2 Hz), 7.79 (1H, 
m), 7.68 (1H, d, J = 9.2 Hz), 7.19 (1H, m), 4.54 (2H, s). 13CNMR (100.6 MHz, CDCl3) δ (ppm), 
162.35, 158.08, 136.65, 127.28, 126.20, 115.58, 102.73, 53.34, 45.66. 
 
 
General synthesis of target molecules via “one-pot” methodology 
 To a vial equipped with a stir bar was added primary or secondary halide (1 eq, 0.1 
mmol), halogenated aromatic compound with nucleophilic character (i.e. 4-chloro-2-
thiopyridazine, 0.95 eq), and cesium carbonate (4 eq).  The solids were suspended in 1,4-dioxane 
(0.2 M) and stirred at either ambient temperature or 80 oC until TLC and/or LC/MS indicated 
satisfactory conversion of starting materials.  At this time, boronic acid/ester or acetylene (1.5 
eq), [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (0.08 eq), and water (0.02M) 
were added and the reaction sparged with argon for thirty seconds then sealed.  The reaction was 
brought to 90 oC and stirred until LC/MS indicated satisfactory formation of desired product.  
The reaction was then cooled, diluted four-fold with ethyl acetate, and filtered through a pad of 
celite.  Upon concentration samples were dissolved in DMSO and purified using preparative 
HPLC.  
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7-fluoro-2-(((6-(8-methoxyquinolin-5-yl)pyridazin-3-yl)thio)methyl)-4H-pyrido[1,2-
a]pyrimidin-4-one (1.19). White solid, 47%.  1HNMR (400.1 MHz, CDCl3) δ (ppm): 9.00 (1H, 
m), 8.93 (1H, m), 8.64 (1H, m), 7.69-7.65 (3H, m), 7.56-7.48 (3H, m), 7.17 (1H, d, J = 8.1 Hz), 
6.79 (1H, s), 4.74 (2H, s), 4.17 (3H, s). 13CNMR (100.6 MHz, CDCl3) δ (ppm) * denotes signals 
from fluorine splitting, 163.21, 158.85, 157.53*, 157.49*, 156.52, 155.18*, 152.73*, 149.45, 
148.90, 140.22, 133.96, 128.95*, 128.77*, 128.70, 128.05*, 127.98*, 127.27*, 127.08*, 126.49, 
126.15, 122.39, 113.55, 113.14, 106.95, 102.96, 56.14, 35.35. 
 
 
7-chloro-2-(((3',4'-dimethoxy-[1,1'-biphenyl]-4-yl)thio)methyl)-4H-pyrido[1,2-a]pyrimidin-
4-one (1.35). Light yellow solid, 15%. %.  1HNMR (400.1 MHz, CDCl3) δ (ppm): 9.05 (1H, d, J 
= 2.1 Hz), 7.68 (1H, dd, J = 9.4, 2.4 Hz), 7.61 (1H, d, J = 9.4 Hz), 7.46 (4H, m), 7.12 (1H, dd, J 
= 8.3, 2.1 Hz), 7.08 (1H, m), 6.95 (1H, d, J = 8.3 Hz), 6.51 (1H, s), 4.13 (2H, s), 3.96 (3H, s), 
3.94 (3H, s). 13CNMR (100.6 MHz, CDCl3) δ (ppm): 164.20, 157.06, 149.52, 149.25, 148.86, 
139.87, 137.67, 133.36, 133.25, 130.70, 127.46, 127.26, 125.16, 124.16, 119.33, 111.55, 
110.27,103.67, 56.04, 56.02, 40.79. 
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7-chloro-2-[[6-(6-methoxy-3-pyridyl)pyridazin-3-yl]sulfanylmethyl]pyrido[1,2-a]pyrimidin-
4-one (1.87).  White solid, 17%. 1HNMR (400.1 MHz, CDCl3) δ (ppm): 9.05 (1H, d, J  = 2.1 
Hz), 8.75 (1H, d, J = 2.1 Hz), 8.36 (1H, dd, J = 8.7, 2.5 Hz), 7.69 (1H, dd, J  = 20.2, 2.3 Hz), 
7.64 (2H, q, J = 13.0, 9.0 Hz), 7.45 (1H, d, J = 9.0 Hz),  6.90 (1H, d, J = 8.7 Hz), 6.76 (1H, s), 
4.69 (2H, s), 4.03 (3H, s).  13CNMR (100.6 MHz, CDCl3) δ (ppm): 165.43, 163.63, 159.05, 
157.16, 154.50, 149.51, 145.50, 137.68, 137.04, 127.29, 126.52, 125.27, 125.17, 124.19, 122.77, 
111.52, 103.88, 53.90, 35.51. 
 
2-((4-(cyclobutylamino)quinazolin-2-yl)methyl)-6-(3,4-dimethoxyphenyl)pyridazin-3(2H)-
one (1.148). Clear oil, 27%.  1HNMR (400.1 MHz, CDCl3) δ (ppm): 7.78 (2H, m), 7.66 (2H, m), 
7.38 (2H, m), 7.30 (1H, m), 7.12 (1H, d, J = 9.7 Hz), 6.92 (1H, d, J = 8.4), 5.87 (1H, br.d, J = 6.2 
Hz), 5.60 (2H, s), 5.32 (1H, s), 4.42 (1H, sextet, J = 22.9, 15.5, 7.9 Hz), 3.93 (3H, s), 3.88 (3H, s), 
2.26 (2H, m), 1.89 (2H, m), 1.74 (1H, m), 1.65 (1H, m).  13CNMR (100.6 MHz, CDCl3) δ (ppm): 
161.26, 160.37, 158.93, 150.27, 150.13, 149.48, 132.46, 130.12, 130.04, 128.27, 127.99, 125.43, 
120.58, 118.67, 113.55, 111.00, 108.92, 58.02, 56.05, 56.06, 46.74, 30.94, 15.55. 
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6-(3,4-dimethoxyphenyl)-2-(4-fluorobenzyl)pyridazin-3(2H)-one (1.314). White solid, 14%. 
1HNMR (400.1 MHz, CDCl3) δ (ppm): 7.63 (1H, d, J = 9.7 Hz), 7.48 (2H, m), 7.36 (1H, m), 
7.27 (1H, m), 7.08 (1H, m), 7.03 (1H, m), 6.99 (1H, m), 6.36 (2H, s), 5.49 (2H, s), 3.96 (3H, s), 
3.94 (3H, s).  13CNMR (100.6 MHz, CDCl3) δ (ppm) *including fluorine peak splitting: 159.59, 
150.54, 144.38, 130.88, 130.80, 130.36, 130.14, 127.58, 119.22, 118.84, 115.62, 115.41, 111.41, 
111.55, 110.51, 108.85, 56.11, 56.07, 54.84. 
 
Synthesis of 7-chloro-2-(2-(3',4'-dimethoxy-[1,1'-biphenyl]-4-yl)ethyl)-4H-pyrido[1,2-
a]pyrimidin-4-one (1.38).  
 To a stirring solution of 3-(4-bromophenyl)propanenitrile (1 eq, 0.95 mmol)  in THF (0. 
7M)  was added activated zinc powder (5.4 eq) .  The resulting solution was brought to reflux 
and ethyl bromoacetate (4 eq)  was added dropwise over 2.5 hours and the reaction allowed to 
stir for an additional 3 hours following complete addition.  The reaction mixture was then cooled 
to 0 oC and quenched by the dropwise addition of 1N  aqueous HCl (3.6mL).  Crude product was 
extracted with DCM (3 x 8mL) and the combined organic extracts washed once with water 
(4mL) and sat. sodium bicarbonate (4 mL).  The resulting organics dried over magnesium sulfate 
and purified using Teledyne ISCO Combi-Flash system (solid loading, 4G column, 0-20% 
EtOAc, 30 min run) to afford ethyl 5-(4-bromophenyl)-3-oxo-pentanoate 
(101.4mg,0.33895mmol, 35.602% yield) (1.46) as a yellow tinted oil. 
 1.46 (1 eq, 0.34 mmol), 2-amino-5-chloropyridine (1 eq) , polyphosphoric acid (2.75 eq) 
were combined in a reaction vessel and briefly purged with argon.  After two hours of heating at 
120 oC, the reaction mixture was quickly poured onto ice water (10 mL) and diluted with 
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DCM(10 mL).  The slurry was washed with sat. sodium bicarbonate (2 x 5mL) and brine (2 x 5 
mL).  The collected organics were passed dried over magnesium sulfate and purified using 
Teledyne ISCO Combi-Flash system (solid loading, 4G column, 10-60% EtOAc, 25 min run) to 
afford 2-[2-(4-bromophenyl)ethyl]-7-chloro-pyrido[1,2-a]pyrimidin-4-one (1.46a) 
(15.8mg,0.04345mmol, 12.817% yield)  as a light yellow solid.  1.46a was elaborated to targeted 
analog 1.38 using the “one-pot” protocol outlined above. 
 
General synthesis of 4-substituted quinazolines (of type 1.112 where R, R2 = H) 
 2-(chloromethyl)quinazolin-4(3H)-one (1 eq, 6.5 mmol) was partially dissolved in 
Benzene (0.1 M) before N,N-diisopropylethylamine (8eq) was added and the mixture sparged 
with argon and warmed to 80 oC.  Upon reaching reflux phosphorus(V) oxychloride (6.8 eq) was 
added dropwise and the reaction stirred for four hours before being cooled to room 
temperature.  The mixed was then carefully poured onto saturated sodium bicarbonate (50mL) 
and the organic layer removed before the aqueous layer was extracted with ethyl acetate (3 x 
75mL).  The organics were combined and washed once with sat. sodium bicarbonate (50 mL) 
then dried over magnesium sulfate and condensed directly onto silica gel for purification using 
Teledyne ISCO Combi-Flash system  (5-50% EtOAc, 25 min run) to afford known 4-chloro-2-
(chloromethyl)quinazoline as a white solid, 21-68% yield. 
 4-chloro-2-(chloromethyl)quinazoline (1.111 where R, R2 = H, 1 eq, 0.1 mmol) was 
dissolved in THF (0.2M) followed by the addition of desired nucleophile (1.1 eq) and either 
triethylamine (for amine nucleophiles, 1.1 eq) or potassium tert-butoxide (for hydroxy 
nucleophiles, 1.1 eq).  The reaction was stirred until LC/MS analysis indicated satisfactory 
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formation of desired product.  The crude mixture was then concentrated under a steady stream of 
air and the material was carried forward without further purification assuming quantitative yield. 
General synthesis of multi-substituted quinazolines (of type 1.112 where R and/or R2 ≠ H) 
via amide coupling approach. 
 
 Substituted chloroactetic acids (1 eq, 4.4 mmol) were dissolved in dichloroethane (0.2 
M)  and treated with N,N-diisopropylethylamine (1.1 eq)   Next, HATU (1.1 eq)  was added and 
the mixture allowed to stir at ambient temperature for 20 minutes before substituted 2-
aminobenzamide (1 eq)  was introduced and the mixture allowed to stir twenty four hours at 60 
oC  At this time the reaction was cooled and partially concentrated to a light orange gel which 
was dissolved in ethyl acetate (20mL) and washed twice with sat. sodium bicarbonate and once 
with water (equal volume).  The organics were then dried over magnesium sulfate before being 
condensed directly on silica and purified using Teledyne ISCO Combi-Flash system to afford 
desired intermediates, 13-45% yield.  These intermediates were then subjected to the above 
protocol for the synthesis of 4-substituted quinazolines to furnish targeted building blocks. 
General synthesis of multi-substituted quinazolines (of type 1.112 where R ≠ H) via 2-
aminobenzonitrile condensation approach. 
 
 Substituted 2-aminobenzonitrile (1 eq, 18.5 mmol) and chloroacetonitrile (2.5 eq) were 
dissolved in 1,4-Dioxane (0.4 M) at 0 oC.  HCl gas was bubbled through the mixture for four 
hours while maintaining an internal 0 oC temperature. The mixture was then allowed to stir at 
room temperature for an additional two hours.  The HCl gas inlet line was removed and the 
mixture purged with argon for several minutes.  The white precipitate (desired product) which 
may form over the course of the reaction is removed by filtration and stored. Additional product 
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is obtained by carefully pouring the supernatant onto 75mL sat. sodium bicarbonate followed by 
dilution with ethyl acetate (60mL).  The layers were separated and the resulting aqueous layer 
extracted twice with ethyl acetate (30mL each).  The resulting organics were pooled and dried 
over magnesium sulfate before being purified using Teledyne ISCO Combi-Flash system to 
afford desired compounds, 13-48%.  Reaction yield could be improved via the addition of 5 eq of 
sulfuric acid to the reaction mixture. 
 
4-chloro-2-(chloromethyl)-5-fluoro-quinazoline (1.374). White solid, 48%.  1HNMR (400.1 
MHz, CDCl3) δ (ppm): 7.33 (1H, m), 6.67 (1H, d, J = 8.5 Hz), 6.47 (1H, t, J  = 17.6, 9.0 Hz), 
4.06 (1/2 H, s). 
 
General synthesis of primary alcohol building blocks from corresponding primary 
chlorides (of type 1.118) 
To a solution of heteroaryl primary chloride (i.e., 1.115) (1 eq, 1.75 mmol) in DMF (0.75 
M) was added potassium acetate  (9 eq) and the mixture was stirred for 2 hours at 80 oC. The 
reaction mixture was then cooled, diluted with DCM (30 mL) and sat. aqueous sodium 
bicarbonate then dried over magnesium sulfate, filtered, and concentrated.  The resulting solid 
residue (containing crude material of type 1.202) was dissolved in a mixture of THF (0.75 M) 
and Water (0.75 M) then treated with lithium hydroxide (9 eq). The mixture was stirred for two 
hours at ambient temperature then was diluted with DCM to triple the volume and washed once 
with water and twice with 5% w/w aqueous lithium chloride then dried over magnesium 
sulfate.  Crude product was purified using Teledyne ISCO Combi-Flash to afford desired 
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primary alcohols, 47-66%.  Higher yields can be obtained using cesium acetate in place of 
potassium acetate.  
General synthesis of polyaromatic precursors to target analogs via nucleophilic aromatic 
substitution (i.e. precursors to analogs of type 1.251). 
 Heterocycles bearing a primary hydroxyl group (i.e. 1.118, 1 eq, 0.38 mmol) were 
dissolved in DMF (0.2 M) and cooled to 0 oC before sodium hydride (60% w/w dispersion in 
mineral oil, 1.1 eq) was added and the reaction stirred for twenty minutes.  Then, desired 
halogenated hetercycles (1.2 eq)  were added and the reaction allowed to slowly warm to 
ambient temperature and stirred an additional for three hours at which time the mixture was 
diluted with ethyl acetate (8 mL) before and brine (3 mL).  The organic layer was removed and 
washed three times with 5% w/w aqueous lithium chloride.  The organics were then dried over 
magnesium sulfate, filtered, and purified using Teledyne ISCO Combi-Flash system to afford 
desired intermeidates, 46-84%. 
 
3-chloro-6-(pyrimidin-2-ylmethoxy)pyridazine (1.375). Brown-yellow solid, 46%.  1HNMR 
(400.1 MHz, CDCl3) δ (ppm): 8.75 (2H, d, J = 4.9 Hz), 7.43 (1H, d, J = 9.1 Hz), 7.24 (1H, t, J  = 
9.8 Hz, 4.9 Hz), 7.19 (1H, d, J = 9.1 Hz), 5.79 (2H, s).  13CNMR (100.6 MHz, CDCl3) δ (ppm): 
162.25, 163.69, 157.37, 151.57, 131.08, 120.29, 119.96, 69.17. 
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General synthesis of polyaromatic precursors to target analogs via substitution chemistry 
with nucleophilic nitrogenous hetereocycles (i.e. precursor to analogs of type 1.265). 
 Desired nucleophilic nitrogenous heterocycle (1 eq, 0.33 mmol) was dissolved in DMF 
(0.33 M) and treated with sodium hydride (60% w/w dispersion in mineral oil, 1.1 eq) at 0 oC for 
thirty minutes.  Then heteroaryl primary halide (of type 1.115, 1.2 eq) was added and then the 
reaction allowed to slowly warm to ambient temperature and stirred an additional two hours.  At 
this time the reaction was diluted with ethyl acetate and washed three times with 5% w/w 
aqueous lithium chloride before being dried over magnesium sulfate.  The crude product was 
purified using Teledyne ISCO Combi-Flash system to provide desired intermediates, 25-45%. 
 
6-bromo-2-[(4-methoxyquinazolin-2-yl)methyl]pyridazin-3-one (1.117). White solid, 31%.  
Prepared using “one-pot” protocol and isolated before Suzuki-Miyaura coupling.  13CNMR 
(100.6 MHz, CDCl3) δ (ppm): 167.35, 159.59, 159.34, 151.10, 136.58, 133.47, 131.66, 127.45, 
126.63, 125.98, 123.29, 115.25, 57.18, 54.07. 
 
methyl 6-bromo-1-[(4-methoxyquinazolin-2-yl)methyl]indole-4-carboxylate (1.378)  White 
solid, 43%.  1HNMR (400.1 MHz, CDCl3) δ (ppm): 8.04 (1H, dd, J  = 8.2, 0.8 Hz), 8.00 (1H, 
br.s), 7.98 (1H, br.d, J = 1.7 Hz), 7.87 (1H, br.d, J  = 8.3 Hz), 7.78 (1H, m), 7.49 (1H, m), 7.45 
(1H, d, J = 3.2 Hz), 7.14 (1H, dd, J  = 3.2, 0.4 Hz), 5.44 (2H, s), 3.97 (3H, s), 3.96 (3H, s). 
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Synthesis of 4H-chromeno[4,3-d]thiazol-2-amine (1.284) 
Thiourea (3.5 eq) and iodine (1.1 eq) were added to a solution of 4-chromanone (1 eq, 
1.35mmol) in Ethanol (0.5 M) in a vial.  The reaction mixture was heated to 100 oC while 
covered with a rubber septa cap pierced with a syringe.  After two hours of stirring the resulting 
viscous residue was allowed to cool before being dissolved in a mixture of water, 5% aqueous 
NaOH, and DCM.  The DCM layer was separated and the aqueous layer extracted twice with 
ethyl acetate.  The combined organics were dried over magnesium sulfate and purified using 
Teledyne ISCO Combi-Flash system (0-40% EtOAc/Hex, 25 min run) to afford known 1.284 
(97mg, 0.47491mmol, 35.181% yield) as an orange solid.  
General synthesis of target amide analogs containing the 4H-chromeno[4,3-d]thiazol-2-
amine core (i.e. of type 1.285) 
4H-chromeno[4,3-d]thiazol-2-amine (1 eq, 0.14 mmol), desired carboxylic acid (1.2 eq), 
4-dimethylaminopyridine (1.2 eq), and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride  (1.2 eq) were dissolved in DMF (0.2 M) and irradiated in a Biotage microwave 
reactor at 120 oC for fifteen minutes.  The reaction mixture was diluted with DCM and washed 
three times with water before the organics were dried over magnesium sulfate. The crude 
products were concentrated under a steady stream of air then dissolved in DMSO and purified 
utilizing preparative HPLC, 26-38%. 
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N-(4H-chromeno[4,3-d]thiazol-2-yl)cyclohexanecarboxamide (1.6).  Orange solid, 27%. 
1HNMR (400.1 MHz, CDCl3) δ (ppm): 9.87 (1H, br.s), 7.66 (1H, dd, J  = 7.5, 1.6 Hz), 7.21 (1H, 
m), 7.03 (1H, td, J  = 14.9, 7.5, 1.0 Hz), 6.97 (1H, dd, J = 8.1, 0.7 Hz), 5.46 (2H, s), 2.24 (1H, 
m), 1.85 (2H, m), 1.77-1.63 (3H, m), 1.49 (2H, m), 1.20 (1H, m), 1.11 (2H, m).  13CNMR (100.6 
MHz, CDCl3) δ (ppm): 174.06, 158.59, 153.50, 140.89, 129.30, 122.53, 122.15, 120.13, 117.04, 
116.65, 64.40, 44.93, 39.23, 25.46, 25.28. 
 
N-(4H-chromeno[4,3-d]thiazol-2-yl)benzamide (1.286). Orange solid, 29%.  1HNMR (400.1 
MHz, CDCl3) δ (ppm): 7.96 (2H, m), 7.60 (2H, m), 7.51 (2H, m), 7.19 (1H, td, J  = 15.5, 7.7, 1.7 
Hz), 6.98 (2H, m), 5.49 (2H, s).  
 
86 
 
CHAPTER II 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF HYBRUBIN A 
 
Background and Introduction  
Natural Products as Foundations for Drug Development 
 Over half of currently used drugs are small molecule natural products derived directly 
from plants and microbial species or synthetically created structural variants thereof. [76] This 
statistic is often explained by humanity’s ability to translate traditional systems of medicine or 
longstanding empirical observations by indigenous populations into medicines as our knowledge 
of science expanded.  An historical example of this is the isolation of morphine from the opium 
poppy in 1804 by German pharmacist Friedrich Serturner after a long understanding of the plants 
properties.  Seven decades later, and after morphine had developed a reputation of being 
addictive, chemist Charles Romley Alder Wright boiled his prescribed morphine in acetic 
anhydride in the hopes of producing a less addictive form of the drug.  Instead, he completed the 
first known synthesis of heroin. [77] Such well-known medicines as ephedrine, taxol, aspirin, and 
countless more were discovered loosely following this early experimental process.  In more 
recent years, for a plethora of reasons, drug discovery efforts have shifted away from natural 
product-based scaffolds in favor of high-throughput-screens (HTS) of large collections of 
chemical space followed by diversity orientated synthetic approaches. [78] This tactic allows for 
the preparation and screening of a large number of small molecules across numerous iterations of 
chemical structure to identify a new drug with optimal properties “from scratch”.  The success of 
this approach in modern times is undeniable as 35% of small-molecule approved drugs from 
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1981-2014 were synthetic while only 6% were unaltered natural products.  However, during that 
same time period 715 drug approvals (59 %) were granted to small molecules which where either 
derivatives of natural products, contained a pharmacophore of a natural product, or were a 
structural mimic of a natural product.  Therefore, the prevalence of natural product scaffolds in 
drug design has remained more constant than some scientists might assume. [76] 
Alongside major research efforts in industrial settings, academic groups have entered the 
arena of drug discovery either independently or with assistance from another organization.  This 
has, in a general sense, allowed for a more expansive look at natural product synthesis and 
analog generation in pursuit of novel drug-like molecules. [79] One major issue with translating a 
known natural product into a novel medication is the lack of understanding surrounding the 
molecule’s biological activity. Lacking decades of anecdotal evidence associated with some of 
the earliest “drug discovery programs” such as aspirin, [80] scientists today rely on more modern 
biochemical testing to elucidate if a given natural product’s biological profile is suitable for 
development.  Vital information such as a molecule’s biological target(s), mechanism of action, 
toxicity, and DMPK parameters all need be assessed.  This task is often burdened by the 
difficulty in isolating natural products in large enough quantities from their natural source to 
support the studies. [81] This hurdle then often places responsibility on chemists to synthesize 
material for biological investigations and is a primary rationale in support of natural product total 
synthesis as it pertains to drug discovery.  When considering that most small molecule 
therapeutics are derivatives of natural products (as opposed to their unaltered forms) an 
additional challenge of natural product analog generation is realized. [82]  
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Combinatorial Biosynthesis and Semisynthesis as Tools for Drug Discovery 
 It is important to note that total synthesis is not the only method to support biological 
investigations of mass production of a natural product.  A classic example is taxol, known 
commercially as paclitaxel.  This complex natural product showed immense potential as an anti-
cancer agent but its scarcity and subsequent endangered nature of its producing organism, the 
Pacific yew, severely restricted initial supplies. [83] To address this issue the Potier group in 
France identified an advanced intermediate of taxol, known as 10-DAB, which was both more 
abundant than taxol and could be harvested from the needles of the nonendangered English yew.  
This discovery was then followed by a facile synthetic strategy developed by the Holton group at 
Florida State University to complete the synthesis of taxol from 10-DAB. [84] Ultimately licensed 
to Bristol-Myers-Squibb and improved upon, this semisynthetic approach to a complex natural 
product allowed global demand to be meet through a nearly fully biosynthetic process. [85] 
 The field of combinatorial biosynthesis is also considered an important player in drug 
discovery.  Combinatorial biosynthesis aims to use genetic engineering to modify known 
biosynthetic pathways to produce novel chemical entities. [86] Many known bioactive natural 
products are secondary metabolites of the producing organism and have been optimized via 
evolution for interaction with a specific receptor in a specific biological environment.  Often this 
optimization sets these small molecules in a poor position relative to desired drug properties (i.e. 
poor DMPK profiles or cytotoxicity).  One pillar of combinatorial biosynthesis is to assist drug 
discovery by modification of biosynthetic pathways to increase structural diversity around 
natural products to improve their drug-like properties.  While currently not considered a robust 
option for large scale production of therapeutic agents in the same manner semisynthesis is, 
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combinatorial biosynthesis is an exciting field for analog generation and discovery chemistry nin 
support of a number of pharmacologically relevant pursuits. [87]  
Discovery of “Unnatural” Natural Products Hybrubins A-C 
While the majority of natural products are created endogenously in organisms, some novel or 
“unnatural” natural products have been created via a combinatorial biosynthetic approach in 
which genes that catalyzes distinct reactions are combined in different ways such that the gene 
cluster’s end product is not native to the endogenous system. [88] In 2016 a novel class of 
“unnatural” natural products were disclosed by Tao and coworkers which arose from the fusion 
of two unrelated biosynthetic genes from different species of Streptomyces (Figure 2.1). [89] The  
 
Figure 2.1. Structure of Hybrubins A- C and related natural products.  
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team began with a ΔredKL mutant Streptomyces lividans bacterium (SBT5) which contains all 
genes necessary for the biosynthesis of a prevalent intermediate of the prodiginine group of 
natural products. [90] This intermediate, 4-methoxy-2,2’-bipyrrole-5-carbaldehyde (MBC, 2.4), is 
however unable to be converted into known natural products in this S.lividans mutant where as 
other related  bacteriums are capable (Figure 2.2).  This truncated biosynthetic pathway was then 
augmented with a genomic bacterial artificial chromosome (BAC) library of Streptomyces 
variablis Snt24 to screen for exconjugants which could restore red pigmentation associated with 
the production of hybrid secondary metabolites. [91] This experiment resulted in the accumulation 
of red pigmentation from 6 exconjugants, which after control experiments and metabolic 
profiling against the endogenous strains of both Streptomyces variablis Snt24 and Streptomyces 
lividans SBT5 revealed three new compounds which were unique to the hybrid system.  These 
“unnatural” natural products were named Hybrubins A-C (2.1-2.3) (Figure 2.1) and consist of a 
bipyrrole 2.4 connected to a tetramic acid motif via a readily isomerizing internal olefin. 
 
 
 
Figure 2.2. Possible biosynthetic transformations of common intermediate MBC (2.4) in different 
organisms.  The bottom route summarizes the work flow resulting in the discovery of the Hybrubins 
91 
 
1HNMR analysis of the material indicated that hybrubin A existed as a 2:1 ratio of products as 
geometrical isomers around this internal olefin.  The hybrubins constitute a novel group of 
prodiginine analogues where the C ring is replaced with a non-native tetramic acid moiety.  
Studies by Tao and coworkers provided evidence as to the exact genes responsible for the 
biosynthesis of the hybrubins. [89] Via mutation studies they elucidated that the bipyrrole motif is 
likely provided by the red gene cluster of the host organism S.lividans while the tetramic acid 
motifs arise cooperation among ΔhbnA, ΔhbnA, and ΔhbnA genes from S.variablis. The 
proposed biosynthetic pathway of this “unnatural” natural product features a Dieckmann 
cyclization to form the tetramic acid followed by an aldol condensation to unite the biosynthetic 
intermediates. [92]  
Both motifs of this chimera molecule are common to a range of bioactive, usually 
cytotoxic, molecules.  The tetramic acid containing natural product Cylindramide (2.7), isolated 
from the marine sponge Halichondria cylindrata, is cytotoxic against B16 mouse melanoma cells 
with an IC50 of 0.8 μg/mL. [93] Numerous other tetramic acid containing natural products have 
displayed antibiotic, antiviral, or cytotoxic bioactivities. [94] The religiously implicated bipyrrole 
containing natural product Prodigiosin (2.6) displays even greater cytotoxicity than 2.7 with IC50 
values against P388 mouse leukemia cells of 0.0004 μg/mL and IC50 values in the range of 0.02 – 
0.05 μg/mL for L-1210 mouse lymphocytic leukemia, B16 mouse melanoma, and 9KB human 
epidermoid nasopharynx carcinoma. [95] Given the nature of the individual building blocks of the 
Hyrbubins, it was postulated that these molecules would have potent biological activities.  
However, the isolation group reported no bioactivity outside of the claim that these molecules 
did not possess any obvious cytotoxic or antibacterial activity. [89] Therefore, we reasoned that 
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the total synthesis of this family of molecules could be of great value so as to add to the 
knowledge of their biological activity. 
Conclusion 
 Natural products have long served as important sources of chemical matter and 
knowledge in the modern drug discovery process.  While only a small percentage of the new 
small molecules approved by the FDA in the past three decades have been unaltered natural 
products, more than half are derived from or inspired by a natural product scaffold.  New natural 
products can be difficult to identify and isolate from their natural sources as well as to synthesize 
synthetically.  To meet this challenge advances in chemical synthesis, semi-synthesis, and 
combinatorial biosynthesis are being made at a rapid pace.  Applications of combinatorial 
biosynthetic techniques allowed for the discovery of a trio of “unnatural” natural products named 
Hybrubin A-C (2.1-2.3).  These novel compounds are chimera molecules of two motifs 
commonly encountered in bioactive natural products; however, no bioactivity was prescribed to 
these compounds upon discovery.  Given their unnatural origin – which perhaps could lead to 
interesting biological activity – we sought to synthesize a member of this family, Hybrubin A 
(2.1) for biological assessment as an impetuous for validation of its potential as a novel 
therapeutic.    
Materials and Methods 
General Synthetic Methods and Instrumentation. 
 All chemical reactions were carried out employing standard laboratory techniques under 
air, unless otherwise noted. Solvents used for extraction, washing, and chromatography were 
HPLC grade. All commercially available reactants and reaction solvents were used as received, 
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unless otherwise noted.  Analytical thin layer chromatography was performed on 250 μm silica 
gel plates from Sorbent Technologies.  Analytical LC/MS analysis was performed on an Agilent 
1200 LCMS with electrospray ionization in positive ion mode and UV detection at 215 and 254 
nM. Compounds submitted for assays were determined to be >95% purity by UV absorbance.  
All NMR spectra were recorded on a 400 MHz Bruker AV-400 instrument unless otherwise 
noted. 1H chemical shifts were reported as δ values in ppm relative to the residual solvent peak 
(CDCl3 = 7.28, (CD3)2SO = 2.50, CD3OD = 3.31).  Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = 
multiplet, br = broad), coupling constant (Hz), and integration.  13C chemical shifts are reported 
as δ values in ppm relative to the residual solvent peak (CDCl3 = 77.16, (CD3)2SO = 39.52, 
CD3OD = 49.00).  Low resolution mass spectra were obtained on an Agilent 1200 LCMS with 
electrospray ionization.  High resolution mass spectra were recorded on a Waters QToF-API-US 
plus Acquity system with electrospray ionization.  Automated flash column chromatography was 
performed on a Teledyne ISCO Combiflash Rf system.  Preparative purification of select 
compounds was performed on a Gilson chromatography system using a GX-271 liquid handler 
and either a Luna 30 x 50 mm 5u C18 100A column using an acetonitrile / 0.1% TFA (aq) 
gradient or a Gemini 30 x 50 mm 5u C18 110A column using an acetonitrile / 0.05% NH4OH 
(aq) gradient. 
HCT116 Colorectal Carcinoma Cell Growth Assay 
 Cells were plated at a concentration of 7,000 cells / well in a black-walled, clear-
bottomed, poly-D-lysine coated 96-well plates and were let to attached for 24 hours.  Either 
vehicle or test compound (2.1, at 7 concentrations: 0.0024, 0.0097, 0.0390, 0.1560, 0.6250, 2.50, 
and 10.0 μM) in RPMI1640 + 10%FBS + pen-strep were then added to the wells.  Cells were 
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then allowed to grow for 48 hours and assayed for cell viability via WST-1 metabolism and 
either 24 or 48 hours. 
Total Synthesis of Hybrubin A 
Retrosynthetic Analysis of Hybrubin A 
 Our primary retrosynthetic analysis mused if a common intermediate could provide both 
2.1 and 2.2 which could later be separated using conditions outlined by the isolation group. [89] 
To this end we devised a synthetic route which culminated in the dehydration of β-hydroxy 
compound 2.8 which we theorized would provide a mixture of 2.1 and 2.2 if the reaction 
proceeded through a carbocation intermediate (Figure 2.3).  We were cognizant that this 
particular approach would rely on the unfavorable formation of the secondary carbocation of 
2.11 (i.e. an E1 mechanism) as the direct, one-step elimination of the alcohol (i.e. an E2 
mechanism) should furnish solely 2.1. [97] Despite this challenge we rested with the knowledge 
that if a mixture was unattainable, or if 2.1 and 2.2 were not readily separable, this route seemed 
promising to furnish the desired Z-exocyclic olefin geometry of 2.1. Precursor 2.8 can be 
constructed using an aldol condensation to unite a protected analog of carbaldehyde 2.4 [98,99] 
with protected tetramic acid 2.9 followed by global deprotection. 2.9 in turn can be obtained in a 
single step starting from commercially available protected L-threonine derivative 2.10 following 
a cyclization procedure utilizing Meldrum’s acid. [100] 
Our secondary retrosynthetic analysis of Hybrubin A (2.1) began with a disconnection of 
the 6’-3’’ internal olefin (Figure 2.4).  This disconnection yielded two fragments, 2.4 and 
tetramic acid 2.11, which could be united via an aldol condensation.  2.11 is envisaged to be 
prepared following a two-step sequence of unmasking the vinylogous ester 2.12 which arises  
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Figure 2.3. Primary retrosynthetic analysis of Hybrubin A/B (2.1/2.2).  Elimination of a β-hydroxyl 
group could furnish a mixture of exocyclic olefins.  The dehydration precursor can be assembled 
following aldol condensation with a protected tetramic acid derivative and subsequent necessary 
transformations. 
 
 
 
 
Figure 2.4. Secondary retrosynthetic analysis of Hybrubin A (2.1).  An aldol condensation between 
known 2.15 and tetramic acid derivative 2.11 can provide the natural product in a single step.  2.11 can be 
obtained from two standard synthetic operations. 
 
 
Scheme 2.1. Synthesis of the bipyrrole precursor of the Prodigiosins (2.15) by Dairi and coworkers. [98]  
Reagents and conditions (a) POBr3, HCONEt2, DCM, 0-40 oC then 15% w/w aq. NaOH; (b) N-Boc-2-
pyrrole boronic acid, Pd(PPh3)4, Na2CO3, 1-4-dioxane:H2O (9:1), 80 oC. 
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from an aldol condensation of acetaldehyde and known lactam 2.13 - which is conveniently the 
precursor to a protected analog of 2.4 (Scheme 2.1). [98,99] Following this analysis, we predicted 
that the olefin geometry of 2.12 would highly favor the Z configuration shown on basis of A1,3 
strain. [101] While perhaps an interesting consequence of reaction mechanism, this would preclude 
us from the synthesis of Hybrubin B (2.2) but also serves as an attractive alternative to the 
synthesis of 2.1 when compared to our primary retrosynthetic analysis. 
 
Pursuit of the Primary Retrosynthetic Analysis 
 The forward direction of our primary retrosynthetic analysis was ultimately 
determined to be operable, but first required significant reaction optimization (Scheme 2.2).  The 
precedented cyclization reaction between protected L-threonine 2.10 and Meldrum’s acid 
proceeded uneventfully following conditions from the literature. [100,102] The proposed aldol 
condensation between protected tetramic acid 2.16 and known bipyrrole 2.15 could be affected 
smoothly with piperidine in refluxing ethanol with concurrent removal of the N-Boc protecting 
group of 2.15.  However, this rather convenient set of conditions was only revealed to us after 
mildly extensive reaction screening (Table 2.1). Initial attempts at an effective aldol 
condensation [103] employed tertiary amine bases such as triethylamine and N-N-
diisopropylethylamine (Hunig’s Base) in ethereal solvents (entries A-C) which afford only traces 
of desired material after several hours.  Heterogenous bases such as sodium hydride, cesium 
carbonate, and sodium tert-butoxide in various solvents failed to improve yield (entries D-F).  
When sodium hydride was employed, a complex mixture was obtained which was attributed to  
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Scheme 2.2. Synthesis of a mixture containing 2.1/2.2 following the strategy outline in our first 
retrosynthetic analysis. 
 
the decomposition of starting materials.  When organocatalysts were employed for the 
transformation, yield improved modestly (entries G-I).  To our excitement when the reaction was 
conducted in warm DMSO we were able to isolate the Boc-deprotected compound 2.17 in small 
quantities alongside 2.19.  Since this transformation was set to occur after the current aldol  
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Table 2.1. Reaction conditions screened for the aldol condensation between 2.15 and 2.16 
 
condensation anyway, we probed conditions which could afford both conversions in the same 
pot.  Believing that the protic nature of the organocatalysts was key to the removal of the labile 
pyrrole-Boc group we sought to employ a protic solvent for our reaction as well as a secondary 
amine as base.  These changes (entry J) resulted in full conversion of 2.15 in 8 hours – the 
quickest conversion noted thus far – as well formation of solely 2.17 in 68% yield. With 
sufficient quantities of the aldol product readily obtainable we next moved on to address the 
global deprotection.  Early attempts at the simultaneous deprotection of both the N-Boc and O-
tBu groups taught us that fully deprotected 2.18 displayed moderate water solubility which 
complicated reaction workups (Table 2.2).  Further complicating the proposed transformation 
was that despite the acid labile nature of both protecting groups it was challenging to find 
conditions which could afford reaction completion without degradation of the starting material 
and desired product. [96,104] Protic acids such as HCl, TFA, and H3PO4 (entries A 
[105] 
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Table 2.2.  Reaction conditions screened for the tandem N-Boc / O-tBu protecting group removal 
 
B-D [106], L-M) under various conditions were unable to afford desired doubly deprotected 2.18.  
Lewis acids TiCl4, AlCl3, and TMSI (entries G-I 
[107], J-K [108], N-O [109]) were also unable to 
produce 2.18 in appreciable quantities but were generally higher yielding.  Interestingly, 
treatment with TMSI produced 2.21 as the sole product with minimal starting material or product 
decomposition within one hour.  When we paired this observation with those from thermal 
conditions for exclusive Boc-deprotection (entries E-F [110]) we concluded that a two-step 
sequence would be necessary to cleanly afford 2.18.  Indeed, first heating 2.17 neat at 180 oC 
followed by treatment with TMSI (entry P) furnished 2.18 in 85% overall yield.  This protocol 
was rapid, reliable, and avoided issues associated with material decomposition, product aqueous 
solubility, and separation of statistical mixtures of 2.20, 2.21, and 2.18.   
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 Having successfully addressed the first two roadblocks in our primary synthetic route we 
next turned out attention to the dehydration of β-hydroxy compound 2.18 (Table 2.3).  Hoping to 
induce an E1 type mechanism [97,111] we first treated 2.18 with a variety or Bronsted acids or 
Lewis acids including HCl (entry A [112]), TFA (entries B-C [113]), AcOH (entry D [114]) thionyl 
chloride (entry E [115]) and others (entries F, J-L).  Even under some forcing conditions none of 
the tested reagents were capable of reacting with 2.18 in a desired fashion.  Basic conditions 
were employed (entries G, H) as well as the dehydrative Martin Sulfurane reagent [116] (entry I) 
to no success.  It was not until the β-hydroxy compound was treated with acetic anhydride did we 
begin to see indication that the desired elimination was occurring (entries J-L).  The only 
successful reaction involved stirring a 0.2 M solution of 2.18 in neat acetic anhydride at 90 oC  
Table 2.3.  Reaction conditions screened for the proposed E1-type dehydration of 2.18 
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for 90 minutes to induce formation of an acetyl derivative.  Subsequent heating of this 
intermediate at an elevated temperature of 110 oC was required to induce the pyrolytic 
elimination, albeit at a slow rate. [117] Interestingly, no material corresponding to pyrrole nitrogen 
acylation [118] was isolated and no m/z corresponding to the acylation of both pyrrolic nitrogen 
was ever observed by LC/MS under these conditions.  Despite earlier success in reaction 
optimization the low yield and uncertainty of the olefin geometry produced under condition L 
was damning.  Next, we reasoned we could use the chemistry discovered en route to 2.18 to 
affect a similar deprotection / dehydration sequence on 2.16 to install the exocyclic olefin prior 
to union with 2.15.  Unfortunately, this attempt failed and indicated the chemistry which was 
refined to work on substrates such as 2.17 and 2.18 was not readily generalizable to simpler 
systems.  Meanwhile significant progress had been made on the second proposed synthetic route 
and at this junction all synthetic efforts here ceased in support of the more robust route. 
Pursuit of the Secondary Retrosynthetic Analysis: Total Synthesis of Hybrubin A 
 In the forward direction our secondary retrosynthetic analysis culminates in an aldol 
condensation to unite two fragments and produce 2.1 (Scheme 2.3).  The bipyrrole fragment 2.15 
can be prepared in two steps from commercial 2.13 as outlined in Scheme 2.1.  Conveniently, 
2.13 is also transformed into the other necessary fragment for the coupling.  Upon treatment with 
acetaldehyde and sodium tert-butoxide in warm ethanol 2.12 is formed via an aldol 
condensation. [119,120] NOESY spectra confirmed the desired Z-olefin geometry and no 
appreciable quantity of the E isomer was ever isolated. We were delighted that our prediction of 
the thermodynamic consequences of A1,3 strain was correct.  However, despite some attempts at 
reaction optimization (i.e. purification of acetaldehyde, different heterogenous bases, methanol  
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Scheme 2.3.  Total Synthesis of Hybrubin A (2.1) 
 
as solvent, room temperature or 60 oC reaction temperatures) the best yield obtained was 45%.  
Treatment of vinylogous ester 2.12 with aq. HCl in THF resulted in clean demethylation and 
formation of 2.11. [120] Careful reaction monitoring was required in this step as yields were often 
widely variable.  In our hands, classic Krapcho demethylation conditions resulted in the 
formation of a complex mixture devoid of desired product. [121] Subjecting 2.11 to previously 
optimized aldol condensation conditions with 2.15 then completed the synthesis of Hybrubin A 
(2.1).  This route allows for the rapid synthesis of Hybrubin A in a three-step linear sequence 
(highest yielding 20.8%).  Two noteworthy aspects of this synthesis are the ease by which 
derivatives of Hybrubin A can be synthesized and that 2.13 is that starting material for both 
linear sequences and is transformed into two distinct intermediates which are ultimately rejoined. 
Also noteworthy is that the entire synthetic sequence (five steps total) requires less than 24 hours 
of reaction time. 
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Biological Activity of Hybrubin A 
 With sufficient quantities of the desired product in hand we were enabled to pursue a 
number of biological surveys.  Understanding that the two “halves” (i.e. tetramic acid and 
bipyrrole) of Hybrubin A were components of known cytotoxic natural products we examined 
the cytotoxicity of 2.1 against human colon cancer cells (HCT116).  To our surprise, 2.1 was 
found to be benign after 24 and 48 hours of incubation with the HCT116 cells (Figure 2.5).  
Eevn after two days of incubation at 10 μM concentrations, the cells displayed no cell rounding 
or blebbing and maintained high viability.  This result was certainly not anticipated and 
encouraged us to further explore the bioactivity of Hybrubin A. 
  
 
Figure 2.5.  Cytotoxicity of 2.1 against HCT116 cells after either 24 or 48 hours of co-incubation.  Cell 
viability was assessed via WST-1 metabolism.  2.1 was assayed at concentrations of 0.0024, 0.0097, 
0.039, 0.156, 0.625, 2.50, and 10 μM. 
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Next, we sent an aliquot of 2.1 to an outside contractor (Eurofins, Eurofins.com) to be assayed 
against a panel of GPCRs, ion channels, transporters, and nuclear hormone receptors alongside a 
panel of kinases in an attempt to identify potential biological targets.  What follows is a brief 
summary of the data received but a full report is readily obtainable. [96] First examining the non-
kinase targets it was reported that 2.1 afforded significant activity in only5 of the 68 targets 
screened ( > 70% inhibition at 10 μM) (Table 2.4).  The greatest activity among these five was 
against the adenosine receptor family and the serotonin 5-HT2B receptor.  Follow-up Ki 
determinations showed that 2.1 is a selective ligand for adenosine receptor A3 (Ki values: A1 = 
2.6 μM, A2 = 550 nM, A3 = 54 nM, serotonin 5-HT2B = 1.05 μM).  A small molecule antagonist 
with a similar selectivity profile against the adenosine family of receptors is expected to enter 
clinical trials for the treatment of glaucoma. [122] A3 Adenosine receptor antagonists are 
characterized by notable structural diversity, and 2.1 can now be considered a novel small 
molecule to add to that group.  
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Table 2.4. Radioligand binding panel of 68 non-kinase targets to asses the inhibitory activity of 2.1 at various potential targets.  Data are reported 
as % Inhibition of radioligand binding at 10 μM concentration of 2.1 from two independent determinations. 
Target/Protein Species % Inhibition Target/Protein Species % Inhibition 
Adenosine A1 Human 80 Histamine H3 Human 29 
Adenosine A2A Human 92 Imidazoline I2, Central Rat 20 
Adenosine A3 Human 101 Interleukin IL-1 Mouse 13 
Adrenergic α1A Rat 33 Leukotriene, Cysteinyl CysLT1 Human 0 
Adrenergic α1B Rat 47 Melatonin MT1 Human 15 
Adrenergic α1D Human 30 Muscarinic M1 Human 26 
Adrenergic α2A Human 21 Muscarinic M2 Human 19 
Adrenergic β1 Human 21 Muscarinic M3 Human 14 
Adrenergic β2 Human 30 Neuropeptide Y Y1 Human 41 
Androgen (Testosterone) AR Rat 29 Neuropeptide Y Y2 Human 8 
Bradykinin B1 Human 30 Nicotinic Acetylcholine Human 12 
Bradykinin B2 Human 19 
Nicotinic Acetylcholine α1, 
Bungarotoxin 
Human 23 
Calcium Channel L.Type, 
Benzothiazepine 
Rat 28 Opiate δ1(OP1, DOP) Human 53 
Calcium Channel L.Type, 
Dihydropyridine 
Rat 36 Opiate κ (OP2, KOP) Human 55 
Calcium Channel N.Type Rat 15 Opiate 9 (OP3, MOP) Human 76 
Cannabinoid CB1 Human 44 Phorbol Ester Mouse 19 
Dopamine D1 Human 30 Platelet Activating Factor (PAF) Human 28 
Dopamine D2S Human 8 Potassium Channel [KATP] Human 24 
Dopamine D3 Human 23 Potassium Channel hERG Human 47 
Dopamine D4.2 Human 18 Prostanoid EP4 Human 63 
Endothelin ETA Human 6 Purinergic P2X Rabbit 29 
Endothelin ETB Human -2 Purinergic P2Y Rat 13 
Epidermal Growth Factor (EGF) Human -3 Rolipram Rat 66 
Estrogen ERα Human 19 Serotonin (5.HT1A) Human 23 
GABAA, Flunitrazepam, Central Rat 30 Serotonin (5.HT2B) Human 97 
GABAA, Muscimol, Central Rat 19 Serotonin (5.HT3) Human 5 
GABAB1A Human 30 Sigma σ1 Human 37 
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Glucocorticoid Human 55 Sodium Channel, Site 2 Rat 36 
Glutamate, Kainate Rat 38 Tachykinin NK1 Human 60 
Glutamate, NMDA, Agonism Rat 29 Thyroid Hormone Rat 2 
Glutamate, NMDA, Glycine Rat 16 Transporter, Dopamine (DAT) Human 17 
Glutamate, NMDA, 
Phencyclidine 
Rat 25 Transporter, GABA Rat 50 
Histamine H1 Human 24 
Transporter, Norepinephrine 
(NET) 
Human 33 
Histamine H2 Human 2 Transporter, Serotonin (SERT) Human 16 
 
Table 2.5. Summary of results obtained from the kinase profiling report against 369 kinases for 2.1 featuring kinases which had their activity at 
least reduced by half. [95] Data are reported as the average % Enzyme Activity relative to DMSO controls from two independent determinations.  
2.1 was tested in single dose duplicate mode at a concentration of 10 μM in the presence of 10 μM ATP. 
Kinase % Enzyme Activity 
(IC50) 
Kinase % Enzyme Activity 
(IC50) 
ABL1 47.2 LCK 46.4 
BMPR2 49.0 LOK/STK10 28.4 
BRAF 18.6 (3.69 μM) LRRK2 42.6 
c-MER 46.8 MINK/MINK1 40.9 
CK1d 47.6 MNK1 28.6 
CK1g1 45.4 MNK2 35.3 
CK1g3 46.6 MYLK4 25.6 (3.25 μM) 
CK2a 34.8 PIM1 48.8 
CK2a2 48.4 PIM3 30.4 
DAPK1 39.1 PKAcb 45.1 
DDR1 36.5 (7.79 μM) RSK4 24.0 
DDR2 104.4 TNIK 14.1 (1.64 μM) 
DYRK2 46.1 TRKB 38.9 
FLT3 5.3 (0.51 μM) TRKC 39.0 
GRK7 34.7 TXK 46.1 
GSK3a 29.9 TYRO3/SKY 29.1 (3.61 μM) 
GSK3b 39.9 YES/YES1 43.9 
HGK/MAP4K4 37.9   
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Hybrubin A was also screened against a panel of 369 wild type and mutant kinases and 
was found to have very limited kinase activity (Table 2.5).  Approximately 5% of the kinases 
screened had their activities reduced to under 40%.  Of that 5%, only seven stood out as being 
the most active.  These seven targets had follow-up IC50 determinations made and it was 
discovered that just a single kinase of the 369 screened had an IC50 below 1 μM.  That kinase, 
fms-like tyrosine kinase 3 (FLT3), is a receptor tyrosine kinase involved in regulating survival, 
proliferation, and differentiation of hematopoietic stem / progenitor cells. [123] FLT3 is overly 
expressed in actue myeloid leukemia (AML) cells in most patients and mutations of FLT3 within 
those patients can lead to more aggressive disease progression. Several inhibitors of FLT3 have 
been identified and are in clinical trials, both alone and with chemotherapy.  A standalone FLT3 
antagonist MLN518 (tandutinib) performed well in Phase 1 clinical trails with the principal dose-
limiting toxicity being reversible generalized muscle weakness and fatigue. [124] The selective 
nature of 2.1 against the kinases screened as well as its noteworthy potency against FLT3 are 
certainly highlights of the bioactivity of this “unnatural” natural product.  The kinome selectivity 
profile is summarized in visual form on the next page (Figure 2.6).   
One familiar with the individual targets / target families against which 2.1 was screened 
could almost certainly find additional interesting facets of this molecule.  For example, work 
conducted not relevant to this dissertation but still during the graduate career focused on the 
receptor tyrosine kinase DDR1.  2.1 displays modest DDR1 vs DDR2 selectivity, a feat which 
has eluded many small molecules. [125] 
 
108 
 
 
Figure 2.6.  Visual summary of the inhibitory activity of 2.1 against a panel of 369 kinases.  White 
coloration indicates kinases which where not tested; cooler colors (i.e. green, blue) indicated kinases 
against which 2.1 had noticeable activity.  Warmer colors (i.e. orange, red) indicate inactivity. 
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Continuation of the Hybrubin A Story 
 A few months after publication of the synthesis and biological activity of Hybrubin A we 
were approached by the isolation group to provide relevant intermediates and synthetic 
analogues thereof to support their biochemical investigations.  Alongside near gram quantities of 
the precursors to Hybrubin A (2.4 and 2.11) we supplied a few tetramic acid derivatives which 
were accessed via the methodologies presented in this chapter (Scheme 2.4). The only synthetic 
variation was that tetramic acid derivatives 2.25 and 2.28 where Boc deprotected utilizing 
traditional conditions of TFA in DCM, resulting in lower yields than the thermal induced Boc 
deprotection conditions employed in the total synthesis of 2.1.  This change was mandatory after 
it was discovered 2.25 and 2.28 were both volatile and prone to decomposition at temperatures  
 
Scheme 2.4.  Synthesis of novel tetramic acid building blocks for use in advancing the work of the 
Hybrubin isolation group’s continued biochemical studies. 
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around 180 oC.  Having material at their disposal, the isolation group was able to provide support 
for their hypothesis that the enzyme RedH from the host organism S.lividans (or its homolog 
PigC [126]) were the enzymes responsible for the final step of the biosynthesis of the Hyrbubins 
(Figure 2.1) At time at of their publication, the role of RedH or PigC within their in vivo 
biosynthetic synthesis of the Hybrubins was postulated but not fully supported. [89] If the isolation 
group could express stable RedH or PigC in an in vitro environment and show that these 
enzymes do indeed catalyze the final step of Hybrubin biosynthesis then this result would both 
support their original hypothesis and also greatly expand the scope of their methodology.   
Table 2.6.  Results from the in vitro biochemical reactions performed with either RedH or its homolog 
PigC, enzymes thought to be responsible for the original biosynthesis of the Hybrubin family. [89] 
Reactions were performed in 200 μL total volume DMSO solutions containing 10 mM MgCl2, 100 μM 
EDTA, 25 mM NH4Cl2, 1.25 mM ATP(Na2), 200 μM 2.4, 200 μM tetramic acid derivative, and 1-10 μM 
enzyme in 100 mM HEPES pH 7.0 buffer.  Reactions were conducted at 30 oC for 12 hours and analyzed 
via HPLC analysis of quenched, soluble reaction aliquots. 
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Indeed, either RedH or PigC was capable of performing the proposed final condensation step of 
the Hybrubin biosynthetic pathway in vitro not only with endogenous substrates but with analogs 
as well (Table 2.6).  Under their conditions both enzymes were capable of producing 2.1 via the 
union of 2.4 and 2.11 (entry A).  Three tetramic acid analogues were also suitable substrates for 
either enzyme (entries B-D) indicating that this combinatorial biosynthetic technique may allow 
for the production of many more diverse hybrubin analogues.  Interestingly, when reduced 
tetramic acid substrate 2.33 (obtained by independent means, entry E) was employed the 
researchers were unable to identify the desired product mass by HPLC, insinuating that the 
electronic properties of the tetramic acid motif are critical for the biochemical reaction.  The 
compounds provided to the isolation group, primarily 2.4 and 2.11, were used for other 
biochemical experiments to validate the role of RedH.  These results will be published in due 
course. 
Conclusion 
 Natural products have both a historical and modern relevancy to drug discovery.  While 
most traditional drug discovery programs no longer rely on the isolation and synthesis of 
unaltered natural products, it is estimated that more than half feature molecules which in some 
way have been derived from a natural product. [76]  Incorporation of natural product scaffolds into 
drug discovery paradigms is often hindered due to difficulties with the isolation of natural 
products from their endogenous source and/or synthetic challenges associated with production of 
natural product analogs.  Two synthetically orthogonal techniques, semisynthesis and 
combinatorial biosynthesis, have thus been developed and used to address these two pitfalls with 
great success over the past decades.  One example of combinatorial biosynthesis is the 
identification of the Hybrubins (2.1-2.3) which result from the fusion of biosynthetic pathways 
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from two distinct bacterial species. These compounds would otherwise not exist in nature and 
were considered an attractive lead for a total synthesis campaign.  After synthesis of Hybrubin A 
(2.1) was completed, biological testing indicated that the “unnatural” natural product was both 
non-cytotoxic and had a surprisingly clean activity profile against a large panel of kinases (Table 
2.5, Figure 2.6) as well as other relevant pharmaceutical targets (Table 2.4).  2.1 most potently 
inhibited the kinase FLT3, a common target for the treatment of acute myeloid leukemia.  The 
synthetic methodology developed for the synthesis of 2.1 was also employed to provide material 
relevant to the production of 2.1 as well as analogues thereof to the isolation group.  With this 
material the researchers were able to extend their biosynthetic methodology from in vivo to in 
vitro (Table 2.6) and help confirm the role of an important enzyme in their proposed 
biosynthetic pathway.  Through the efforts detailed in this chapter it is clear that Hybrubin A is 
an attractive lead molecule for the development of FLT3 (or the A3 receptor).  This “unnatural” 
natural product is readily prepared in three linear steps with 21% overall yield in a synthetic 
route which can allow for rapid diversification of the Hybrubin scaffold in support of 
optimization, if needed.  The preparation of analogues of 2.1 as well as studies on other relevant 
parameters (i.e. DMPK) should be pursued. 
Experimental Methods 
General Synthetic Methods and Instrumentation 
 All reagents and solvents were commercial grade and used as received.  All reactions 
were carried out employing standard chemical technique under air, unless otherwise noted.  Thin 
layer chromatography (TLC) was performed on glass-backed silica gel of 250 μm thickness.  
Visualization was accomplished with UV light and/or the use of KMnO4 stain.  Analytical HPLC 
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was performed on an Agilent 1200 LCMS with UV detection at 215 and 254 nm and 
electrospray ionization.  MS parameters were as follows: capillary voltage: 3000V, nebulizer 
pressure: 40 psi, drying gas flow: 11 L/min, drying gas temperature: 350 oC.  Samples were 
separated on an internal column (Thermo Accucore C18 2.1 x 30 mm, 2.6 μm) before ionization 
with the following solvent gradient: 7% to 95% MeCN in H2O (0.1% TFA) over 1.6 min, hold at 
95% MeCN for 0.35 min, 1.5 mL/min flow, 45 oC. Chromatography on silica gel was performed 
using Teledyne ISCO pre-packed silica gel columns using gradients of EtOAc/Hexanes or 
DCM/MeOH.  1H and 13C NMR spectra were recorded on Bruker DRX-400 (400 MHz) 
instrument and chemical shifts are reported in ppm relative to residual solvent as outlined 
previously in this chapter 
 
tert-butyl 5'-formyl-4'-methoxy-1H,1'H-[2,2'-bipyrrole]-1-carboxylate (2.15) 
       1-Boc-pyrrole-2-boronic acid (3.13g, 14.8mmol) and N-((5-bromo-3-methoxy-2H-pyrrol-2-
ylidene)methyl)-N-ethylethanamine (2.56g, 9.88mmol) were dissolved in degassed 1,4-dioxane 
(74.1mL) and water (8.2mL).  Sodium carbonate ( 3.14g, 29.64mmol) was then added and the 
mixture purged with argon for one minute before Tetrakis(triphenylphosphine)palladium(0) 
(1.14g, 0.988 mmol) was added and the reaction vessel sealed and heated to 85oC for 3.5 hours. 
The mixture was then cooled to ambient temperature and poured into water (130mL) followed by 
the slow addition of 1N aq. HCl to achieve pH = 7.  The solution was next transferred to a 
separatory funnel and extracted with DCM (3 x 70mL).  The resulting organic layers were dried 
over magnesium sulfate, filtered, and condensed directly onto silica gel for purification using 
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Teledyne ISCO Combi Flash system (solid loading, 40G column, 0-30% EtOAc, 35 min run) to 
afford tert-butyl 5'-formyl-4'-methoxy-1H,1'H-[2,2'-bipyrrole]-1-carboxylate as a light orange 
solid (1.27g, 4.37mmol, 44% yield).  1H NMR (400.1 MHz, CDCl3) δ (ppm): 10.74 (br.s, 1H), 
9.51 (s, 1H), 7.32 (m, 1H), 6.65 (m, 1H), 6.23 (t, J= 3.6Hz, 1H). 6.06 (d, J= 2.6 Hz, 1H), 3.87 (s, 
3H), 1.59 (s, 9H). 13C {1H} NMR (100.6 MHz, CDCl3) δ (ppm): 174.3, 157.7, 149.7, 130.3, 
125.9, 124.5, 118.3, 116.9, 111.5, 94.8, 85.7, 57.9, 27.9. LCMS: RT: 0.988 min., m/z = 291.1 [M 
+ H]+. HRMS-ESI: m/z calcd for C15H16N2O4 [M + H]
+ 290.1267 found 290.1267. 
 
(Z)-5-ethylidene-4-methoxy-1,5-dihydro-2H-pyrrol-2-one (2.12) 
       To a 50mL round bottom flask equipped with a magnetic stir bar was added 4-methoxy-3-
pyrrolin-2-one (1g, 8.84mmol), sodium tert-butoxide (1.7g, 17.68mmol), and lastly acetaldehyde 
(2mL, 35.36mmol).  The resulting mixture was warmed to 40oC and allowed to stir for four 
hours.  Following this, all volatiles were removed via rotovaporation with four sequential 
portions of DCM (20mL).  The resulting orange oil was condensed directly onto silica gel for 
purification using Teledyne ISCO Combi-Flash system (12G column, 30-90% EtOAc, 45 min 
run).  Careful TLC analysis of the resulting column fractions was used to selectively collect (Z)-
5-ethylidene-4-methoxy-1,5-dihydro-2H-pyrrol-2-one which upon concentration was afforded as 
a white solid (551mg, 3.96mmol, 45%). 1H NMR (400.1 MHz, CDCl3) δ (ppm): 9.01 (s, 1H), 
5.46 (q, J= 7.5 Hz, 1H), 5.09 (d, 1H, J= 1.5 Hz), 3.81 (s, 3H), 1.86 (d, J= 7.5Hz). 13C {1H} NMR 
.(100.6 MHz, CDCl3) δ (ppm): 172.8, 166.0, 134.1, 105.8, 92.4, 57.8, 12.4.  LCMS: RT: 0.112 
min., m/z = 140.1 [M + H]+, >99% abs @ 215 nm. HRMS-ESI: m/z calcd for C7H9NO2 [M + 
H]+ 139.0633 found 139.0630. 
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N-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-N-ethylethanamine (2.14) 
       A 250mL round bottom flask containing a stir bar was charged with N,N-diethylformamide 
(4.72mL, 42.44mmol) and DCM (35mL).  The mixture was then cooled in an ice bath and a 
solution of phosphorus (V) oxybromide (15.21g, 53.05mmol) in DCM (10.6) was added 
dropwise over the course of several minutes.  After addition was complete the reaction was 
allowed to stir for twenty additional minutes before a solution of 4-methoxy-3-pyrrolin-2-one 
(3g, 26.52mmol) in DCM (26mL) was introduced dropwise over the course of several minutes.  
Once the addition was complete the reaction mixture was transferred directly from the ice bath to 
metal round bottom warmer preheated to 42oC and allowed to stir for 3.5 hours.  Upon cooling of 
the reaction mixture to ambient temperature the material was transferred to a 1 L round bottom 
flask, cooled in an ice bath, and quenched with the dropwise addition of water (30mL).  Then, a 
solution of aqueous sodium hydroxide (15% w/w, 350mL) was carefully added and the resulting 
mixture allowed to stir at ambient temperature for 20 minutes.  The material was then transferred 
to a separatory funnel and extracted with DCM (3 x 120mL).  The combined organic layers were 
dried over magnesium sulfate, filtered, and condensed directly onto silica gel for purification 
using Teledyne ISCO Combi Flash system (solid loading, 40G column, 0-20% EtOAc, 25 min 
run) to afford N-((5-bromo-3-methoxy-2H-pyrrol-2-ylidene)methyl)-N-ethylethanamine as pale 
yellow crystals (3.33g, 12.8 mmol, 49% yield).  1H NMR (400.1 MHz, CDCl3) δ (ppm): 6.98 (s, 
1H), 5.58 (s, 1H), 4.11 (q, J= 7.1Hz, 2H), 3.70 (s, 3H), 3.39 (q, J= 7.2Hz, 2H), 1.28 (m, 6H) 13C 
{1H} NMR (100.6 MHz, CDCl3) δ (ppm): 165.2, 138.5, 133.4, 120.7, 96.2, 57.9, 51.1, 44.4, 
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14.5, 12.4. LCMS: RT: 0.552 min., m/z = 259.2 [M + H]
+ >99% abs @ 215 and 254nm. HRMS-
ESI: m/z calcd for C10H15BrN2O [M + H]
+ 258.0368 found 258.0368. 
 
tert-butyl 2-((R)-1-(tert-butoxy)ethyl)-3,5-dioxopyrrolidine-1-carboxylate (2.16) 
       To a solution of 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid, 1.73g, 11.99mmol) 
and 4-dimethylaminopyridine (1.86g, 15.25mmol) in DCM (72.6mL) at 0oC was added 3-tert-
butoxy-2-(tert-butoxycarbonylamino)butanoic acid (3g, 10.9mmol) and then N-(3-
dimethylaminopropyl-N`-ethylcarbodiimide hydrochloride (EDC, 2.53g, 13.07mmol).  The 
resulting mixture was warmed to ambient temperature and allowed to stir for 21 hours.  At this 
time all solvent was removed in vacuo and the resulting yellow oil resuspended in EtOAc 
(175mL) and washed with brine (2 x 80mL), 1M citric acid (3 x 100mL), and again brine 
(100mL).  The resulting organic layer was passed through a phase separator and heated to 77oC 
for 90 minutes.  Upon cooling all volatiles were removed in vacuo to afford crude tert-butyl 2-(1-
(tert-butoxy)ethyl)-3,5-dioxopyrrolidine-1-carboxylate as a yellow foamy solid (2.93g, 
9.78mmol, 89% yield).  1H NMR (400.1 MHz, CDCl3) δ (ppm): 4.59 (p, J = 6.2Hz, 1H), 4.34 (d, 
J= 5.2 Hz, 1H), 3.60 (s, 2H), 1.48 (s, 9H), 1.26 (s, 9H). 0.99 (d, J= 6.4 Hz, 3H) LCMS: RT: 
0.919 min., m/z = 621.2 [2M + Na]+, >99% abs @ 215 and 254nm. HRMS-ESI: m/z calcd for 
C15H25NO5 [M + Na]
+ 299.1733 found 299.1733. 
 
117 
 
 
tert-butyl-2-((R)-(1-(tert-butoxy)ethyl)-4-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-
yl)methylene)-3,5-dioxopyrrolidine-1-carboxylate (2.17) 
       Piperidine (389.2µL, 2.41mmol) was added to a stirring solution of tert-butyl 2-(1-tert-
butoxyethyl)-3,5-dioxo-pyrrolidine-1-carboxylate (613.55mg, 2.05mmol) in ethanol (4.8196mL).  
The resulting solution was allowed to briefly stir before tert-butyl 2-(5-formyl-4-methoxy-1H-
pyrrol-2-yl)pyrrole-1-carboxylate (350.mg, 1.21mmol) was introduced and the reaction warmed 
82oC.  After 6 hours of stirring LC/MS confirmed reaction completion and all volatiles were 
removed in vacuo to produce crude product as a pitch colored oil.  Upon purification using 
Teledyne ISCO Combi-Flash system (silica gel loading, 12G column, 15-40% EtOAc, 30 min 
run) to afford tert-butyl-2-(1-(tert-butoxy)ethyl)-4-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-
yl)methylene)-3,5-dioxopyrrolidine-1-carboxylate was obtained as a red solid and mixture of 
olefin regioisomers (387.5mg, 0.82mmol, 68% yield).  1H NMR (400.1 MHz, CDCl3) δ (ppm): 
7.42 (s, 1H), 7.10 (m, 1H), 6.91 (m, 1H), 6.39 (m, 1H), 6.20 (d, J= 2.4Hz, 1H), 4.28 (m, 1H), 
4.25 (m, 1H), 3.95 (s, 3H), 1.61 (s, 9H), 1.27 (2, 9H), 1.13 (d, J= 6.4Hz, 3H). 13C {1H} NMR 
.(100.6 MHz, CDCl3) δ (ppm):192.2, 169.8, 163.2, 149.8, 140.3, 124.2, 123.9, 123.7, 122.5, 
112.7, 111.1, 106.0, 92.7, 82.2, 74.4, 68.0, 66.5, 58.4, 28.3, 28.1, 19.9.  LCMS: RT: 1.098 min., 
m/z = 472.3 [M + H]+, >99% abs @ 215 and 254nm. HRMS-ESI: m/z calcd for C25H33N3O6 [M 
+ H]+ 471.2369 found 471.2371. 
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5-((R)-1-hydroxyethyl)-3-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)pyrrolidine-
2,4-dione (2.18) 
       A stirred solution of (E/Z)-5-(1-(tert-butoxy)ethyl)-3-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-
yl)methylene)pyrrolidine-2,4-dione (59.5mg, 0.160mmol) in chloroform (1.62mL) was treated 
with trimethylsilyl iodide (47.6µL, 0.320mmol) and allowed to stir at 45oC for one hour.  The 
reaction mixture was then cooled to ambient temperature and diluted with MeOH (1mL) before 
all volatiles were removed in vacuo.  The resulting deep red solid was dissolved in MeOH (1mL) 
and purified over a strong cation exchange cartridge with product eluting following addition of 
2M ammonia in MeOH solution after several rinses of pure MeOH.  In this manner, (E&Z)-5-(1-
hydroxyethyl)-3-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)pyrrolidine-2,4-dione was 
obtained as a fine red solid (43.3mg, 0.137mmol, 85.7%) after complete removal of all volatiles.  
1H NMR (400.1 MHz, CD3OD, inseparable mixture of olefins) δ (ppm): 7.30 (s, 2H), 7.10 (s, 
2H), 6.88 (s, 2H), 6.35 (m, 3H), 6.33 (s, 1H), 4.16 (m, 2H), 4.01 (s, 3H), 3.99 (s, 3H),  3.77 (d, 
J=3.3 Hz, 1H), 1.34 (d, J=6.5 Hz, 3H),  1.12 (d, J=6.4 Hz, 3H). 13C {1H} NMR (150 MHz, 
DMSO-d6, inseparable mixture of olefins) δ (ppm):195.83, 195.34, 173.33, 171.37, 161.47, 
161.00, 137.43, 137.13, 123.85, 123.25, 123.08, 122.12, 120.78, 120.39, 117.68, 117.38, 110.75, 
110.47, 109.75, 108.80, 107.69, 107.17, 93.16, 92.36, 67.21, 66.88, 66.66, 65.01, 58.63, 58.48, 
20.63, 17.13.  LCMS: RT: 0.833 min., m/z = 316.1 [M + H]
+, >99% abs @ 215, 254, and 300nm. 
HRMS-ESI: m/z calcd for C16H17N3O4 [M + H]
+ 315.1219 found 315.1219. 
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(Z)-5-ethylidenepyrrolidine-2,4-dione (2.11) 
       To a stirred solution of (Z)-5-ethylidene-4-methoxy-1,5-dihydro-2H-pyrrol-2-one (451mg, 
3.24mmol) in THF (64.5mL) at ambient temperature was carefully added concentrated HCl 
(38mL).  The resulting faint yellow solution was stirred at ambient temperature for 90 minutes at 
which time TLC confirmed reaction completion. Saturated aqueous sodium bicarbonate (40mL) 
was then slowly added to quench the reaction. The reaction mixture was transferred to a 
separatory funnel and extracted with EtOAc (3 x 50mL) and the resulting pooled organics were 
dried over magnesium sulfate.  Crude product was purified using Teledyne ISCO Combi-Flash 
system (solid loading on silica gel, 4G column, 20-70% EtOAc, 25 min run) to afford (Z)-5-
ethylidenepyrrolidine-2,4-dione as a light yellow solid (268.7mg, 2.15mmol, 66% yield).  1H 
NMR (400.1 MHz, CDCl3) δ (ppm): 9.32 (s, 1H), 5.76 (q, J=7.5 Hz, 1H), 3.10 (s, 2H x 1/2), 
1.82 (d, J=7.5Hz, 3H).[127,128]  13C {1H} NMR .(100.6 MHz, CDCl3) δ (ppm): 192.5, 170.9, 
136.7, 106.8, 40.7, 12.1.  LCMS: RT: 0.116 min., m/z = 126.2 [M + H]
+, >99% abs @ 215 and 
254 nm. HRMS-ESI: m/z calcd for C6H7NO2 [M + H]
+ 125.0477 found 125.0476. 
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(5Z)-5-ethylidene-3-((4-methoxy-1H,1'H-[2,2'-bipyrrol]-5-yl)methylene)pyrrolidine-2,4-
dione (7) 
       To a stirred solution of (5Z)-5-ethylidenepyrrolidine-2,4-dione (47.07mg, 0.380mmol) in 
ethanol (1.07mL) and piperidine (86.75µL, 0.54mmol) was added tert-butyl 2-(5-formyl-4-
methoxy-1H-pyrrol-2-yl)pyrrole-1-carboxylate (78.0 mg, 0.270mmol) and the resulting mixture 
warmed to 82oC and allowed to stir for 8 hours. Upon reaction completion as determined by 
LC/MS the mixture was cooled to ambient temperature and all volatiles were removed in vacuo.  
The resulting deep red gel was dissolved in a 1 mL of methanol and purified over a strong cation 
exchange column.  Desired material eluted after addition of 2M ammonia solution in MeOH; the 
organics collected from this method were brought to dryness under a steady stream of air before 
being resuspended in a 15% MeOH in DMSO solution for purification using Gilson reverse-
phase chromatography system (30 x 100mm column, 32-51% MeCN / 0.1% trifluoroacetic acid 
(aq), 9 min gradient, 300nm wavelength) to afford (5Z)-5-ethylidene-3-((4-methoxy-1H,1'H-
[2,2'-bipyrrol]-5-yl)methylene)pyrrolidine-2,4-dione as a red solid (56.2mg, 0.189mmol, 70% 
yield).  1H NMR (400.1 MHz, DMSO-d6, major regioisomer) δ (ppm): 9.87 (s, 1H), 7.188 (s, 
1H), 7.179 (s, 1H),  6.79 (br.s, 1H), 6.56 (s, 1H), 6.34 (m, 1H), 5.55 (q, J= 7.2Hz, 1H), 3.97 (s, 
3H), 1.78 (d, J= 7.2Hz, 3H).   13C {1H} NMR .(150 MHz, DMSO-d6, major regioisomer) δ 
(ppm): 182.01, 169.02, 161.61, 137.97, 136.57, 124.14, 123.53, 122.49, 121.13, 111.03, 110.38, 
105.49, 103.05, 93.30, 58.81, 12.06. FTIR: (neat) υ 2916, 2848, 2356, 2335, 1670, 1613, 1549, 
1504, 1454, 1365, 1212, 1133, 952, 808 cm-1. LCMS: RT: 0.883 min., m/z = 298.1 [M + H]
+, 
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>99% abs @ 215, 254, and 300n, HRMS-ESI: m/z calcd for C16H15N3O3 [M + Na]
+ 297.1113 
found 297.1112. 
 
(Z)-5-propylidenepyrrolidine-2,4-dione (2.23) 
       To a solution of 4-methoxy-3-pyrrolin-2-one (2.13, 330 mg, 2.91 mmol) in anhydrous 
methanol (12.9 mL) at ambient temperature was added potassium tert-butoxide (785 mg, 7.00 
mmol) followed by propionaldehyde (1.05 mL, 14.6 mmol).  The resulting mixture was sealed 
and warmed to 40 oC until TLC (5% MeOH/DCM) indicated reaction completion.  The reaction 
mixture was then cooled and condensed onto silica gel for purification using Teledyne ISCO 
Combi-Flask system (solid loading, 12G column, 0-5% DCM/MeOH, 30 minute run) to afford 
(5Z)-4-methoxy-5-propylidene-pyrrol-2-one (2.22) as a slight yellow oil (204 mg, 1.33 mmol, 
45.7% yield) . 1HNMR (400.1 MHz, CDCl3) δ (ppm): 9.09 (s, 1H), 5.34 (t, J = 15.6, 7.8 Hz, 1H), 
5.04 (s, 1H), 3.75 (s, 3H), 2.21 (p, J = 15.4, 7.7 Hz, 2H), 1.03, (t, J = 15.0, 7.7 Hz, 3H). 13C {1H} 
NNMR (150 MHz, CDCl3) δ (ppm): 172.4, 166.2, 132.6, 112.6, 92.6, 57.9, 20.4, 13.6 LC/MS RT 
0.749 min, m/z = 154.2 [M + H]+ >99% abs @ 215 & 254 nM. 
       (5Z)-4-methoxy-5-propylidene-pyrrol-2-one (2.22) (204 mg, 1.33 mmol) was dissolved in 
THF (2.25 mL) and treated with concentrated aqueous HCl (2.25 mL) at ambient temperature 
until TLC (5% MeOH/DCM indicated reaction completion.  The mixture was then neutralized at 
0 oC with the careful addition of 2N NaOH (aq) and extracted three times with ethyl acetate.  
Crude product was purified using Teledyne ISCO Combi-Flask system (solid loading on silica 
gel, 4G column, 0-60% EtOAc/Hex, 30 minute run) to afford (5Z)-5-propylidenepyrrolidine-2,4-
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dione (2.23) as an off white solid (41 mg, 0.294 mmol, 22.1% yield) 1HNMR (400.1 MHz, 
CDCl3) δ (ppm): 9.44 (s, 1H), 5.72 (t, J = 15.6, 7.8 Hz, 1H), 3.12 (s, 2H), 2.21 (p, J = 22.8, 15.2, 
7.6 Hz, 2H), 1.13 (t, J = 15.1, 7.5 Hz, 3H). 13C {1H} NNMR (150 MHz, CDCl3) δ (ppm): 192.83, 
170.87, 134.98, 113.51, 40.53, 20.10, 13.03.  LC/MS RT 0.281 min, m/z = 140.1 [M + H]
+ >99% 
abs @ 215 & 254 nM. 
 
(S)-5-propylpyrrolidine-2,4-dione (2.26) 
       To a solution of 2,2-dimethyl-1,3-dioxane, 4,6-dione (Meldrum’s acid, 364 mg, 2.53 mmol) 
and 4-dimethylaminopyridine (393 mg, 3.22 mmol) in DCM (15.3 mL) at 0 oC was added N-
Boc-L-norvaline (500 mg, 2.30 mmol) then N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (535 mg, 2.76 mmol).  The resulting mixture was warmed to ambient temperature 
and stirred for twenty hours then partially concentrated in vacuo and poured into EtOAc (25 mL)  
The organics were was with twice with brine, twice with 1M citric acid, and then once again 
with brine.  The resulting organics were dried over MgSO4, filtered, and refluxed in a sealed 
container for 90 minutes.  The organics were then dried to afford crude 2.25 as an orange foamy 
solid. 2.25 was then immediately dissolved in a 1:1 mixture of TFA:DCM and stirred at ambient 
temperature for ten minutes.  The solution was then diluted with toluene (2 mL) and brought to 
dryness.  Crude product was purified using Teledyne ISCO Combi-Flask system (solid loading, 
12G column, 0-8% DCM/MeOH, 30 minute run) to afford (5S)-5-propylpyrrolidine-2,4-dione 
(2.26) as a white solid. (83 mg, 0.587 mmol, 25.3% yield) 1HNMR (400.1 MHz, MeOD) δ 
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(ppm): 3.86 (t, J = 12.4, 6.3 Hz, 1H), 3.33 (s, 1H), 1.88 (m, 2H), 1.50 (m, 2H), 1.02 (t, J = 14.6, 
7.28 Hz, 3H). LC/MS RT 0.242 min, m/z = 142.1 [M + H]
+ >99% abs @ 215 & 254 nM. 
 
 
(S)-5-isopropylpyrrolidine-2,4-dione (2.29) 
       To a solution of 2,2-dimethyl-1,3-dioxane, 4,6-dione (Meldrum’s acid, 477.65 mg, 3.31 
mmol) and 4-dimethylaminopyridine (507 mg, 4.14 mmol) in DCM (18.4 mL) at 0 oC was added 
N-Boc-L-valine (600 mg, 2.76 mmol) then N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (696 mg, 3.59 mmol).  The resulting mixture was warmed to ambient temperature 
and stirred for twenty hours then partially concentrated in vacuo and poured into EtOAc (35 mL)  
The organics were was with twice with brine, twice with 1M citric acid, and then once again with 
brine.  The resulting organics were dried over MgSO4, filtered, and refluxed in a sealed container 
for 90 minutes.  The organics were then dried to afford crude 2.28 as an orange foamy solid. 2.28 
was then immediately dissolved in a 1:1 mixture of TFA:DCM and stirred at ambient temperature 
for ten minutes.  The solution was then diluted with toluene (2.5 mL) and brought to dryness.  
Crude product was purified using Teledyne ISCO Combi-Flask system (solid loading, 24G 
column, 0-8% DCM/MeOH, 30 minute run) to afford (5S)-5-isopropylpyrrolidine-2,4-dione 
(2.29) as a yellow solid. (93.8 mg, 0.678 mmol, 24.5% yield) 1HNMR (400.1 MHz, CDCl3) δ 
(ppm): 3.86 (d, J = 3.5 Hz, 1H), 3.44 (s, 1/2H), 2.94 (m, 1H), 2.15 (m, 1H), 1.04 (d, J = 7.0 Hz, 
3H), 0.91 (d, J = 6.9 Hz, 3H). 13C {1H} NNMR (150 MHz, CDCl3) δ (ppm): 207.59, 172.41, 69.47, 
41.37, 30.81, 18.77, 16.46. RT 0.193 min, m/z = 142.2 [M + H]
+ >99% abs @ 215 & 254 nM. 
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CHAPTER III 
 
SYNTHESIS OF NATURAL AND UNNATURAL DIBENZYLBUTANE LIGNANS FROM A 
SHARED INTERMEDIATE 
 
Background and Introduction  
Lignan Natural Products 
 
 Lignans are an enormous class of secondary metabolites found in over seventy families 
of the plant kingdom [129] including edible species such as flaxseed [130].  Classic lignans are 
derived from the shikimic acid biosynthetic pathway and can possess one of ten known structural 
subtypes which arise from the dimerization of two phenylpropane units in a β-β’ (or 8-8’) 
fashion. (Figure 3.1A/B). [131] If more than two phenylpropane units are incorporated into a 
compound they are then referred to as lignins (i.e. cellulose). [132] In brief, the seven step 
shikimate pathway yields chorismic acid which undergoes a Claisen rearrangement mediated by 
chlorismate mutase followed by a decarboxylate aromatization and transamination to afford 
phenylalanine.  Action of phenylalanine ammonialyase then produces cinnamic acid which can 
be subjected to several different pathways resulting in different aromatic oxygenation profiles.  
Reduction of these advanced biosynthetic intermediates by cinnamyl alcohol dehydrogenase 
eventually leads to the phenylpropane lignan building blocks. At this juncture several enzymes 
have been identified which promote dimerization and these are referred to as divergent proteins 
(DIR).  Following dimerization continued biosynthetic transformations may still occur. Several 
other classes of lignans are known (i.e. neolignans) and these differ from classical lignans by the 
lack of β-β’ dimer linkages and additional structural diversity.  For this reason, only classical 
lignans will be addressed here.  In their endogenous biological systems the exact role of plant 
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lignans is unclear.  They are known secondary metabolites and some speculate they serve as 
defense against pathogens and pests, although anecdotal evidence exists counter to that point. 
[133] Many plants containing lignans serendipitously found use in traditional folk medicine in 
would healing, anti-inflammatory, and anti-rheumatic settings. [134]   More recent profiling of 
isolated lignans has revealed numerous pharmacological roles for this group of natural products.  
Some roles include antiviral activity [135] including HIV [136], mild anti-cancer (colon carcinoma) 
 
Figure 3.1. (A) Generalized biosynthesis of lignan natural product precursor phenylpropane units starting 
from Shikimic acid; (B) The ten known structural classes of lignans; (C) Structures of some select lignans 
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activity [137], neuroprotective effects against CoCl2 and H2O2 induced cell injury 
[138] as well as 
against glutamate induced neurotoxicity in primary cultures of rat cortical cells [139],  
antileishmanial potential against axenic amastigote forms of Leishmania amazonensis [140], 
antifungal [134], and several other activities including anti-inflammatory, immunosuppression, and 
antioxidant [129,131].  One particular lignan, podophyllotoxin, is an FDA approved treatment for 
genital warts (under the name Podofilox) as well as a promising lead for treatment of non-small 
cell lung cancer. [141]   Even increasing intake of dietary lignans has been shown to produce a 
beneficiary effect in the form of lowering low-density lipoprotein levels. [142]    
Previous Syntheses of Dibenzylbutane Lignans  
The synthetic targets to be presented in this chapter are of the dibenzylbutane type and as such 
only a select, informative few syntheses of these natural products are featured here as opposed to 
a survey of synthetic techniques for the entirety of classic lignans.  An early example of rapid 
entry into this class of natural products was presented in 1978 by the Williams group at Brandies 
University (Figure 3.2A)  [143]  Compounds of type 3.3 and 3.6 (either prepared meso or racemic 
dependent on choice of reactants) can be prepared via the alkylation of the sodium enolate of 3.1 
with α-bromo compounds of types 3.2 or 3.5 in liquid ammonia. [144] The resulting intermediates 
could then be smoothly transformed into desired lignans by action of palladium on carbon under 
hydrogen gas.  Despite the robust nature of this synthetic approach, it is limited by its ability to 
produce only racemic (or meso) materials.  Kumada and coworkers also described a robust route 
to dibenzylbutane lignans (Figure 3.2B). [146] Beginning with 3,4-dibromo thiophene 3.8 a 
double Kumada coupling with Grignard reagents of type 3.9 yields thiophene derivatives 3.10 (R 
groups on each phenyl ring do not need to be equivalent).  This thiophene derivative can then 
undergo desulfurization by Raney nickel to afford a stereochemical 
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Figure 3.2. (A) – (C) A sampling of methods to synthesize dibenzylbutane lignans.  See references 143, 
145, and 146.  
mixture of lignan cores.  Initial approaches to optical active lignans focused on the exploitation 
of chiral lactone building blocks such as 3.13 / 3.14 (Figure 3.2C). [147] These lactones could be 
prepared following a Stobbe condensation between a desired aryl aldehyde and methyl succinate 
followed by hydrogenation of the resulting olefin and separation of enantiomers, usually via 
crystallization.  Several synthetic manipulations were then required to advance to a diverse array 
of lignans, not just dibenzylbutanes.  Similar optically active lactones can be prepared from L-
glutamic acid, although the synthetic route is cumbersome and will not be reported here. [147] To 
date stereoselective synthesis of dibenzylbutane lignans remains underrepresented in the  
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Figure 3.3. Ender’s and coworkers asymmetric approach to a dibenzylbutane lignan natural product. See 
reference 148. 
 
literature, despite the potential pharmacological promise these compounds hold.  An important 
precedent in this regard was set by Enders and coworkers in 2005 (Figure 3.3). [148]  Piperonal 
(3.15) was first condensed with chiral amine auxiliary 3.16 under modified Strecker conditions.  
The resulting α-cyano amine was deprotonated with LDA and reacted with enone 3.18 to provide 
the Michael adduct 3.19 in > 96% de.  Formation of the potassium enolate of 3.19 with 
potassium diisopropylamide (KDA) and alkylation with methyl iodide furnished amino nitrile 
3.20 in high yields with excellent stereoselectivity.  Finally, hydrolysis provided desired 
dibenzylbutane lignan 3.21.  It should be noted the enantiomer of the final product could also be 
prepared utilizing the opposite enantiomer of 3.16 as chiral auxiliary.  This method provides 3.21 
in a longest linear sequence of four steps (six total) and an overall yield of 48%.  While brief and 
high yielding, unlike previous asymmetric synthesis of dibenzylbutane lignans, this method is 
hindered by a lack of readily incorporated structural diversity. 
 As an alternative to chiral auxiliaries, advantageous use of reactive intermediate species 
has been employed to generated asymmetric lignan analogues. [149] En route to a tetra-substituted  
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Figure 3.4.  Discovery by Maesaki and coworkers of a diastereoselective alkylation reaction of lignan 
like materials without use of a chiral auxillary.  See references 149 and 150. 
 
tetrahydrofuran lignan Maesaki and coworkers identified a diastereoselective methylation of an 
advanced intermediate (Figure 3.4).  They discovered that by adding 5 equivalents of HMPA to 
the reaction mixture they could achieve a dr of 14:1 of the resulting alkylation.  Support for this 
observation is provided by consideration of A1,3 strain of the intermediate enolate which would 
situate the large benzyl alcohol “R” group in such a manner that it could block approach of the 
electrophile from the same face.  The presence of HMPA may be critical for the solubility of the 
potassium ion which in turn may help reinforce the steric constraints of the A1,3 strain; removal 
of the potassium ion from the mixture with 18-crown-6 reduced dr significantly.  This approach 
was exploited in the total synthesis of Gymnothelignan N in which the team achieved a 
diastereoselective alkylation of a similar intermediate with dr = 12:1. [150]   
The Concept of “Drug-likeness”  
 The rationale as to why it is important to pursue natural products for novel small 
molecule drug discovery was presented in chapter II, and now here a brief discussion on the 
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concept of drug-likeness is due.  Drug-likeness is a term coined to describe how similar a 
particular compound is to the average properties of approved small molecule therapeutics. [151]  
This concept is most widely recognized as an extension of Lipinski’s rules [152] which state that 
drug-like molecules should be small, have minimal hydrogen bonding capability, and not be 
overly lipophilic.  The subject of much debate and critical first-hand evidence of their 
shortcomings, Lipinksi’s rules have been subjected to a number of critiques and modifications. 
[153] Strict adhesion to these rules has led largely to aromatic, planar compounds often suffering 
from poor solubility and the repeated occurrence of related chemotypes.  Recently an interest in 
nontraditional drug-like space has emerged after success of molecules in the clinic which 
completely ablate the now two decade old Lipinski Rules. [154]  Since the physical, biological, and 
toxicological properties of a small molecule are linked to its structure it is generally accepted that 
novel structures may have novel (and worthwhile) drug-like profiles.  One major aspect of 
nontraditional drug-like space is the inclusion of small molecules with chiral centers and 
increasing the amount of sp3 character in a molecule (that is mainly to reduce the number of 
aromatic systems).[154]  It is for this reason that natural products, again, are enticing leads for drug 
discovery programs given their often chiral nature and unique structural elements. 
Conclusion 
 Classic lignans represent a class of natural products with enormous structural diversity 
and potential pharmacological benefits. [129,131,133-141]  When coupled with their apparent 
“druglikeness” (i.e. minimum hydrogen bond donors/acceptors, high sp3 character, moderate 
lipophilicity) [154]  the possibility of exploring these compounds as leads for drug discovery 
efforts becomes more viable.  The subset of classic lignans referred to as dibenzylbutanes remain 
relatively underexplored in terms of biological effects as compared to some other subsets of 
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classic lignans. [129,131]  Several synthesis of these types of compounds have been reported, but 
historically these synthetic routes prepared either racemic materials [143,145] or rely on tedious 
syntheses of chiral precursors beginning from the chiral pool [147] or from asymmetric catalysis 
[103].  More recent syntheses of dibenzylbutanes employ chiral auxiliaries [148] or take advantage 
of fundamental thermodynamic constraints (i.e. A1,3 strain) 
[149,150] to achieve desired 
stereocontrol.  Given the lack of synthetic routes - to our knowledge - which fail to combine the 
ease of analog generation seen in early, racemic routes to dibenzylbutanes with the desired levels 
of stereocontrol in modern routes we desire to develop a generalized synthetic sequence capable 
of producing a number of lignans from a common intermediate(s).  Ideally, such a sequence will 
incorporate chiral elements with a high degree of control, minimize extraneous synthetic 
operations, and feature a handle for late-stage derivatization to produce unnatural analogs.  The 
proceeding chapter will detail the realization of these goals alongside a brief discussion of the 
current state of the project. 
Materials and Methods 
General Synthetic Methods and Instrumentation. 
 All chemical reactions were carried out employing standard laboratory techniques under 
air, unless otherwise noted. Solvents used for extraction, washing, and chromatography were 
HPLC grade. All commercially available reactants and reaction solvents were used as received, 
unless otherwise noted.  Analytical thin layer chromatography was performed on 250 μm silica 
gel plates from Sorbent Technologies.  Analytical LC/MS analysis was performed on an Agilent 
1200 LCMS with electrospray ionization in positive ion mode and UV detection at 215 and 254 
nM. Compounds submitted for assays were determined to be >95% purity by UV absorbance.  
All NMR spectra were recorded on a 400 MHz Bruker AV-400 instrument unless otherwise 
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noted. 1H chemical shifts were reported as δ values in ppm relative to the residual solvent peak 
(CDCl3 = 7.28).  Other calibrations may be employed when necessary to match previous 
literature reports and this will be made clear when applicable.   Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = 
quartet, m = multiplet, br = broad), coupling constant (Hz), and integration.  13C chemical shifts 
are reported as δ values in ppm relative to the residual solvent peak (CDCl3 = 77.1).  Low 
resolution mass spectra were obtained on an Agilent 1200 LCMS with electrospray ionization.  
High resolution mass spectra were recorded on a Waters QToF-API-US plus Acquity system 
with electrospray ionization.  Automated flash column chromatography was performed on a 
Teledyne ISCO Combiflash Rf system.  Preparative purification of select compounds was 
performed on a Gilson chromatography system using a GX-271 liquid handler a Gemini 100 x 
30 mm 5u C18 110A column using an acetonitrile / 0.05% NH4OH (aq) gradient. 
Asymmetric Synthesis of Lignans 
Identification of Lignan Natural Product Targets 
 Given the breadth of diversity available to pursue synthetically in the dibenzylbutane 
family of classic lignans it was decided to screen the literature and find a collection of isolated 
natural products which could potentially arise from common intermediate(s) (Figure 3.5).  This 
culminated in the observation that intermediate 3.25 could be transformed in a few synthetic 
operations to a suite of lignans including: Schibitubin G (3.26) [138] , lignans from Nectandra 
puberula (3.27, 3.28) [155] , Oleiferin-F (3.29) [133] , a lignan from Virola Aff. Pavonis (3.30) [156] , 
magnovatin B (3.31) [157], and austrobailignan-6 (3.7) [158].  One key feature of 3.25 is the 
inclusion of the benzyl protected phenol motif which upon deprotection can allow for the  
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Figure 3.5.  Structures of known lignans which might all be synthetically derived from intermediate 3.25.  
See text for all references. 
 
synthesis of veratyl and guaiacyl groups as well as unnatural analogs.  A second key feature of 
3.25 is the single stereocenter present which, based off of literature precedent [149,150] , could be 
used to set future asymmetric centers precluding the need for chiral auxiliaries.  With a common 
precursor in mind a brief synthetic scheme for a robust synthesis was proposed (Scheme 3.1).  
An Evan’s asymmetric alkylation reaction [159] between an (S)-Evans auxiliary and known benzyl 
bromide 3.33 [160] would produce the (S)-methyl compound 3.35.  Then a twostep sequence of 
auxiliary cleavage and Appel reaction [161] should produce alkyl iodide 3.36.  Incorporation of the 
piperonyl motif was envisaged to proceed one of two ways.  First, a lithium- halogen exchange  
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Scheme 3.1.  Proposed forward route to achieve the synthesis of common intermediate 3.25. 
 
[162] between alkyl iodide 3.36 and t-BuLi followed by attack of this nucleophilic species on 
piperonal and a subsequent oxidation could furnish aryl ketone 3.25.  Second, a reductive 
coupling approach of 3.36 with commercially available acid chloride 3.37 mediated under nickel 
catalysis with a stoichiometric metal reductant [163], palladium catalysis and the corresponding 
alkyl zinc species formed via use of a zinc-copper couple [164], or uncatalyzed addition of the 
organozinc directly into the acid chloride [165].  From 3.25 desired lignan targets could be 
achieved by sequences comprising mainly of α-keto methylation or methyleneation, keto 
reductions, benzyl ether cleavage, and alkylation of phenolic species. 
Synthesis of Natural and Unnatural Lignans 
 Naturally, efforts towards the total synthesis of dibenzylbutane lignans began with the 
synthesis of key intermediate 3.25 (Scheme 3.2, Table 3.1).  Following known chemistry, 
commercially available benzyl protected vanillin was converted into benzyl bromide 3.33. [160] 
The asymmetric Evan’s alkylation proceeded in high yield and excellent diastereoselectivity 
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Scheme 3.2. Synthesis of alkyl iodide 3.36. Reagents and conditions: (a) NaBH4, MeOH, r.t., 30 min; (b) 
PBr3, Et2O, 3 hr, 57% yield over two steps [92]; (c) LiHMDS, THF, -78 oC – 0 oC 2.5 hr, 90% d.r. >20:1; 
(d) LAH, THF, 0 oC, 30 min, 85%; (e) PPh3, ImH, I2, DCM, r.t., 2 hr, 87%. 
 
when LiHMDS was employed as the base with the commercially available and readily prepared 
(S)-benzyl auxillary 3.39.  When freshly prepared LDA was used for this transformation, a dr of 
20:1 was still obtained but yields dropped dramatically to 44-48%.  Conversion of intermediate 
3.40 to alkyl iodide 3.36 proceed in 74% yield across a two-step sequence of lithium aluminum 
hydride mediated auxiliary cleavage and Appel reaction with molecular iodine.  This particular 
Appeal reaction was rather sensitive to workup protocol.  For highest yields the crude reaction 
mixture must be diluted with excess DCM and shaken with the least volume possible of aq. 
sodium thiosulfate to completely remove the mixture of color.  At this stage the pursuit of 
coupling 3.36 with the desired piperonyl unit began (Table 3.1).  Attempts at employing a 
lithium-halogen exchange revealed that this particular transformation is highly sensitive to 
reaction conditions.  First, the best yields are obtained when both 3.15 and 3.26 are in solution 
together before treatment with t-BuLi as opposed to attempting to form the lithiate then adding 
piperonal (entries A, D).  Second, the quality of t-BuLi employed was of great importance as, 
rather oddly, an older bottled titrated to 0.85 M performed much better than a fresh, unopened 
bottle from Sigma-Aldrich used at the label indicated concentration of 1.7 M (entries A, B).  The  
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Table 3.1.  Survey of some reaction conditions employed for the unison of alkyl iodide 3.36 with the 
piperonyl unit of the desired advanced intermediate 3.25. Yields refer to isolated products, except for 
entry H in which the yield is based off of crude LC/MS. See text for additional details. 
 
major side product of this reaction was identified to be protodehalogenated anisole 3.43.  A 
reasonable assumption as to its formation was the presence of advantageous water which might 
quenched the highly reactive organolithium intermediate.  To address that concern it was 
discovered that first drying a mixture of 3.36 and 3.15 azeotropically with toluene improved 
yields nearly two-fold (entries A, C) although formation of 3.43 still occurred. Although 
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inconsequential, reactions with t-BuLi produce material with a d.r. of 2:1 regardless of reaction 
scale.  No efforts were made to identify the favored diastereomer. Attempts at forming the more 
stable organozinc species following by trapping with piperonal were unsuccessful (entries E-G). 
The formation of 3.43 (entry E) indicated that zinc insertion was occurring [165] but the resulting 
intermediate was too unreactive to react with 3.15.  The use of elemental indium as the metal 
reductant with a catalytic amount of CuI for this Barbier-Grignard type reaction was also found 
to be an unreactive system (entry G). [166] Using palladium catalysis to couple the organozinc 
compound with 3.37 failed and was one of the first reactions attempted to bring in an acid 
chloride to circumvent the necessary oxidation of 3.42 (entry H). [164] A nickel catalyzed 
reductive coupling employing zinc as the metal reductant furnished no desired material and 
complete conversion of the starting alkyl iodide to the corresponding organozinc was not noted 
after three days (entry I). [167]   Fortuitously, similar reaction conditions with manganese as the 
metal reductant were able to provide access to pure 3.25 in yields matching the best reaction 
outcome of the lithium-halogen exchange (entry J). [163] Several attempts to utilize zinc-copper 
couple [164] for the desired transformation were employed but all provided either no reaction or 
intractable mixtures and as such these experiments are summarized as a single entry (entry K). 
 Despite difficulty in optimizing yields an operable route to the key intermediate 3.25 has 
been developed. In the event that benzylic alcohol 3.42 is on hand, an oxidation mediated by 
catalytic amounts of 2,2,6,6-Tetramethylpiperidinyloxy (TEMPO) and phenyliodine(III) 
diacetate (PIDA) can provide 3.25 (Scheme 3.3). [168] From this key intermediate a number of 
targets were readily synthesized.  Following literature precedent, the methylation of ketone 3.25 
proceeded well, but with dr of 5:1 as opposed to >10:1 obtained in other analogous systems. 
[149,150] One observation to support this experimental outcome is that the lignans employed in the  
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Scheme 3.3.  Synthesis of natural and unnatural lignans from 3.25.  Reagents and conditions: (a) 
TEMPO, PIDA, DCM. 40 oC 2 hrs, 79%; (b) KHMDS, HMPA, MeI, THF, -78 oC 50 min, 70%, d.r. 5:1 
inseparable; (c) Pd/C, H2, EtOH, r.t. 17 hrs, 36% d.r. > 20:1 3.44 to 3.45; (d) K2CO3, MeI, MeCN, 40 oC 7 
hrs, 74%; (e) K2CO3, 1-iodopropane, MeCN, 40 oC 18 hrs, 71%; (f) AlCl3, anisole, DCM, r.t. 2hrs, 42% 
3.44 to 3.27; (g) PPh3, DIAD, 3-butyn-1-ol, DCM, r.t. 18 hrs, 47%. 
 
literature feature a bulky silyl protected alcohol functionality on the butane chain which may 
play a role in guiding the stereochemical outcome of the reaction.  The important role of the 
HMPA additive was confirmed by these experiments, as the reaction performed on 3.25 without 
HMPA resulted in product with dr < 3 :1.  Separation of the diastereomers of 3.44 by either 
normal or reverse phase chromatography proved unsuccessful.  Initial attempts at elaborating 
aryl ketone 3.44 to target lignans considered a two-step keto reduction / benzyl deprotection 
sequence.  This consideration was quickly cast aside when it was discovered that high catalyst 
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loadings of palladium on carbon under an atmosphere of hydrogen can effect both 
transformations in the same reaction. [143] The major constituent of the crude reaction mixture 
obtained after removal of the palladium was determined to be 3.45 after isolation and 
spectroscopic identification by comparison to reported lignans. [156] The most feasible 
explanation for the preferential formation of the (S)-benzyl alcohol is that the vic-dimethyl 
functionality blocks the approach of the large palladium catalyst from the same face in which 
they reside.  After column chromatography, 3.45 can be obtained in high diastereomeric purity 
(dr 20:1).  While not a natural lignan in its own right, 3.45 can be considered an unnatural lignan: 
7-epi-Oleiferin-F. [133] Access to this material may be of interest as “anticipated natural products” 
and pseudo-natural products are emerging as popular leads for some pharmacological studies. 
[169] Indeed, given the great diversity that exists within the class of dibenzylbutane lignans, 3.45 
may be a lignan waiting to be discovered.  Diversification of this intermediate can either furnish 
a known lignan from Virola Aff. Pavonis (3.30, dr >20:1) [156] or an unnatural analog thereof 
(3.46, d.r. > 20:1) depending on choice of electrophile in the phenol alkylation reaction.  As 
presented this synthetic route provides access to 3.45 and 3.30 in 6 steps and 7% yield or 7 steps 
and 5% yield, respectively.  The synthetic route is modular, capable of producing products with 
excellent d.r. without the use of chiral auxiliaries throughout, and has the potential for late-stage 
modification.  Propoxy congener 3.46 was prepared to increase the lipophilicty of molecule and 
showcase potential late-stage modifications that can be made on this scaffold. 
 A slightly different synthetic path from 3.25 & 3.44 was simultaneously cultivated to 
arrive at an additional set of natural and unnatural lignans (Scheme 3.3).  Selective O-
debenzylation of 3.44 with aluminum chloride and anisole [170] proceeded smoothly and provided 
a polar enough compound such that the diastereomers could be separated via column 
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chromatography resulting in the isolation of 3.27 with dr >20:1.  This transformation was pivotal 
as it allowed for protecting group removal without affecting the aryl ketone. The spectra of 
synthetic 3.27 matched that of the natural isolated material with great agreement, thus 
representing the synthesis of another natural lignan from 3.25. [155]  The related dimethoxy lignan 
natural product 3.28 was prepared following identical conditions as the previous phenol 
methylation.  An unnatural analog (3.47) was prepared by subjecting 3.27 to standard Mitsunobu 
reaction [171] conditions with 3-butyn-1-ol.  Attempting to employ the primary bromide congener 
of 3-butyn-1-ol in a standard substitution reaction with potassium carbonate as base was 
unsuccessful.  This result is most likely explained by the inferior stability of the parent bromide 
as compared to the alcohol.  The incorporation of the alkyne reactive handle is of great 
importance as it may be utilized for relevant biochemical pursuits via “click” chemistry. [172] 
 In total this work has produced three natural lignans (3.27, 3.28, and 3.30) alongside 
three unnatural analogs (3.45, 3.46, 3.47).  This particular set of products is derived from the 
common intermediate 3.44 which is prepared in just five steps from known materials in 20% 
overall yield.  Routing synthetic manipulations from 3.44 are sufficient enough to produce these 
materials which can be isolated in high diastereomeric purity via column chromatography.  Key 
to the success of this synthetic route is the ability of the initially set stereocenter of 3.40 to guide 
the stereochemical outcome of proceeding transformations thus obviating the need of a chiral 
auxiliary to be continually present.  Additionally, the presence and ease of removal of the benzyl 
protected phenol allows for late stage derivatization.  To our knowledge the asymmetric 
synthesis of each natural lignan has yet to be reported in the literature.  Furthermore, this 
platform also represents the first of its kind which allows the rapid synthesis of a suite of 
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stereodefined dibenzylbutane analogs which may enable studies on the biological properties of 
these molecules. 
Efforts Towards the Synthesis of Schibitubin G 
 Concurrent with the studies discussed above, the potential for 3.25 to be advanced via 
methyleneation and converted into the lignan Schibitubin G (3.26) [138] were undertaken.  This 
endeavor was met with immediate strife as the proposed methyleneation reaction proved difficult 
to optimize (Table 3.2).  Initially, the utility of Eschenmoser’s salt (3.49) for this transformation 
was explored under mild basic conditions (entry A [173]) and forcing acidic conditions (entries B, 
D).  While the former permitted no reaction to occur the later was able to provide an inseparable 
mixture of desired material and unreacted starting material; microwave irradiation did not 
improve reaction outcome but rather decomposed the reaction mixture.  Conditions featuring the 
in situ formation of an active iminium ion were employed (entries C [174] , F [175], G [176], H, and L 
[177]) all struggled to convert 3.25 even after ample reaction times.  Less traditional conditions 
such as a boronic acid catalyzed methyleneation (entry E) and conditions in with the methylene 
group is derived from the reaction solvent (DMSO, entry J [178] ; DMA, entry K [179]) also proved 
unfitting to affect the desired transformation.  It seemed that a one-step methyleneation would be 
incompatible with 3.25 so a stepwise procedure involving formation and isolation of the 
Mannich intermediate followed by a Cope elimination was attempted (entry M [180]) which to our 
delight furnished spectroscopically pure 3.48.  A similar condition employing diiodomethane 
(and a predicted base-promoted elimination) instead of Eschenmoser’s salt was attempted to no 
success (entry N). 
 With the challenging methyleneation transformation addressed we next sought to fully 
deoxygenate the aryl ketone motif (Table 3.3).  Direct reductions are typically challenging for α-  
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Table 3.2.  Screening of reaction conditions for the methyleneation of 3.25. All yields refer to isolated 
materials. 
 
β-unsaturated systems. [97] Wolff-Kisher conditions often give cyclized pyrazoline products while 
Clemmensen conditions are capable of both 1,2 and 1,4 reductions and often provide reaction 
mixtures containing both products.  With this in mind we first reduced 3.48 to benzyl alcohol 
3.50 via treatment with LAH.  This transformation provided a crude mixture of 3.50 in high yield 
and as an inconsequential 2:1 mixture of diastereomers.  Several deoxygenation protocols were 
attempted and are presented here in terms of alcohol activating reagent and reductant. 
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Table 3.3.  Screening of various reagent combinations to afford the desired deoxygenation of 3.50. (a) 
Results were based of analysis of LC/MS spectra.  All yields refer to isolated materials. 
 
  First, we attempted a method reported by Corey and coworkers involving activation of the 
alcohol followed by reduction with LAH (entry A). [181] This method was reported to not induce 
olefin isomerization in allylic systems and we were able to confirm that feature in our system.  
However, these conditions furnished solely a cyclized product, presumably of structure 3.51 
based off analogy with other lignan natural products.  Activation of the alcohol via formation of 
a tosylate and subsequent reduction with LAH proved to be too mild as a significant amount of 
starting material was recovered without formation of desired product (entry B).  The use of the 
common reagent combination of BF3-OEt2 and triethylsilane 
[182] (entry C) resulted in the 
formation of a complex mixture devoid of any desired product observable by LC/MS.  Next, we 
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attempted activation with strong protic acid trifluoroacetic acid (TFA) which did not result in 
reaction mixture decomposition but also did not provide the desired deoxygenation (entry D).  
Milder acidic activation via lithium perchlorate was insufficient to induce the deoxygenation 
(entry E). [183] Reduction and activation by the highly reactive chemical species alane (entry F 
[184] ), standard Barton-McCombie deoxygenation conditions (entry G [185]), and conditions which 
presumably proceed through a carbanionic intermediate (entry H [186] ) all failed to produce the 
desired deoxygenated product.  It appeared fairly obvious to us that the competing Friedel-Crafts 
type alkylation is the preferred pathway regardless of reaction condition choice.  For this reason, 
and also due to the success of the other aspects of this project, we elected to abandoned pursuit 
of Schibitubin G. 
Conclusion 
 Lignans are an enormous class of natural products with great structural and 
pharmacological diversity. [129,131,133-141] When paired with their apparent “druglikeness” these 
natural products can be viewed as attractive chemical matter to pursue in the development of 
therapeutic small molecules. [154] Key to the success of such a goal is the viability of a synthetic 
route which can be used to generate natural lignans and unnatural analogs thereof to advance a 
program.  Some structural classes of lignans, such as dibenzylbutyrolactones, have platforms 
developed to rapidly synthesize desired analogs. [160] While several syntheses of dibenzylbutane 
analogs have been reported which are high-throughput and modular, [129,131,143,145,187] these fail to 
produce asymmetric analogs.  Initial reports of asymmetric dibenzylbutane lignan synthesis 
require special chiral auxiliaries, tedious synthetic manipulations, and have been shown to 
produce only a single natural product. [148] To address this shortcoming we have developed a 
synthetic route capable of both lignan analog generation which simultaneously can achieve target 
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molecules in high diastereomeric purity. Relevant extensions of this methodology and biological 
assessments of lignan analogs represent future directions for this project.  Given the ease by 
which the cyclization of 3.50 proceeded, a logical starting point would be the pursuit of 
aryltetralin lignans. 
Experimental Methods 
General Synthetic Methods and Instrumentation 
 All reagents and solvents were commercial grade and used as received.  All reactions 
were carried out employing standard chemical technique under air, unless otherwise noted.  Thin 
layer chromatography (TLC) was performed on glass-backed silica gel of 250 μm thickness.  
Visualization was accomplished with UV light and/or the use of KMnO4 stain.  Analytical HPLC 
was performed on an Agilent 1200 LCMS with UV detection at 215 and 254 nm and 
electrospray ionization.  MS parameters were as follows: capillary voltage: 3000V, nebulizer 
pressure: 40 psi, drying gas flow: 11 L/min, drying gas temperature: 350 oC.  Samples were 
separated on an internal column (Thermo Accucore C18 2.1 x 30 mm, 2.6 μm) before ionization 
with the following solvent gradient: 7% to 95% MeCN in H2O (0.1% TFA) over 1.6 min, hold at 
95% MeCN for 0.35 min, 1.5 mL/min flow, 45 oC. Chromatography on silica gel was performed 
using Teledyne ISCO pre-packed silica gel columns using gradients of EtOAc/Hexanes or 
DCM/MeOH.  1H and 13C NMR spectra were recorded on Bruker DRX-400 (400 MHz) 
instrument and chemical shifts are reported in ppm relative to residual solvent as outlined 
previously in this chapter 
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(S)-4-benzyl-3-((R)-3-(4-(benzyloxy)-3-methoxyphenyl)-2-methylpropanoyl)oxazolidin-2-
one (3.40) 
  (S)-(+)-4-benzyl-3-propionyl-2-oxazolidinone (4.8g, 20.6 mmol) was placed in an oven 
dried vial under an argon atmosphere.  The solid was suspended in THF (43.0 mL), cooled to -78 
oC, and treated with LiHMDS (22.6 mL, 1.1 equiv., 1 M solution in THF) for one hour.  Then, 1-
benzyloxy-4-(bromomethyl)-2-methoxy-benzene (12.6 g, 2 equiv., as a solution in 24 mL THF) 
was added and the mixture warmed to 0 oC and stirred for an additional two hour and a half 
hours.  The reaction mixture was quenched via the addition of sat. aq. NH4Cl and extracted with 
diethyl ether. The combined organics were dried over MgSO4, filtered, and condensed directly 
onto silica gel for purification using Teledyne ISCO Combi-Flash system (solid loading, 120G 
column, 5-35% EtOAc, 16 CV) to afford (4S)-4-benzyl-3-[(2R)-3-(4-benzyloxy-3-methoxy-
phenyl)-2-methyl-propanoyl]oxazolidin-2-one (3.40) (8.5 g, 18.5 mmol, dr >20:1, 90.1% yield) 
as a white foamy oil.  1HNMR (400 MHz, CDCl3): δ 7.29 (d, J = 6.0 Hz, 2H), 7.20 (m, 2H), 7.14 
(m, 4H), 6.91 (m, 2H), 6.81 (d, J = 1.5 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 6.64 (dd, J = 8.1, 1.6 
Hz, 1H), 4.98 (s, 2H), 4.53 (m, 1H), 4.02 (m, 2H), 3.95 (dd, J = 9.1, 3.0 Hz, 1H), 3.77 (s, 3H), 
2.98 (q, J = 20.8, 13.2, 7.5 Hz, 1H), 2.91 (dd, J = 13.6, 3.2 Hz, 1H), 2.51 (q, J = 20.8, 13.2, 7.5 
Hz, 1H), 2.45 (dd, J = 13.6, 9.0 Hz, 1H), 1.09 (d, J = 6.8 Hz); 13CNMR (100 MHz, CDCl3): δ 
176.5, 153.1, 149.5, 146.8, 137.3, 135.1, 132.5, 129.4, 128.8, 127.7, 127.2, 127.2, 121.4, 113.9, 
112.9, 71.0, 65.8, 55.9, 55.0, 39.7, 39.5, 37.6, 16.7; HRMS (ESI): for C28H30NO5
+ [M+H]+ : 
calculated: 460.2119; found: 460.2119; [α]D20 = -44.6 (c = 1, CHCl3); 
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(R)-3-(4-(benzyloxy)-3-methoxyphenyl)-2-methylpropan-1-ol (3.41) 
(4S)-4-benzyl-3-[(2R)-3-(4-benzyloxy-3-methoxy-phenyl)-2-methyl-
propanoyl]oxazolidin-2-one (3.40) (8.3 g, 18.1 mmol) was dissolved in THF (78.5 mL) and 
placed under an atmosphere of argon at 0 oC.  Lithium aluminum hydride (43.4 mL, 2.4 equiv., 
1M solution in THF) was then added and the reaction stirred for 40 minutes.  The reaction was 
carefully quenched with 170 mL sat. aq. NH4Cl and 17.0 g solid Na2SO4.  The mixture was 
warmed to ambient temperature and extracted with EtOAc.  The combined organics were washed 
once with brine before being dried over MgSO4, filtered, and condensed onto silica gel for 
purification using Teledyne ISCO Combi-Flash system (solid loading, 80G column, 15-45% 
EtOAc/Hex, 13 CV) to afford (2R)-3-(4-benzyloxy-3-methoxy-phenyl)-2-methyl-propan-1-ol 
(3.41) (4.4 g, 15.3 mmol, 84.5 % yield) as a clear oil. 1HNMR (400 MHz, CDCl3): δ 7.47 (d, J = 
7.2 Hz, 2H), 7.39 (t, J = 14.7, 7.1 Hz, 2H), 7.32 (m, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.76 (d, J = 
1.9 Hz, 1H), 6.67 (dd, J = 8.3, 1.9 Hz, 1H), 5.15 (s, 2H), 3.90 (s, 3H), 3.54 (dd, J = 10.2, 5.9 Hz, 
1H), 3.48 (dd, J = 10.8, 6.0 Hz, 1H), 2.72 (dd, J = 13.5, 6.3 Hz, 1H), 2.38 (dd, J = 13.4, 8.0 Hz, 
1H), 1.94 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 149.5, 146.4, 137.4, 
134.0, 128.5, 127.7, 127.3, 121.1, 114.1, 113.0, 71.2, 67.6, 56.0, 39.3, 37.8, 16.5; HRMS (ESI): 
for C18H22O3
+ [M+H]+ : calculated: 287.1642; found: 287.1643; [α]D20 = +54.9 (c = 1, CHCl3); 
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(R)-1-(benzyloxy)-4-(3-iodo-2-methylpropyl)-2-methoxybenzene (3.36) 
Triphenylphosphine (3.1 g, 1.7 equiv.) was dissolved in DCM (42 mL) at ambient 
temperature in an oven dried round bottom under an atmosphere of argon.  To this solution was 
added imidazole (1.0 g, 2.1 equiv.) followed by iodine (3.2 g, 1.8 equiv.).  Upon complete 
dissolution of iodine, (2R)-3-(4-benzyloxy-3-methoxy-phenyl)-2-methyl-propan-1-ol (3.41) (2.0 
g, 7.0 mmol, as a solution in 8.5 mL DCM) was added and the reaction was stirred for two hours. 
The mixture was diluted with excess DCM and shaken with 2.5 mL sat. aq. Na2S2O3 until the 
solution became clear and yellow.  The organic layer was removed and dried over MgSO4, 
filtered, and concentrated directly onto silica gel.  Crude product was purified using Teledyne 
ISCO Combi-Flash system (solid loading, 40G column, 0-20% EtOAc, 32 CV) to afford 1-
benzyloxy-4-[(2R)-3-iodo-2-methyl-propyl]-2-methoxy-benzene (3.36) (2.4 g, 6.1 mmol, 87.1% 
yield) as a clear oil which rapidly turns yellow upon standing. 1HNMR (400 MHz, CDCl3): δ 
7.50 (d, J = 7.3 Hz, 2H), 7.41 (t, J = 14.7, 7.1 Hz, 2H, 7.34 (m, 1H), 6.87 (d, J = 8.2 Hz, 1H), 
6.81 (d, J  = 1.9 Hz, 1H), 6.72 (dd, J = 8.2, 1.9 Hz, 1H), 5.17 (s, 2H), 3.93 (s, 3H), 3.26 (dd, J  = 
9.6, 4.7 Hz, 1H), 3.15 (dd, J = 9.6, 5.4 Hz, 1H), 2.64 (dd, J = 13.6, 7.4 Hz, 1H), 2.53 (dd, J = 
13.6, 6.7 Hz, 1H), 1.73 (m, 1H), 1.06 (d, J = 6.6 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 149.4, 
146.5, 137.2, 132.9, 128.4, 127.6, 127.1, 120.9, 114.0, 112.8, 71.0, 55.9, 41.9, 36.5, 20.6, 17.4; 
HRMS (ESI): for C18H22IO2
+ [M+H]+ : calculated: 397.0659; found: 397.0658; [α]D20 = - 41.9 
(c = 1, CHCl3). 
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(R)-1-(benzo[d][1,3]dioxol-5-yl)-4-(4-(benzyloxy)-3-methoxyphenyl)-3-methylbutan-1-one 
(3.25) 
 To an oven dried round bottom under argon was added NiCl2 glyme (17.6 mg, 0.1 
equiv.), 4-4’-di-tert-butyl-2-2’-dipyridyl (25.6 mg, 0.12 equiv.), and Manganese powder (130.6 
mg, 3 equiv.).  The solids were then suspended in DMA (1.6 mL) and stirred at ambient 
temperature until the reaction mixture turned green-black (about 15 minutes).  After cooling to 0 
oC, piperonyloyl chloride (220 mg, 1.5 equiv.) and 1-benzyloxy-4-[(2R)-3-iodo-2-methyl-
propyl]-2-methoxy-benzene (3.36) (314 mg, 0.8 mmol) (together as a solution in 1.6 mL DMA) 
were added under argon via syringe.  After 48 hours of stirring the reaction mixture was diluted 
with EtOAc and filtered over a pad of celite and the pad washed with a generous portion of 
EtOAc.  The crude organics were washed two times with water then once with brine before 
being dried over MgSO4, filtered, and condensed onto silica gel.  Crude product was purified 
using Teledyne ISCO Combi-Flash system (solid loading, 12G column, 0-25% EtOAc, 28 CV) 
to afford (3R)-1-(1,3-benzodioxol-5-yl)-4-(4-benzyloxy-3-methoxy-phenyl)-3-methyl-butan-1-
one (3.25) (138.8 mg, 0.33 mmol, 41.2% yield) as an oily colorless solid.  1HNMR (400 MHz, 
CDCl3): δ 7.47 (m, 3H), 7.38 (m, 3H), 7.32 (m, 1H), 6.83 (dd, J = 8.2, 1.8Hz, 2H), 6.76 (d, J = 
1.5Hz, 1H), 6.67 (dd, J = 8.2, 1.5 Hz, 1H), 6.05 (s, 2H), 5.15 (s, 2H), 3.89 (s, 3H), 2.91 (dd, J = 
15.7, 5.3 Hz, 1H), 2.67 (dd, J = 16.0, 8.0 Hz, 1H), 2.61 (dd, J = 13.1, 7.6 Hz, 1H), 2.54 (m, 1H), 
2.45 (m, 1H), 0.99 (d, J = 6.5 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 198.2, 151.6, 149.5, 
148.1, 146.5, 137.4, 133.8, 132.2, 128.5, 127.7, 127.3, 124.2, 121.2, 114.1, 113.0, 107.9, 107.8, 
101.8, 71.2, 56.0, 44.7, 42.9, 32.0, 20.0; HRMS (ESI): for C26H27O5
+ [M+H]+ : calculated: 
419.1853; found: 419.1853; [α]D20 = -116.52 (c = 1, CHCl3); 
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(2S,3R)-1-(benzo[d][1,3]dioxol-5-yl)-4-(4-(benzyloxy)-3-methoxyphenyl)-2,3-
dimethylbutan-1-one (3.44) 
 To a solution of (3R)-1-(1,3-benzodioxol-5-yl)-4-(4-benzyloxy-3-methoxy-phenyl)-3-
methyl-butan-1-one (570 mg, 1.36 mmol) (3.25) in THF (15 mL) at -78 oC in an oven dried vial 
under an atmosphere of argon was added KHMDS (5.45 mL, 2 equiv., 0.5M solution in PhMe) 
followed by hexamethylphosphoramide (1.18 mL, 5 equiv.).  After 10 minutes, iodomethane 
(424 uL,5 equiv.) was added and stirring continued at the same temperature for 40 minutes.  The 
reaction was quenched via the addition of sat. aq. NH4Cl and extracted with diethyl ether.  The 
crude organics were dried over MgSO4, filtered, and condensed onto silica gel for purification 
using Teledyne ISCO Combi-Flash system (solid loading, 24G column, 0-15% EtOAc/Hex, 18 
CV) to afford (2S,3R)-1-(1,3-benzodioxol-5-yl)-4-(4-benzyloxy-3-methoxy-phenyl)-2,3-
dimethyl-butan-1-one (3.44) (130 mg, 0.30 mmol, dr = 5:1 inseparable, 72.1% yield) as a clear 
oil. 1HNMR (400 MHz, CDCl3, major diastereomer): δ 7.47 (m, 2H), 7.38 (m, 2H), 7.30 (m, 
3H), 6.87 (d, J = 8.1 Hz, 1H), 6.76 (d, J = 1.7 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 6.68 (dd, J = 
8.1, 1.7 Hz, 1H), 6.00 (d, J = 1.7 Hz, 2H), 5.17 (s, 2H), 3.89 (s, 3H), 3.30 (m, 1H), 2.58 (dd, J = 
13.5, 7.8 Hz, 1H), 2.49 (dd, J = 13.5, 6.9 Hz, 1H), 2.27 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H), 0.87 
(d, J = 6.8 Hz, 3H); 13CNMR (100 MHz, CDCl3, major diastereomer): δ 202.0, 151.4, 149.6, 
148.1, 146.6, 137.3, 133.9, 131.3, 128.4, 127.7, 127.3, 124.2, 121.2, 114.1, 112.8, 108.2, 107.7, 
101.7, 71.1, 55.9, 42.9, 41.2, 37.5, 15.2, 11.0; HRMS (ESI): for C27H29O5
+ [M+H]+ : calculated: 
433.2010; found: 433.2011. 
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(8S, 8’R)-4’-hydroxy-3’-methoxy-3,4-methylenedioxy-7-oxo-8,8’-neolignan (3.27) 
 To a solution of (2S,3R)-1-(1,3-benzodioxol-5-yl)-4-(4-benzyloxy-3-methoxy-phenyl)-
2,3-dimethyl-butan-1-one (3.44) (73.0 mg, 0.17 mmol) and anisole (110 uL, 6 equiv) in DCM 
(0.9 mL) at room temperature was added aluminum chloride (67.5 mg, 3 equiv) in a single 
portion.  The reaction was stirred for 2 hours then quenched via the addition of 1N aq. HCl.  The 
mixture was extracted three times with DCM and the combined organic layers were washed with 
5% aq. NaHCO3 and brine then dried over MgSO4 and filtered.  The crude organics were 
condensed onto silica gel and purified using Teledyne ISCO Combi-Flash system (solid loading, 
4G column, 0-20% EtOAc, 56 CV) to afford product with dr ~5:1.  This material was brought to 
dryness and suspended in 1.5 mL DMSO / 0.1 mL H2O for further purification using Gilson 
system (100 x 30 mm column, 43-73% MeCN / 0.5%  NH4OH (aq), 10 min gradient collect all) 
to afford (8S, 8’R)-4’-hydroxy-3’-methoxy-3,4-methylenedioxy-7-oxo-8,8’-neolignan (3.27)  
(27.5 mg,0.080 mmol, dr > 20:1, 47.6% yield) as a clear oil. 1HNMR (400 MHz, CDCl3): δ 7.29 
(dd, J = 12.2, 1.7 Hz, 1H), 7.26 (m, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.68-
6.65 (m, 2H), 6.02 (d, J = 0.7 Hz, 2H), 5.52 (s, 1H), 3.86 (s, 3H), 3.27 (dq, J = 6.7, 5.2 Hz, 1H), 
2.55 (dd, J = 13.5, 7.7 Hz, 1H), 2.44 (dd, J = 13.5, 7.1 Hz, 1H), 2.22 (m 1H), 1.12 (d, J = 6.8 Hz, 
3H), 0.84 (d, J = 6.8 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 202.4, 151.6, 148.3, 146.6, 144.2, 
132.7, 131.6, 124.5, 122.1, 114.3, 111.7, 108.4, 107.9, 101.9, 56.0, 43.3, 41.5, 37.8, 15.4, 11.4; 
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HRMS (ESI): for C20H23O5
+ [M+H]+ : calculated: 343.1540; found: 343.1542; [α]D20 = +90.35 
(c = 0.79, MeOH); 
 
4-((2R,3S,4S)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxy-2,3-dimethylbutyl)-2-methoxyphenol 
(3.45) 
 (2S,3R)-1-(1,3-benzodioxol-5-yl)-4-(4-benzyloxy-3-methoxy-phenyl)-2,3-dimethyl-
butan-1-one (3.44) (126 mg, 0.29 mmol) was dissolved in Ethanol (3.8 mL) an treated with 
palladium on carbon (126 mg, 40 mol%, 10%w/w solid) under an atmosphere of hydrogen for 18 
hours.  The mixture was diluted with chloroform and filtered over a thin pad of celite and 
brought to dryness.  The crude material was dissolved in 1.5 mL DMSO / 0.1 mL H2O and 
purified using Gilson system (100 x 30 mm column, 36-76% MeCN / 0.5% NH4OH (aq), 10 min 
gradient collect all) to afford 4-[(2R,3S,4S)-4-(1,3-benzodioxol-5-yl)-4-hydroxy-2,3-dimethyl-
butyl]-2-methoxy-phenol (3.45) (36.1 mg, 0.10 mmol, dr >20:1, 35.9% yield) as a clear oil. 
1HNMR (400 MHz, CDCl3, residual solvent peak calibrated to 7.26 ppm): δ 6.81 (d, J = 8.0 Hz, 
1H), 6.78 (d, J = 1.0 Hz, 1H), 6.75-6.72 (m, 1H), 6.72-6.69 (m, 2H), 6.66 (dd, J = 8.0, 1.8 Hz, 
1H), 5.93 (s, 2H), 5.54 (s, 1H), 4.30 (dd, J  = 9.6, 3.0 Hz, 1H), 3.86 (s, 3H), 2.56-2.50 (m, 1H), 
2.47-2.43 (m, 1H), 2.43-2.38 (m, 1H), 1.83-1.79 (m, 2H), 0.84 (d, J = 6.4 Hz, 3H), 0.57 (d, J = 
7.0 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 147.8, 147.0, 146.4, 143.6, 138.4, 133.4, 121.8, 
120.4, 114.1, 111.6, 107.9, 107.0, 101.0, 77.2, 55.9, 42.8, 41.8, 33.9, 13.0, 10.1; HRMS (ESI): 
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for C20H23O4
+ [M+H][-H2O]
+ : calculated: 327.1591; found: 327.1589; [α]D20 = -90.8 (c = 0.24, 
CHCl3) 
 
(8S, 8’R)-3’,4’-dimethoxy-3,4-methylenedioxy-7-oxo-8,8’-neolignan (3.28) 
  (8S, 8’R)-4’-hydroxy-3’-methoxy-3,4-methylenedioxy-7-oxo-8,8’-neolignan (3.27) (12.0 
mg, 0.035 mmol) was dissolved in MeCN (0.17 mL) at treated with K2CO3 (9.8 mg, 2 equiv.) 
and iodomethane (6.5 uL, 3 equiv.) at 40 oC for seven hours.  The mixture was diluted with 
DCM and filtered through a syringe filter and brought to dryness in vacuo.  This material was 
then condensed onto silica gel and purified using Teledyne ISCO Combi-Flash system (solid 
loading on silica gel, 4G column, 0-30% EtOAc, 60 CV) to afford (8S, 8’R)-3’,4’-dimethoxy-
3,4-methylenedioxy-7-oxo-8,8’-neolignan (3.28) (9.1 mg, 0.025 mmol, dr >20:1, 72.8% yield) as 
a clear oil. 1HNMR (400 MHz, CDCl3): δ 7.29 (dd, J = 8.2, 1.7 Hz, 1H), 7.26 (m, 1H), 6.81 (d, J 
= 8..0 Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.73-6.70 (m, 2H), 6.01 (d, J = 1.3 Hz, 2H), 3.88, (s, 
3H), 3.86 (2, 3H), 3.27 (dq, J = 6.7, 5.1 Hz, 1H), 2.57 (dd, J = 13.5, 7.7 Hz, 1H), 2.47 (dd, J = 
13.5, 7.0 Hz, 1H), 2.24 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H); 13CNMR 
(100 MHz, CDCl3): δ 202.2, 151.4, 148.9, 148.1, 147.4, 133.2, 131.4, 124.2, 121.2, 112.1, 111.1, 
108.3, 107.7, 101.7, 55.9, 55.8, 43.1, 41.2, 37.5, 15.2, 11.1; HRMS (ESI): for C21H25O5
+ 
[M+H]+ : calculated: 357.1697; found: 357.1697; [α]D20 = +80.60 (c = 0.53, MeOH). 
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(8S, 8’R)-3’-methoxy-4’-but-3-yn-1-yloxy-3,4-methylenedioxy-7-oxo-8,8’-neolignan (3.47) 
 A solution of (2S,3R)-1-(1,3-benzodioxol-5-yl)-4-(4-hydroxy-3-methoxy-phenyl)-2,3-
dimethyl-butan-1-one (3.27) (11.0 mg, 0.032 mmol) in DCM (0.13 mL) at ambient temperature 
was treated sequentially with diisopropyl azodicarboxylate (8.2 uL, 1.3 equiv.), 
triphenylphosphine (10.1 mg,1.2 equiv.), then 3-butyn-1-ol (3.7 uL, 1.5 equiv.).  After sixteen 
the reaction was diluted with excess DCM and washed once each with sat. aq. NaHCO3 and 
water.  The crude organics were dried over MgSO4, filtered, and condensed onto silica gel for 
purification using Teledyne ISCO Combi-Flash system (solid loading, 4G column, 0-25% 
EtOAc/Hex, 60 CV) to afford (8S, 8’R)-3’-methoxy-4’-but-3-yn-1-yloxy-3,4-methylenedioxy-7-
oxo-8,8’-neolignan (3.47) (5.9 mg,0.015 mmol, dr >20:1, 46.6% yield) as a clear oil. 1HNMR 
(400 MHz, CDCl3): δ 7.32 (dd, J = 8.2, 1.7 Hz, 1H), 7.27 (d, J = 1.6 Hz, 1H), 6.87 (d, J = 8.6 
Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 6.72 (m, 2H), 6.04 (d, J = 1.2 Hz, 2H), 4.18 (t, J = 7.4 Hz, 
2H), 3.86 (s, 3H), 3.29 (dq, J = 6.8, 5.4 Hz, 1H), 2.75 (td, J = 7.5, 2.7 Hz, 2H), 2.59 (dd, J = 
13.5, 7.7 Hz, 1H), 2.48 (dd, J = 13.5, 7.0 Hz, 1H), 2.26 (m, 1H), 2.06 (t, J = 2.6 Hz, 1H), 1.14 (d, 
J = 6.8 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 202.2, 151.5, 149.7, 
148.2, 146.2, 134.5, 131.5, 124.3, 121.5, 114.3, 113.1, 108.4, 107.9, 101.9, 80.4, 70.1, 67.5, 56.1, 
43.2, 41.4, 37.6, 19.6, 15.3, 11.4; HRMS (ESI): for C24H27O5
+ [M+H]+ : calculated: 395.1853; 
found: 395.1853; [α]D20 = +82.67 (c = 0.30, MeOH); 
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(7S, 8S, 8’R)-3’-4’-dimethoxy-3,4-methylenedioxylignan-7-ol (3.30) 
 4-[(2R,3S,4S)-4-(1,3-benzodioxol-5-yl)-4-hydroxy-2,3-dimethyl-butyl]-2-methoxy-
phenol (3.45) (7.0 mg, 0.02 mmol) was dissolved in MeCN (0.10 mL) at treated with K2CO3 (5.7 
mg, 2 equiv.) and iodomethane (3.8 uL, 3 equiv.) at 40 oC for seven hours.  The mixture was 
diluted with DCM and filtered through a syringe filter and brought to dryness in vacuo.  This 
material was then condensed onto silica gel and purified using Teledyne ISCO Combi-Flash 
system (solid loading on silica gel, 4G column, 0-30% EtOAc, 60 CV) to afford (7S, 8S, 8’R)-
3’-4’-dimethoxy-3,4-methylenedioxylignan-7-ol (3.30) (5.4 mg, 0.015 mmol, dr >20:1, 74.1% 
yield) as a clear oil. 1HNMR (600 MHz, CDCl3, residual solvent peak calibrated to 7.27 ppm): δ 
6.79 (m, 2H), 6.75 (d, J = 7.9 Hz, 1H), 6.73-6.71 (m, 3H), 5.95 (s, 2H), 4.31 (d, J = 9.4 Hz, 1H), 
3.88 (s, 3H), 3.87 (s, 3H), 2.56 (dd, J = 12.8, 6.7 Hz, 1H), 2.50-2.43 (m, 2H), 1.82 (ddq, J = 9.5, 
7.0, 2.4, 1H), 1.74 (br.s, 1H), 0.86 (d, J = 6.4 Hz, 3H), 0.58 (d, J = 7.0 Hz, 3H); 13CNMR (150 
MHz, CDCl3, residual solvent peak calibrated to 77.0 ppm): δ 148.7, 147.8, 147.0, 146.9, 138.3, 
134.0, 120.9, 120.3, 112.2, 111.0, 107.9, 106.9, 100.9, 77.1, 55.84, 55.78, 42.8, 41.6, 33.7, 12.9, 
10.0; HRMS (ESI): for C21H25O4
+ [M+H][-H2O]
+ : calculated: 341.1747; found: 341.1748; 
[α]D20 = -54.44 (c = 0.18, CHCl3). 
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(7S, 8S, 8’R)-3’-methoxy-4’-propoxy-3,4-methylenedioxylignan-7-ol (3.46) 
4-[(2R,3S,4S)-4-(1,3-benzodioxol-5-yl)-4-hydroxy-2,3-dimethyl-butyl]-2-methoxy-phenol (3.45) 
(7.0 mg, 0.02 mmol) was dissolved in MeCN (0.10 mL) at treated with K2CO3 (5.7 mg, 2 equiv.) 
and 1-iodopropane (5.9 uL, 3 equiv.) at 40 oC for eighteen hours.  The mixture was diluted with 
DCM and filtered through a syringe filter and brought to dryness in vacuo.  This material was 
then condensed onto silica gel and purified using Teledyne ISCO Combi-Flash system (solid 
loading on silica gel, 4G column, 0-25% EtOAc, 60 CV) to afford (7S, 8S, 8’R)-3’-methoxy-4’-
propoxy-3,4-methylenedioxylignan-7-ol (3.46) (5.6 mg, 0.014 mmol, dr > 20:1, 71.3% yield) as 
a clear oil. 1HNMR (400 MHz, CDCl3): δ 6.82 (d, J = 7.8 Hz, 2H), 6.76-6.70 (m, 4H), 5.97 (s, 
2H), 4.34 (dd, J = 9.5, 2.8 Hz, 1H), 3.99 (t, J = 6.9 Hz, 2H), 3.88 (s, 3H), 2.60-2.54 (m, 1H), 
2.53-2.47 (m, 1H), 2.47-2.42 (m, 1H), 1.93-1.79 (m, 3H), 1.68 (d, J = 3.0 Hz, 1H), 1.06 (t, J = 
7.4 Hz, 3H), 0.87 (d, J = 6.4 Hz, 3H), 0.59 (d, J = 7.0 Hz, 3H); 13CNMR (100 MHz, CDCl3): δ 
149.3, 147.9, 147.1, 146.7, 138.5, 134.1, 121.1, 120.5, 113.0, 112.9, 108.0, 107.0, 101.1, 77.3, 
70.7, 56.1, 42.8, 41.7, 33.8, 22.7, 13.1, 10.5, 10.2; HRMS (ESI): for C23H29O4
+ [M+H][-H2O]
+ : 
calculated: 369.2060; found: 369.2058; [α]D20 = -85.25 (c = 0.18, CHCl3) 
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(R)-1-(benzo[d][1,3]dioxol-5-yl)-4-(4-(benzyloxy)-3-methoxyphenyl)-3-methyl-2-
methylenebutan-1-one (3.48) 
 (3R)-1-(1,3-benzodioxol-5-yl)-4-(4-benzyloxy-3-methoxy-phenyl)-3-methyl-butan-1-one 
(3.25) (660 mg, 1.6 mmol) was placed in an oven dried vial under an atmosphere of argon.  The 
solid was suspended in dry THF (6.5 mL) and cooled to -78 oC.  LiHMDS (2.4 mL, 1.5 equiv., 
1M solution in THF) was added and the mixture was stirred at the same temperature for 60 
minutes.  Then, Eschenmoser’s salt (875 mg, 3 equiv.) was added in a single portion against a 
weak flow of argon. The reaction was gradually warmed to ambient temperature and stirred for 
40 minutes.  The reaction mixture was then quenched with brine and excess EtOAc.  The 
organics were separated and washed with small portions of 1N aq. HCl, water, then brine.  Upon 
concentration, Mannich product (815 mg) was obtained a yellow/orange tinted foamy solid and 
used directly in the next step without further purification. 
To a rapidly stirring solution of the Mannich product (815mg) in DCM (4.3 mL) and sat. 
aq. NaHCO3 (2.2 mL) solid 3-chloroperoxybenzoic acid (517 mg, 1.9 euqiv.) in a single 
portion.  The mixture was stirred at ambient temperature for approx. 10 minutes then warmed to 
40 oC for 16 hours.  The reaction mixture was diluted with excess DCM and washed sequentially 
with sat. aq. NaHCO3, water, and brine. The crude organics were dried over MgSO4, filtered, and 
condensed onto silica gel for purification using Teledyne ISCO Combi-Flash system (solid 
loading, 12G column, 0-15% EtOAc, 28 CV) to afford (3R)-1-(1,3-benzodioxol-5-yl)-4-(4-
benzyloxy-3-methoxy-phenyl)-3-methyl-2-methylene-butan-1-one (3.48) (415 mg, 0.96 mmol, 
61.1% yield over two steps) as a white solid. 1HNMR (400 MHz, CDCl3): δ 7.45 (d, J = 7.2 Hz, 
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2H), 7.38 (m, 2H), 7.33 (d, J = 1.5 Hz, 1H), 7.31 (d, J = 1.7 Hz, 1H), 7.27 (d, J = 1.6 Hz, 1H), 
6.81 (d, J = 4.9 Hz, 1H), 6.79 (d, J = 4.9 Hz, 1H), 6.75 (d, J = 1.9 Hz, 1H), 6.66 (dd, J = 7.8, 1.9 
Hz, 1H), 6.05 (s, 2H), 5.67 (s, 1H), 5.49 (s, 1H), 5.13 (s, 2H), 3.86 (s, 3H), 3.17 (m, 1H), 2.88 
(dd, J = 13.6, 6.3 Hz, 1H), 2.56 (dd, J = 13.6, 8.6 Hz, 1H), 1.14 (d, J = 6.9 Hz, 3H); 13CNMR 
(100 MHz, CDCl3): δ 197.2, 152.6, 151.5, 149.5, 147.8, 146.6, 137.5, 133.7, 132.3, 128.5, 127.8, 
127.3, 126.2, 121.6, 121.3, 114.1, 113.0, 109.5, 107.6, 101.8, 71.2, 56.0, 41.7, 37.7, 19.1; [α]D20 
= -9.00 (c = 1, CHCl3). 
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Appendix A 
 
Relevant Spectra for Chapter I 
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Relevant Spectra for Chapter II 
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Relevant Spectra for Chapter III 
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1HNMR and 13CNMR comparison of synthetic and natural lignan 3.27 from Nectandra 
puberula. 
 
1HNMR (CDCl3) 13CNMR (CDCl3) 
Natural 1,a Synthetic b Natural 1,c Synthetic d 
7.29 (dd, J = 8, 2 Hz, 1H) 7.29 (dd, J = 12.2, 1.7 Hz, 1H) 202.5 202.4 
7.27 (1He) 7.26 (1He) 152.8 151.6 
6.86 (d, J = 8 Hz, 1H) 6.85 (d, J = 8.4 Hz, 1H) 148.7 148.3 
6.76 (d, J = 8 Hz, 1H) 6.76 (d, J = 8.1 Hz, 1H) 146.7 146.6 
6.67f (d, J = 1.5 Hz, 1H) 
6.68-6.65 (m, 2H) 
144.2 144.2 
6.67f (dd, J = 8, 1.5 Hz, 1H) 132.6 132.7 
6.02 (s, 2H) 6.02 (d, J = 0.7 Hz, 2H) 129.5 131.6 
 5.52 (s, 1H)g 124.4 124.5 
3.86 (s, 3H) 3.86 (s, 3H) 122.1 122.1 
3.27 (dq, J = 7, 5 Hz, 1H) 3.27 (dq, J = 6.7, 5.2 Hz, 1H) 114.4 114.3 
2.58 (dd, J = 13.5, 7 Hz, 1H) 2.55 (dd, J = 13.5, 7.7 Hz, 1H) 111.8 111.7 
2.42 (dd, J = 13.5, 7 Hz, 1H) 2.44 (dd, J = 13.5, 7.1 Hz, 1H) 108.4 108.4 
2.22 (dqt, J = 7, 6.5, 5 Hz, 1H) 2.22 (m, 1H) 107.9 107.9 
1.12 (d, J = 7 Hz, 3H) 1.12 (d, J = 6.8 Hz, 3H) 101.9 101.9 
0.84 (d, J = 6.5 Hz, 3H) 0.84 (d, J = 6.8 Hz, 3H) 56.0 56.0 
  43.3 43.3 
  41.5 41.5 
  37.8 37.8 
  15.3 15.4 
  11.4 11.4 
1 Moro, J.C., Fernandes, J.B., Vieira, P.C., Yoshida, M., Gottlieb, O.R., Gottlieb, H.E. Phytochemistry, 
1987, 26, 269-272. a Measured at 270 MHz. b Measured at 400 MHz. c Measured at 20 MHz. d Measured 
at 100 MHz. e covered by residual solvent peak. f Interchangeable assignments. g Phenolic O-H resonance 
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1HNMR and 13CNMR comparison of synthetic and natural lignan 3.28 from Nectandra 
puberula. 
 
1HNMR (CDCl3) 13CNMR (CDCl3) 
Natural 1,a Synthetic b Natural 1,c Synthetic d 
7.29 (dd, J = 8, 2 Hz, 1H) 7.29 (dd, J = 8.2, 1.7 Hz, 1H) 202.0 202.2 
7.27 (1He) 7.26 (1He) 151.5 151.4 
6.82 (d, J = 8 Hz, 1H) 6.81 (d, J = 8.0 Hz, 1H) 149.0 148.9 
6.76 (d, J = 8 Hz, 1H) 6.76 (d, J = 8.1 Hz, 1H) 148.1 148.1 
6.72 (dd, J = 8, 1.5 Hz, 1H) 
6.73-6.70 (m, 2H) 
147.5 147.4 
6.70 (dd, J = 1.5 Hz, 1H) 133.2 133.2 
6.02f (s, 2H) 6.01 (d, J =- 1.3 Hz, 2H) 128.1 131.4 
3.88 (s, 3H) 3.88 (s, 3H) 124.2 124.2 
3.86 (s, 3H) 3.86 (s, 3H) 122.6 121.1 
3.27 (dq, J = 7, 5 Hz, 1H) 3.27 (dq, J = 6.7, 5.1 Hz, 1H) 112.4 112.1 
2.60 (dd, J = 13.5, 7 Hz, 1H) 2.57 (dd, J = 13.5, 7.7 Hz, 1H) 111.3 111.1 
2.44 (dd, J = 13.5, 7 Hz, 1H) 2.47 (dd, J = 13.5, 7.0 Hz, 1H) 108.3 108.3 
2.24 (dqt, J = 7, 6.5, 5 Hz, 1H) 2.24 (m, 1H) 107.7 107.7 
1.12 (d, J = 7 Hz, 3H) 1.12 (d, J = 6.8 Hz, 3H) 101.8 101.7 
0.84 (d, J = 6.5 Hz, 3H) 0.84 (d, J = 6.8 Hz, 3H) 55.9 55.9 
  55.8 55.8 
  43.0 43.1 
  41.3 41.2 
  37.5 37.5 
  15.2 15.2 
  11.2 11.1 
1 Moro, J.C., Fernandes, J.B., Vieira, P.C., Yoshida, M., Gottlieb, O.R., Gottlieb, H.E. Phytochemistry, 
1987, 26, 269-272. a Measured at 270 MHz. b Measured at 400 MHz. c Measured at 20 MHz. d Measured 
at 100 MHz. e covered by residual solvent peak. f splitting was noted but no J values reported  
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1HNMR and 13CNMR comparison of synthetic and natural lignan 3.30 from Virola Aff. 
Pavonis. 
 
1HNMR (CDCl3) 13CNMR (CDCl3) 
Natural 2,a Synthetic a Natural 2,b Synthetic c 
6.9-6.7 (m, 6H) 
6.79 (m, 2H) 148.7 148.7 
6.75 (d, J = 7.9 Hz, 1H) 147.7 147.8 
6.73-6.71 (m, 3H) 147.0 147.0 
5.95 (s, 2H) 5.95 (s, 2H) 146.9 146.9 
4.31 (d, J = 9.5 Hz, 1H) 4.31 (d, J = 9.4 Hz, 1H) 138.3 138.3 
3.88 (s, 6H) 
3.88 (s, 3H) 134.0 134.0 
3.87 (s, 3H) 120.9 120.9 
2.56 (dd, J = 12.4, 6.1 Hz, 1H) 2.56 (dd, J = 12.8, 6.7 Hz, 1H) 120.3 120.3 
2.46 (m, 2H) 2.50-2.43 (m, 2H) 112.2 112.2 
1.81 (ddq, J = 9.5, 6.9, 2.4 Hz, 
1H) 
1.82 (ddq, J = 9.5, 7.0, 2.4 Hz, 
1H) 
110.9 111.0 
1.67 (br.s, 1H) 1.74 (br.s, 1H) 107.9 107.9 
0.84 (d, J = 6.3 Hz, 3H) 0.86 (d, J = 6.4 Hz, 3H) 106.9 106.9 
0.57 (d, J = 6.9 Hz, 3H) 0.58 (d, J = 7.0 Hz, 3H) 100.9 100.9 
  77.1 77.1 
  55.9 55.84 
  55.8 55.78 
  42.8 42.8 
  41.8 41.6 
  33.7 33.7 
  12.8 12.9 
  10.1 10.0 
2 Martinez, J.C.,Torres, R.  Phytochemistry, 1997, 44, 1179-1182. . a Measured at 600 MHz. b Measured at 
500 MHz. c Measured at 150 MHz..  
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